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Functional Signature Ontology-Based Identification
and Validation of Novel Therapeutic Targets and
Natural Products for the Treatment of Cancer
Abstract
Beth K. Neilsen, Ph.D.
University of Nebraska Medical Center, 2018
Supervisor: Robert E. Lewis, Ph.D.
Multiple studies have revealed that Ras-driven tumors acquire vulnerabilities by adapting
cellular mechanisms that promote uncontrolled proliferation and suppress apoptosis. Kinase
Suppressor of Ras 1 (KSR1) modulates ERK activation downstream of oncogenic Ras, and
knockdown of KSR1 selectively kills malignant, Ras-driven cancer cells, but does not kill
immortalized, non-transformed human colon epithelial cells (HCECs). KSR1-/- mice are fertile
and phenotypically normal, but resistant to Ras-driven tumor formation suggesting KSR1
represents a vulnerability in cancer cells.
To identify additional vulnerabilities in cancer, a screening approach termed Functional
Signature Ontology (FUSION) was used to screen 14,355 genes and 1,200 natural product
fractions in K-Ras-mutant HCT116 colon cancer cells for functional similarity to KSR1 and a
selective requirement in colon cancer cells. FUSION identified numerous targets including
TIMELESS, WDR5, and an AMPK inhibitor, 5’-hydroxy-staurosporine.
Downstream of oncogenic signaling, TIMELESS is constitutively overexpressed in
multiple types of cancer and required for increased cancer cell proliferation. TIMELESS
depletion increases γH2AX, a marker of DNA damage, and triggers downstream G2/M arrest via
increased CHK1 and CDK1 phosphorylation. Wee1 or CHK1 inhibition in combination with
TIMELESS depletion demonstrates at least additive effects suggesting this combination may be
efficacious for the treatment of cancer.
WDR5 is overexpressed, and WDR5 depletion reduces cell viability in colon cancer cells
by reducing H3K4Me3 and increasing γH2AX, which further sensitizes cells to radiation-induced

vi

DNA damage. WDR5 inhibition also reduces colon cancer cell viability, but less so than WDR5
depletion.
The catalytic, kinase-containing 2 subunit isoform of AMPK is expressed at variable
levels in colon cancer cells and is selectively required for colon cancer cell survival suggesting
that AMPK kinase inhibition may be a useful component of cancer therapeutic strategies.
FUSION identified 5´-hydroxy-staurosporine as a competitive inhibitor of AMPK that is
selectively toxic to colon cancer cells.
Our results demonstrate the ability of FUSION to reveal functional similarities between
genes, identify novel inhibitors, and expose oncogene-induced changes in cancer that promote
proliferation and survival, but may also leave cancer cells vulnerable to targeted therapies.
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Chapter 1: Introduction

Portions of the content covered in this chapter are the subject of a published
review article in Expert Opinion on Therapeutic Targets by Neilsen BK et al.2

2

Cancer
In 2018, the American Cancer Society estimates that more than 1.7 million people will be
diagnosed with cancer for the first time, and just over 600,000 people will die from cancer in the
United States 4. Cancer is the second leading cause of death among Americans with only heart
disease causing more deaths 5. Colon cancer is the third most common cancer in men and women
with projections that more than 140,000 individuals will be diagnosed with this disease in 2018.
Even though colon cancer has a high survival rate if caught in early stages, it remains the third
most lethal type of cancer and is projected to kill more than 50,000 individuals in 2018 4. Patients
with early stage or only locally advanced disease can be treated with multiple modalities
including surgical resection and radiation therapy with the potential for curative outcomes.
However, the only real treatment option for patients with any type of advanced or metastatic
cancer are systemic therapies that include chemotherapy, hormone therapy, immune-based
therapy, and/or targeted therapy. Most chemotherapeutics are often not curative, not selective
(target all rapidly dividing cells), and not effective after resistance develops. Hormone therapies
are highly efficacious in tumors that are reliant on hormone receptors for growth (e.g. breast and
prostate cancers), but not all tumors rely on these receptors and those that do, often evolve so they
are no longer susceptible to these therapies. Immune-based therapies (a.k.a immunotherapies)
represent a new, promising category of therapeutics, but very few of these therapies have been
developed and tested such that they are ready for clinical use. Studies have shown that
immunotherapy is particularly effective in tumors with high mutational burdens (e.g. melanoma)
or in tumors that have mechanisms promoting immune escape (e.g. increased PD-L1 expression
in lung cancer), which has limited the approval of immunotherapies for use in specific tumor
types with these characteristics. While often very effective and without significant side effects,
very few targeted therapies exist and those that do are commonly specific for one type of cancer
(e.g. imatinib targeting BCR-ABL in CML). Therefore, developing novel therapeutic strategies to
target and kill cancer cells, preferably with little or no harm to normal tissues, is vital. Specific
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targeting of cancer cells can be achieved by targeting the vulnerabilities that develop in tumors as
a result of driving mutations altering normal cellular mechanisms to promote uncontrolled growth
and suppress apoptosis. Specifically, oncogenic Ras mutations have been shown to induce
changes in cancers that introduce targetable vulnerabilities in cancer cells that are not present or
significantly diminished in normal cells.

Ras Mutations in Cancer and Therapeutic Targeting of Ras
Oncogenic Ras mutations are a common trait of more than one third of all tumors 6.
There are three isoforms of Ras: K-Ras, H-Ras, and N-Ras. K-Ras mutations, the most commonly
mutated isoform of the Ras gene, are present in 25%-30% of all human cancers 6. Mutations in HRas and N-Ras are present in 3% and 8% of all tumors, respectively 7,8. Ras mutations are also
present at much higher frequencies in certain types of cancers. Approximately one fifth of lung
cancers, one third of colon cancers, and more than two thirds of pancreatic cancers have
oncogenic Ras mutations 8.
Based on its prevalence, substantial efforts have been directed towards developing a
targeted Ras inhibitor; however, despite these efforts, very few efficacious therapies have been
developed that specifically target Ras. Based on our understanding of Ras, inhibition could be
achieved by decreasing the amount of activated, GTP-bound Ras, disrupting the interaction
between Ras and its downstream effectors, stabilizing non-active protein complexes, or
preventing Ras membrane localization 9. Despite substantial understanding of Ras regulation and
function, inhibiting Ras has been problematic. This is due, at least in part, to difficulty interfering
with the nucleotide-binding pocket of the protein, which is much more difficult than blocking the
ATP-binding pocket of kinases. This is likely due to the incredibly high affinity of Ras for GTP,
which is in the picomolar range 10. Instead of inhibiting nucleotide binding, the possibility of
inhibiting the guanine exchange factor SOS, which catalyzes the conversion of GDP-bound Ras
(inactive) to GTP-bound Ras (active), has been explored. Compounds have been identified that
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bind to Ras and interfere with SOS binding 11-13; however, it is unclear if this interference will be
clinically efficacious or if drugs with a high enough affinity to substantially displace SOS can be
developed from the recently identified starting compounds. Recently, a drug specifically targeting
the G12C mutant isoform of Ras (RasG12C), but not wildtype Ras has been identified. This
compound specifically binds to RasG12C because it binds to a pocket that is only exposed on the
RasG12C mutant and alters its nucleotide preference such that it favors GDP over GTP thereby
suppressing mutant Ras signaling 12. More recently, another group has identified an inhibitor that
preferentially binds to RasG12D that demonstrated some efficacy in xenograft models re-opening
the possibility of directly targeting Ras 14.
Alternatively, instead of targeting Ras GTP binding, groups have attempted to inhibit Ras
by interfering with its localization to the cell membrane, which is required for Ras activation and
is dependent upon post-translational lipid modifications. Initial attempts to block Ras
farnesylation, demonstrated some efficacy, but, surprisingly, were only effective at inhibiting HRas localization and activation. Subsequent studies revealed that in addition to farnesylation, KRas and N-Ras can also undergo lipid modifications by geranylgeranyltransferases effectively
circumventing their dependency on farnesyltransferases for cell membrane localization and
activation 15,16.
Since targeting Ras directly has proven difficult and complicated, several inhibitors of
proteins downstream of Ras have been developed. An attempt to interfere with the interaction
between Ras and Raf was made, but the identified compound that reduced this interaction
demonstrated low efficacy in preclinical models 17. Some success has been achieved through the
development of Raf and MEK inhibitors, yet efficacy is still highly variable in tumors.
Additionally, resistance to Raf and MEK inhibitors often develops and is characterized by
reestablishment of ERK signaling suggesting that more robust disruption of Ras signaling is still
likely to be efficacious 18.
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Kinase Suppressor of Ras
Kinase Suppressor of Ras (KSR) proteins were identified more than twenty years ago in
Drosophila melanogaster (Drosophila) (KSR) and C. elegans (KSR1 and KSR2) and shown to
modulate Ras-mediated signaling 19-21. It was immediately recognized that KSR had a larger
effect on signaling from mutant Ras than wildtype Ras. This result was counterintuitive as the
more robust signal from constitutively active Ras was thought to be more difficult to repress than
signals from wildtype Ras. This is intriguing as it opens the possibility of selectively targeting
Ras-mutated tumors through KSR 22. In Drosophila, heterozygous mutations in KSR reverted the
phenotype of a mutant, constitutively active form of Ras (RasG12V), which demonstrates the
ability of KSR to suppress mutant Ras signaling 21. Several groups have shown that KSR acts
downstream of Ras as a molecular scaffold for the Raf/MEK/ERK kinase cascade to promote
downstream Ras signaling unless KSR is significantly overexpressed 23-37. Therefore, the name
Kinase Suppressor of Ras is a misnomer as endogenous levels of KSR promote Ras signaling,
while only substantial overexpression of KSR serves to suppress Ras signaling. Therefore, KSR
plays a role in regulating several cellular mechanisms to promote cell proliferation and survival
including increasing the metabolic capacity, cell cycle re-initiation following DNA damage
repair, and translational regulation of key mediators that promote the transformation such as
MYC 3,33,38-42. However, the mechanisms behind these effects have not been fully elucidated.
Phenotypic analysis of KSR genetic inactivation
KSR proteins have been studied by genetic inactivation in several model systems. In
Drosophila, there is only one KSR protein and homozygous inactivating or truncating mutations
are lethal 21. In contrast, in a genetic screen to identify modifiers of Ras signaling, it was
discovered that heterozygous loss of ksr suppresses RasG12V signaling and prevented the
roughening of the eye that is seen with increased Ras signaling in Drosophila 21. In comparison,
two KSR proteins (KSR1 and KSR2) are present in C. elegans, as well as in mammals. KSR1 and
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KSR2 have different expression profiles in mammals and both unique and overlapping functions
43

. KSR2 is largely expressed in the brain including the pituitary. While KSR1 is also highly

expressed in the brain, it is also expressed at relatively low levels in most other tissues and has
been shown to be overexpressed in tumors 3. In all cases, KSR proteins contribute positively to
ERK phosphorylation and activation downstream of Ras 19-21; however, either due to their distinct
functions or varied expression profiles, animals lacking KSR1 or KSR2 have different
phenotypes.
Apart from a few minor defects, ksr1-/- knockout mice are fertile and otherwise
phenotypically and developmentally normal (Fig. 1.1). Ksr1-/- mice have hair follicle defects
similar to the phenotype of egfr-/- mice reinforcing the idea these proteins are within the same
pathway 24,44,45. As a result of reduced ERK signaling, ksr1-/- mice have a marginally impaired
immunological response, particularly in regards to T-cell activation 24,34,46,47. Most importantly,
ksr1-/- mice are resistant to Ras-driven tumor formation 24. This fact is demonstrated by the
reduced mammary tumor burden in ksr1-/- mice with transgenic expression of polyomavirus
Middle T-Antigen 24. Induction of skin tumors with v-Ha-Ras was also completely lost in ksr1-/mice 45. These observations demonstrate that KSR1 modulates Ras signaling in vivo, but it is
largely dispensable for normal cell survival. This selective requirement for KSR1 in Ras-driven
tumor formation makes it an attractive target for therapeutic intervention.
In contrast to the mild phenotype of ksr1-/- mice, ksr2-/- mice have reduced fertility and
become spontaneously obese 48-51 (Fig. 1.1). Although ksr2-/- mice have not been assessed for
their resistance to tumor formation, there is in vitro evidence for a role of KSR2 in promoting
tumor formation. In ksr1-/- mouse embryo fibroblasts (MEFs), ectopic expression of KSR2
restored ERK1/2 activation and mutant Ras-dependent anchorage-independent growth 52. KSR2 is
expressed in a mouse neuroendocrine cell line (Min-6) and mouse neuroblastoma/rat glioma
hybrid cell line (NG108-15) and shRNA-mediated depletion of KSR2 in these cell lines reduced
proliferation and anchorage-independent growth 52. Consistent with observations from the ksr2
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Fig. 1.1: KSR Knockout Mice. Ksr1-/- mice are largely developmentally and phenotypically
normal, yet resistant to Ras-driven transformation. Ksr2-/- mice have an abnormal metabolic
profile and become obese. (Images of KSR1 and KSR2 knockout mice were taken by Diane
Costanzo-Garvey. This figure has been previously published in 2).
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knockout mice, RNAi-mediated depletion of KSR2 in insulinoma cell lines showed decreased
ERK1/2 and AMPK activation leading to reduced metabolic activity. Therefore, while the role of
KSR2 in human cancers has not been defined, substantial evidence suggests a potential, protumorigenic role for KSR2 in cancer. However, thus far, KSR2 has not been shown to be
significantly expressed and required in any type of tumor, suggesting that while KSR2 may
possess oncogenic capabilities, its contribution in cancer may be limited due to its restricted
tissue-specific expression 52,53. Additionally, the profound differences in the phenotype of ksr1-/and ksr2-/- mice demonstrate that while there is likely significant overlap in their functions, KSR1
and KSR2 must have unique and distinct physiological roles and therefore may contribute
differently to tumorigenesis.
The role of KSR in cancer
KSR1 has been extensively implicated as playing a key role in Ras-driven cancers
3,24,29,32,38,41,42,45,52,54-56

. Consistent with its role as a molecular scaffold for the Raf/MEK/ERK

cascade, KSR1 interacts with each kinase in this cascade 31,32,57, and increasing levels of KSR1
enhance Ras signaling to a maximum point 32. As predicted of a scaffold, exceeding the optimal
cellular KSR1 expression disrupts ERK signaling and inhibits Ras transformation likely by
separating and sequestering the members of the kinase cascade from one another 32,56. Comparing
KSR1 expression in a panel of colon cancer cell lines to non-transformed human colon epithelial
cells demonstrated that colon cancer cells have increased KSR1 expression, which suggests that
enhanced ERK signaling may be accomplished, at least in part, through upregulation of KSR1 in
colorectal cancer 3. Ksr1-/- mouse embryo fibroblasts that exogenously express RasG12V are
resistant to Ras-driven transformation, maintain contact inhibition, and fail to form colonies in
soft agar 32. In preclinical, mechanistic studies, stable depletion of KSR1 using multiple shRNA
sequences reduces the ability of colon cancer cells expressing mutant K-Ras to grow in an in vitro
soft agar assay as well as in an in vivo xenograft mouse model 3. Finally, RNAi-mediated
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depletion of KSR1 robustly induces cell death in the Ras-mutated colon cancer cell line HCT116
cells, but not in non-transformed human colon epithelial cells 3. Taken together, these results
support the conclusion that KSR1 is required for mutant Ras to promote the development and
maintenance of cancer such that targeting KSR1 is likely to be selectively toxic to Ras-driven
cancers with relatively little toxicity to the patient.
Structural analysis of KSR proteins
KSR is highly conserved from invertebrates to mammals. However, Drosophila express
only one KSR protein, while C. elegans and mammals encode two members, KSR1 and KSR2
21,31

. KSR proteins are structurally related to Raf proteins; however, they have diverged to obtain

significant structural and functional differences (Fig. 1.2). KSR proteins are highly homologous,
containing five conserved areas (CA1-CA5) 21. The first conserved region on the N-terminus end
is CA1. B-Raf binding to KSR1 requires a 40 amino acid sequence within CA1 and prior MEK
binding via the CA5 area of KSR1 28,58,59. Within the CA1 domain, amino acids 25-170, termed
CA1α, contain a coiled coil and sterile-α-motif (SAM), which promotes KSR1 membrane
association that is essential for its effects on MAPK signaling 60. The CA2 is a proline-rich
region with an unknown function. CA3 is a cysteine-rich atypical C1 motif that mediates the
membrane localization of KSR by recruiting phospholipids and is largely homologous with the
CR1 cysteine-rich region in Raf 61,62. Studies on the cysteine-rich region of KSR, in contrast to C1
regions in Raf and PKCγ, have demonstrated that the KSR1 C1 domain is structurally unique,
particularly within the ligand binding region, such that KSR does not react to phorbol esters or
ceramide and does not directly interact with Ras 62. CA4 is a serine/threonine rich region
containing a FXFP motif that mediates interaction with ERK 28,63,64 and is similar to the CR2
region in Raf proteins. Interaction of KSR1 with ERK is not constitutive and requires Ras
activation 65,66. The CA5 domain in KSR proteins encodes a kinase domain highly homologous to
Raf family CR3 kinase domains 20,21. While CA5 contains a putative kinase domain, there are
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Fig. 1.2: KSR Structure. KSR proteins are structurally similar to Raf proteins with the CA3, CA4,
and CA5 regions in KSR sharing significant homology with the CR1, CR2, and CR3 regions in Raf
respectively. (This figure has been previously published in 2).
CR1-3: Conserved Regions 1-3
RBD: Ras-binding domain
CRD: Cysteine-rich domain
Ser/Thr-rich: Serine/Threonine-rich domain
CA1-5: Conserved Areas 1-5
CC-SAM: Coiled coil-sterile alpha motif domain
Pro-rich: Proline-rich domain
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multiple mutations within this domain including an important lysine to arginine exchange in a
lysine residue that is generally required for kinase activity (Table 1.1) 21,28. Substantial effort has
been exerted to clarify if KSR can or does phosphorylate any substrates within cells, and if so
whether this activity contributes to the downstream effects of KSR. The general consensus
currently is that KSR is not likely to have any biologically relevant kinase activity and instead
exerts its effects through protein-protein interactions and altered subcellular localization.
MEK1/2 bind to the CA5 region of KSR proteins and the interaction is constitutive in
both quiescent and cells activated with growth factors 57,65,66. Mutations within the CA5 region
that abrogate binding of KSR to MEK also reduce ERK signaling (Table 1.1) 19-21,57,66. However,
due to the location of these mutations either within or near the ATP binding domain, they
potentially also interfere with ATP binding or other KSR functions that may be independent of
interaction with MEK (Table 1.1). Mutation C809Y within the C terminal tail of KSR1, and distal
to the ATP binding domain, also disrupts MEK binding to KSR, yet allows for increased Rasmediated ERK signaling (Table 1.1) 56. These data suggest that the interaction between KSR and
MEK is dispensable for Ras-induced ERK signaling and raises the possibility that this interaction
reflects a negative regulatory role for KSR1 that controls the timing and spatial location of MEK
activation. The CA5 domain is also required for KSR to bind to Raf, but the mechanism is
incompletely understood 58. Another region has been identified in KSR2 between CA2 and CA3
that is required for the interaction between KSR proteins and AMPK. Mutations in this and
nearby regions reduced the binding of AMPK to KSR (Table 1.1) 50,53,59,67. Tissue-specific splice
variants have also been identified. B-KSR1 is a splice variant of murine KSR1 that is
preferentially expressed in neural tissues that largely acts like KSR1 in regards to Raf/MEK/ERK
interactions and signaling regulation, but specifically plays a role in cells within the central
nervous system 66. A truncated version of KSR2 (T-KSR2) was found in mouse testes, which may
play a role in male fertility 68.
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Mutation
W255X, R277H
G549E, P696L, Q733X
G484E
R531H
G494E
P630S, P630L
Intron 12 Change
GA generating a stop
codon following G678
C727Y
A696V
A703T
S721+10bp in N727 
frameshift
S548+4bp L50G, R51S

C359S and C362S (CRMKSR1)

CA3 domain
(amino acids 319–390)
CRM CA3 domain

Myristylated N-Terminus
KSR1 (Myr-KSR)

CRM Myr-KSR
R589M, R589L
G580V and A587T
S190, T256, T274, S297,
S320, T411, S429, S434,
S518

C540

N539

Effects
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling

Location

Species

References

CA3

C. elegans

19

CA5

C. elegans

19

CA5, ATPbinding region

C. elegans

20

CA5

C. elegans

20

CA5

C. elegans

20

CA5

C. elegans

19,20

CA5

C. elegans

20

CA5

C. elegans

20

CA5

Drosophila

21

CA5

Drosophila

21

Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Decrease constitutively active
Ras-mediated signaling
Weak disruption of
constitutively active Rasmediated signaling
Prevented the enhanced
RasV12-mediated signaling
seen with the expression of
exogenous WT KSR1, but did
not disrupt RasV12-mediated
maturation
Loss of KSR1 membrane
localization

CA5

Drosophila

21

N-terminus

Drosophila

21

CA3

Xenopus
oocyte meiotic
maturation
assays using
exogenous
mouse KSR1

61

Augments Ras signaling

CA3-Only

Mouse KSR1

61

CA3

Mouse KSR1

61

N-terminus

Xenopus
oocyte meiotic
maturation
assays using
exogenous
mouse KSR1

61

Mouse KSR1

61

Mouse KSR1

69,70

CA5

Mouse

69

N-Terminus to
the CA5
domain

Mouse

70

Truncated Cterminus,
kinase domain
preserved

Mouse

55,63,69,70

Truncated Nterminus

Mouse

55,58,63,69,70

Abolished augmented Ras
signaling
Constitutively localized to the
plasma membrane
Accelerates RasV12-induced
maturation
Expression of Myr-KSR alone
was unable to promote oocyte
maturation
Abolished the positive effect
of Myr-KSR on Ras signaling
Inactivates kinase domain and
blocks MEK binding
Decreased MEK:KSR
association
Decreased ERK activation
KSR phosphorylation sites
confirmed with mutagenesis
Suppressed ERK and MEK
activation
Interacts with MEK1
Decreased Ras signaling
(suppressed Xenopus oocyte
maturation, cellular
transformation, and
Drosophila eye development)
No effect on the activation of
ERK
Fails to interact with MEK1
Unable to bind B-Raf
Interacts with ERK2

CA3, Nterminus
CA5, ATPbinding site
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C809Y

FSFP/AAAP
DEF docking motif for
activated ERK (FxFP)
(AxAP- KSR1)

S392A, S392A/S297A

L360A/R363A (KR/AA)
L360Q/R363G (KR/QG)

S518A
(CK2 phosphorylation site)
L56G and R57S
T260A/T274A/S320A/S443A
(FBm-KSR1)
ERK-dependent S/TP sites
mutated to alanine
Loss of CA3
Frameshift mutations and
nonsense mutation that
disrupt the kinase domain
E667V, A373T

Asp-529A
DEVA mutant

C-terminal KSR1 fragment
(CTF-KSR1)
Result of caspase cleavage
during apoptosis

Lacks KSR:MEK interaction
Unable to bind B-Raf
Increased Ras signaling
Lacks KSR:ERK interaction
Decreased Ras signaling
(decreased RasG12V-induced
senescence associated βgalactosidase activity)
Required for Ras-induced
senescence
Decreased proliferative rate
with activated Ras
Increased binding to
endogenous B-Raf
Defective 14-3-3 binding
Enhanced growth-factor
mediated binding to B-Raf
Increased plasma membrane
localization even without
growth factor stimulation
Accelerates Ras-induced
oocyte maturation
Unable to promote oocyte
maturation without activated
Ras
Promotes ERK activation and
cell cycle progression
following growth factor
treatment
Abolished CK2 binding
No decrease in MEK, ERK, or
14-3-3 binding
Decreased Ras-mediated
MEK and ERK activation
No apparent effects on Ras
signaling
Biological effect is unknown
Disrupted binding of
mammalian KSR1 to
endogenous B-Raf.
Increased/Prolonged plasma
membrane localization
Increased association with BRaf
Increased Ras signaling

Disrupt or reduce AMPK
binding to KSR2

Inhibition of caspase cleavage
Reduced apoptotic signaling
in response to tumor necrosis
factor and cycloheximide
treatment due to decreased
caspase cleaved C-terminal
KSR fragments

Reduced ERK activation and
enhanced apoptotic signaling

CA5 MEK
docking site

Mouse

56-58,66,69

FXFP Motif
ERK docking
site
CA4

Mouse

56,58,64,71

CA3

Xenopus
oocyte meiotic
maturation
assays using
exogenous
mouse KSR1

38,65,72,73

CA3

Xenopus
oocyte meiotic
matu- ration
assay

74

CA5

Mouse

74

CA1

Mouse

58

CA5

Mouse

58,65

Mouse
Human

50,53,67

CA5
C-Terminus
DEVD site for
caspasemediated
cleavage

Mouse

75

C-Terminus

Mouse

75

CA3
Region
between CA2
and CA3

Table 1.1: KSR Mutations and Associated Characteristics
(This table has been previously published in 2).
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KSR proteins are molecular scaffolds of the Raf/MEK/ERK kinase cascade
Substantial evidence has demonstrated that KSR proteins act as molecular scaffolds for
the Raf/MEK/ERK kinase cascade 23-37,76. KSR promotes Raf phosphorylation of MEK 26,61,63 and
is required for maximal Ras-mediated ERK phosphorylation and activation by MEK 21,24,31,32,38,63.
Prior to experiments that controlled the level of KSR1 expression, publications reported a
conflicting role for KSR overexpression, suggesting that KSR1 could both promote and inhibit
Ras signaling 19-21,32,55,61,63,65,69,77,78. These data were consistent with the idea that KSR1 acts as a
scaffold for the Raf/MEK/ERK kinase cascade as increasing this scaffold to an optimum level
increases signaling; however, once the optimal level is exceeded, models predict that the scaffold
will dilute and sequester the individual signaling components and disrupt signaling. This dosedependent action of KSR1 was demonstrated in ksr1-/- mouse embryo fibroblasts expressing
various levels of a transgene KSR1 32. ERK signaling and proliferation, as well as KSR1
interaction with Raf, MEK, and ERK, all increased with increasing KSR1 expression until KSR1
was approximately 14-fold higher than endogenous levels in wild type mouse embryo fibroblast
cells. ERK signaling and cell proliferation then dramatically decreased, while the interaction of
Raf, MEK and ERK with KSR1 plateaued when KSR1 was further increased to a level 20-fold
higher than endogenous levels 32. When excessively high levels of KSR inhibits signaling of the
MAPK cascade, these inhibitory effects can be abrogated by overexpressing additional
components of the MAPK pathway. This was elegantly demonstrated in Drosophila S2 cells
where the overexpression of Raf and MEK in conjunction with KSR overexpression still
demonstrates robust MEK phosphorylation by Raf even with levels of KSR that would normally
interfere with MEK phosphorylation 31. These characteristics are consistent with the defining
features of scaffolding proteins 79,80. Furthermore, the scaffolding activity of KSR is both
temporally and spatial regulated allowing for additional levels of regulation of the Ras pathway.
In resting conditions, KSR1 is bound to MEK and an autocatalytic ubiquitin ligase, IMP, and is
sequestered in the cytoplasm as a result of C-TAK1 phosphorylating KSR1 at S392, which
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promotes 14-3-3 binding 57,58,65,69,72,77,81 (Fig. 1.3A). The crystal structure of KSR2 kinase domain
bound to MEK demonstrated that these proteins interact at two primary locations: the activation
segments within their kinase domains and the alpha G helixes on the C-terminal lobe of each
protein 26, and mutations within the alpha G helix of MEK 58, or mutations that either disrupt the
secondary structure of or are within the alpha G helix of KSR inhibits the binding of KSR to
MEK (Table 1.1) 26. Of note, when KSR is bound to MEK, the activation segments of both
proteins are constrained. MEK cannot be phosphorylated and activated, and KSR is in an inactive
conformation 26. This inactive state may reflect KSR1:MEK heterodimers in the cytoplasm of
quiescent cells. Upon Ras activation, Raf is phosphorylated, and PP2A dephosphorylates KSR1 at
S392, such that 14-3-3 no longer binds 82 (Fig. 1.3B). IMP dissociates simultaneously from
KSR1, interacts with GTP-bound Ras, autoubiquitinates, and is targeted to the proteasome for
degradation 81 (Fig. 1.3B). KSR1 is then free to move to the plasma membrane with MEK in tow
23,31,32

(Fig. 1.3C). The localization of KSR1 to the plasma membrane is dependent upon its

interaction with Caveolin-1 and is required for KSR1-mediated ERK activation and Ras-driven
transformation 36. Once KSR1 localizes to the plasma membrane, MEK is phosphorylated by
activated Raf 23,31,32,61,83. Based on the observation that KSR1 bearing C809Y mutations fails to
interact with MEK and promotes ERK activation better than wildtype KSR1, MEK is predicted to
phosphorylate ERK when it is dissociated from KSR1 (Table 1.1). Once phosphorylated by
MEK, ERK interacts with KSR1, and this interaction is required for normal ERK signaling 56,58
(Fig. 1.3D). The sustained and coordinated activation of ERK ultimately promotes the
transformation, survival, and proliferation of Ras-driven cancer cells 24,32,39,45. The activation of
ERK also controls a negative feedback loop, in which activated ERK when bound to KSR1
phosphorylates and inhibits both KSR1 and B-Raf 58,84. This phosphorylation by ERK causes
KSR1 and B-Raf to dissociate from the plasma membrane and halts additional ERK activation.
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Fig. 1.3: KSR1 as a scaffold for the Raf/MEK/ERK kinase cascade. (A) When Ras is bound to
GDP and inactive, KSR1 is constitutively bound to MEK1/2 and IMP and is phosphorylated (yellow
circle) at S392 by C-TAK1 allowing for 14-3-3 binding and cytoplasmic sequestration. (B) Upon Ras
activation, PP2A dephosphorylates KSR1 at S392 causing 14-3-3 and IMP to dissociate and IMP to
autoubiquitinate and be degraded. (C) Through interaction with caveolin-1, KSR1 and MEK1/2 then
move to the plasma membrane where Raf activates MEK1/2 by phosphorylation at S217/S221. (D)
MEK1/2 then dissociates from KSR1 and activates ERK1/2 through phosphorylation at T202/Y204
and T185/Y187. Activated ERK1/2 then associates with KSR1, which allows ERK1/2 to
phosphorylate KSR1 and Raf and initiate a negative feedback loop. (This figure has been previously
published in 2).
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KSR proteins form heterodimers with Raf proteins to regulate MEK and ERK activation
Dimerization of Raf proteins is thought to be crucial for wildtype Raf activation. This
dimerization is not unique to Raf proteins within the MAPK pathway as both Ras and ERK have
also been shown to form dimers 85-89. The similarity between KSR and Raf proteins is
specifically conserved within the region required for Raf dimerization, and KSR has been shown
to form heterodimers with Raf, particularly B-Raf 26,54,83. This dimerization regulates an allosteric
conformational change in KSR that allows for the phosphorylation of MEK 26. Specifically, when
KSR forms a dimer with a Raf protein (cis interaction), the conformational change in KSR
facilitates the exposure of the activation site on MEK and allows for its phosphorylation.
However, the dimerization of KSR and Raf orients the Raf protein such that the catalytic site of
Raf is not in proximity to its phosphorylation target site on MEK 26. Therefore, this
phosphorylation must be completed by another Raf protein (trans interaction) 26. More recently,
it has been shown that KSR2 is also able to homodimerize through a side-to-side interface that is
specifically dependent upon Arg718 26. In a genetic screen, mutations at this site were previously
shown to suppress Ras signaling, suggesting that dimerization of KSR proteins is required to
promote Ras signaling 19-21. This is consistent with results demonstrating that mutations that
inhibit the KSR-Raf heterodimerization decrease Raf activity (Table 1.1) 83; however, the
functional role of KSR homodimers is still incompletely understood.
The effects of Raf kinase inhibitors on KSR and Raf dimerization
Raf kinase inhibitors were developed in the hopes they would be able to suppress Ras
signaling even in the presence of oncogenic, activating Ras or Raf mutations. Unfortunately,
while these inhibitors were shown to strongly antagonize Raf activity in RafV600E mutant cells,
paradoxical increases in Raf activity and downstream signaling were often seen in cells with Ras
or Raf mutations following treatment with Raf kinase inhibitors 90-92. Several follow-up studies
demonstrated that this effect was due to increased Raf dimerization and subsequent activation
90,92-94

. This led to several studies that revealed there are multiple classes of Raf mutations
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including highly activating mutations (e.g. V600E) that resulted in constitutively-activated,
monomeric Raf, in addition to mutations that only weakly improved the catalytic activity of Raf
or even decreased it, yet promoted Raf dimer formation and therefore increased subsequent Raf
activation 90,92. Initial Raf kinase inhibitors targeted kinase activity and therefore were largely
only functional against the highly activating Raf mutations 92. It is important to note, that Raf
inhibitor binding also demonstrated inverse cooperativity as binding of the inhibitor to one Raf
protein in a Raf protein dimer, decreased the affinity of the other Raf protein to inhibitor binding
95,96

. The initial Raf inhibitors also promoted increased dimer formation, such that the use of Raf

inhibitors could cause paradoxical Raf activation by promoting Raf activation through
dimerization, while only inhibiting one Raf protein within the dimer and leaving the other
catalytically active.
Raf inhibitors also promote KSR1-B-Raf heterodimer formation 27. In this manner, KSR1
can compete with other Raf proteins (C-Raf) for inhibitor-induced dimerization to B-Raf. The
dimerization between C-Raf and B-Raf promotes ERK signaling; however, complex formation of
KSR and B-Raf actually limits ERK activation 27. This suggests that high KSR expression in cells
being treated with Raf kinase inhibitors may actually limit paradoxical, rebound ERK activation
downstream of inhibitor-induced Raf dimerization and activation. While dimerization of B-Raf
with KSR2 has been shown to allosterically alter the orientation of KSR2 into a more
catalytically active conformation, KSR expression reduced Raf inhibitor-induced paradoxical
ERK signaling, which suggests that the overall effects of KSR in this scenario are not likely to be
a result of its kinase activity, but instead are a consequence of its interaction with B-Raf 27.
Non-Canonical Functions of KSR Proteins
Recent work has demonstrated additional functions for KSR that are either independent
of or downstream of its role as a scaffold for the Raf/MEK/ERK kinase cascade. Both KSR1 and
KSR2 have been shown to promote AMPK expression or activity 3,34,50,52. While the role of
AMPK in cancer is still controversial, multiple groups have shown that after transformation,
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AMPK can promote tumor cell survival by mediating an increase in the overall metabolic
capacity allowing the cells to survive in stressful conditions. One mechanism by which this
occurs is through the upregulation of PGC1β and its transcriptional partner ERRα 3,41. An
additional KSR-regulated mechanism promoting the expression of PGC1β has recently been
described where KSR1 promotes ERK activation in colon cancer cells, which is required for
increased MYC translation. MYC then acts as a transcription factor and increases PGC1β
transcript levels 42. KSR proteins also play a role as overall metabolic regulators in cells by
regulating glucose metabolism 40 and adipogenesis 33. The scaffold function of KSR1 promotes
adipogenesis by coordinating the timing and intensity of ERK-dependent p90 RSK activation
with the expression of its key adipogenic substrate C/EBP. Defective adipogenesis in vitro
caused by loss of KSR1 can be rescued by adding back low levels of KSR1. Increasing KSR1
levels above the optimal level inhibits adipogenesis through sustained ERK signaling while
inducing the phosphorylation and inhibition of the key adipogenic transcription factor PPAR33.
The presence of a kinase domain within the CA5 region of KSR has led numerous groups
to examine the potential of KSR to act as a kinase. Initial reports suggested KSR was a ceramideactivated kinase 97 even though amino acids critical for phosphotransferase activity, including the
lysine involved in exchange of the gamma phosphate of ATP with a substrate, are not conserved
within the kinase domain of KSR proteins 21,43,66. More recently, a crystal structure of the kinase
domain of KSR2 and MEK1 with ATP bound within the catalytic site combined with in vitro
assays and chemical genetics data suggested KSR2 has the potential to phosphorylate MEK 26.
However, the evidence supporting a role for KSR as a kinase has shown very low levels of
substrate phosphorylation in vitro (low stoichiometry), has demonstrated phosphorylation on sites
different than those required to activate MEK, has largely been based on experiments performed
outside of cellular systems, and may be a consequence of co-precipitating kinases as many
subsequent experiments have demonstrated KSR1 lacks catalytic activity 61,70. This raises the
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question as to whether any residual intrinsic kinase activity, if present, within KSR proteins has
biological relevance. Expression of the isolated kinase domain of KSR inhibited ERK signaling
and suppressed Ras-dependent Xenopus oocyte maturation, cellular transformation, and
Drosophila eye development 63. This supports the role of KSR proteins as molecular scaffolds,
where the isolated expression of the CA5 domain, which could only bind and sequester MEK, but
not regulate its cellular localization or coordinate interactions with Raf, would be expected to
antagonize MAPK signaling 57,63,69. In contrast, the conservation of the binding site residues for
ATP within KSR and the prevalence of mutations within the ATP binding pocket in loss-offunction KSR mutants do suggest that ATP binding itself may play an important role in KSR
activity (Table 1.1) 20,21,63. Thus, KSR proteins have largely been considered pseudokinases.
KSR1 has been shown to travel through the nucleus when in complex with MEK 98. The
functional significance of this subcellular localization is unknown, but may facilitate activity of
ERK toward nuclear substrates. Further investigation may provide additional understanding of the
complex role KSR plays in modulating ERK signaling as well as other processes. These and
additional undiscovered pathways could reveal novel approaches for targeting of KSR-dependent
actions specific to tumor cell maintenance.
KSR as a Target for Therapy
Based on the role KSR1 plays in modulating signaling through the Raf/MEK/ERK kinase
cascade, and the fact that ksr1-/- mice are largely phenotypically normal, inhibiting KSR1 in Rasdriven cancers appears to be a reasonable approach to selectively target cancer cells without
subjecting patients to the side effects that normally accompany chemotherapeutics. Supporting
this strategy, RNAi approaches depleting cancer cells of KSR both within in vitro and in vivo
models demonstrated a decrease in tumor growth 3. Further, a continuous infusion of
phosphorothioate antisense oligonucleotides that inhibited KSR1 expression caused regression of
established tumors and inhibited metastases without overt toxicity in Ras-driven PANC-1
pancreatic and A549 non-small cell lung cancer xenografts in nude mice 99.
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Recent studies have attempted to target KSR proteins directly for therapy. The small
molecule APS-2-79 is able to bind and stabilize KSR in an inactive state, interfere with KSR:Raf
heterodimerization, and inhibit oncogenic Ras signaling 54. Based on the finding that mutations in
KSR that suppress oncogenic Ras signaling largely mapped to a region adjacent to the ATPbinding pocket, it was hypothesized that a small molecule that bound KSR within the ATPbinding pocket could interfere with Ras signaling. APS-2-79 blocks heterodimerization with Raf
and conformationally biases KSR towards an inactive state 54 similar to the conformation of the
KSR2 kinase domain bound to MEK1 and ATP 26. In this conformational state, MEK cannot be
phosphorylated because the active segments of both MEK and KSR2 interact directly with
additional stabilization provided by interactions between the alpha G helices on the C-terminal
lobe of each protein 26.
The efficacy of APS-2-79 has been demonstrated with a simplified cell-based
reconstitution system that monitored KSR-dependent MEK and ERK signaling. KSR enhanced
MEK phosphorylation at Ser218/Ser222 by Raf in a dose-dependent manner. This increased
phosphorylation was inhibited by APS-2-79, but not a similar small molecule that due to small
modifications was no longer able to bind to KSR2. The effect of APS-2-79 was also lost when
KSR was mutated within the active site (A690F) such that KSR can promote MEK
phosphorylation even in the absence of ATP binding. APS-2-79 had no ability to affect MEK
phosphorylation in the absence of KSR, suggesting that the effect of APS-2-79 on ERK signaling
is dependent on KSR, and APS-2-79 does not inhibit MEK phosphorylation by interacting
directly with Raf proteins even though Raf shares a high degree of homology with KSR1 and
KSR2 54. Unfortunately, APS-2-79 was only modestly able to decrease cell viability in two Rasmutated cancer cell lines (HCT116 and A549) and did not affect Raf-mutated cancer cells (A375
and SK-MEL-293) 54. In contrast to APS-2-79 treatment, in HCT116 cells, transient siRNAmediated depletion of KSR1 dramatically reduced viability in vitro and stable shRNA-mediated
depletion of KSR1 reduced tumor growth in vivo 3. There are several reasons that may explain the
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discrepancy between APS-2-79 treatment and RNAi-induced protein loss. The ability of APS-279 to bind and directly inhibit KSR1 has not yet been demonstrated, and therefore it may not bind
and inhibit KSR1 as well as it binds to KSR2, potentially limiting its efficacy in cancer cell lines
that express high levels of KSR1. The limited efficacy of APS-2-79 could also result from
compensation by alternative MAPK pathway scaffolds. Several scaffolds have been shown to
allow for increased Ras-mediated signaling such as IQ motif-containing GTPase activating
protein 1 (IQGAP1), Sef, dystroglycan, β-arrestin, MEK partner 1 (MP1), and Paxillin
29,79,80,85,86,100

. However, this possibility is less likely as the RNAi-mediated depletion of KSR1

robustly disrupts Ras signaling even with potential compensation by other scaffolds. It is also
possible that APS-2-79 only inhibits a subset of KSR-dependent signaling events and therefore is
less effective than RNAi-mediated depletion of KSR1. Interestingly, APS-2-79 treatment shows
substantial synergy with the MEK inhibitor trametinib in Ras-mutated, but not Raf-mutated,
cancer cells. This observation suggests that robustly inhibiting Ras-mediated ERK signaling in
conjunction with inhibition of non-canonical components of KSR1-dependent signaling is
efficacious though the exact mechanism behind this combinatory effect is not known 54.
Demonstrating the ability of APS-2-79 to bind and inhibit KSR1, as it was only tested against
KSR2, and evaluating its ability to suppress both canonical and non-canonical KSR1-dependent
effects will be important moving forward.

Alternative Approach to Identify Novel Effectors of Ras-driven Tumorigenesis
Despite being identified more than 20 years ago, the functions of KSR proteins and the
mechanisms by which they modulate Ras signaling and promote cancer cell survival are still not
fully understood. It is well established that KSR acts as a scaffold for the Raf/MEK/ERK kinase
cascade and promotes phosphorylation and activation of Ras downstream effectors through
protein:protein interactions and subcellular trafficking. However, fully understanding the
dynamics of these interactions, the regulatory mechanisms controlling KSR subcellular
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localization, and the regulation of KSR expression in cells is vital because KSR has the potential
to both promote and inhibit ERK signaling. This behavior is consistent with KSR acting as a
scaffold protein and suggests that since KSR modulates Ras signaling in normal cells, KSR itself
must be tightly regulated. These regulatory mechanisms, while likely still at play in cancer cells,
are at least somewhat disrupted as evidenced by increased KSR1 protein expression. This
increased expression in cancer and selective requirement for KSR1 for cancer cell survival, but
not normal cell survival, suggests that KSR1 would be a selective, efficacious therapeutic target
in pancreatic, colon, and lung cancers where Ras mutations are commonly required for tumor
growth and survival.
Recent work has further characterized KSR proteins, and several new functional and
physical interactions have been identified. The introduction of Raf inhibitors has expanded the
understanding of KSR:B-Raf heterodimerization and the mechanisms behind Raf activation. The
recent publication by Dhawan et al. demonstrated the possibility of targeting KSR proteins with a
small molecular inhibitor that stabilizes KSR in an inactive state to effectively limit Ras
signaling. The limited efficacy of APS-2-79 as monotherapy against Ras- and Raf-mutated cancer
cells is disappointing; however, more selective targeting of KSR1 may substantially improve its
effectiveness and is still a viable therapeutic approach based on the promising signaling studies.
However, studies on Raf inhibitors has also highlighted the complex nature of these signaling
pathways and the potential for paradoxical re-activation of Raf, which may complicate the
targeting of KSR as well. Thus, it will be important to examine the effects of KSR inhibition in a
global context, particularly in light of the potential for side effects given the obesity phenotype
seen in KSR2 knockout mice and evidence that KSR expression antagonizes Raf kinase inhibitorinduced Raf dimerization and paradoxical activation.
Therefore, identifying additional targets that represent selective vulnerabilities that are
only present in cancer cells provides the opportunity for the development of novel therapeutics
that would possess a large therapeutic index with the potential to dramatically improve both
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patient outcomes and quality of life while undergoing treatment. To identify additional genetic
targets that, like KSR1, are selectively required in cancer cells, but not in normal cells, KSR1 was
applied as a positive control to a functionality-based genome-scale screen termed Functional
Signature Ontology (FUSION). FUSION identified numerous potential therapeutic targets based
on Euclidean distance and Pearson correlation similarity metrics, which were further filtered and
prioritized based on bioinformatic analysis. Biological validation of the prioritized hits
demonstrated an increased requirement for these targets in cancer cells as compared to normal
cells. Targets were further evaluated to elucidate their mechanisms of action in cancer and
evaluate their potential to serve as therapeutic targets either independently or in combination with
current therapies for the treatment of cancer.
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Chapter 2: Materials and Methods
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FUSION Analysis
Only abbreviated methods describing the experimental completion of the FUSION screen
that are required to understand the computational and bioinformatic analysis that is the topic of
Chapter 3: FUSION are included as the genome-scale screen was previously completed by Dr.
Kurt Fisher and its methods are fully described in his dissertation and published manuscripts
3,42,101

.

FUSION Screen Experimental Details
Gene expression for genes within the KSR1-depletion genes expression-based signature
(BNIP3, NDRG1, ACSL5, ALDOC, and BNIP3L) and control genes (PPIB and HPRT) was
measured using the Affymetrix Quantigene 2.0 Multiplex assay. This assay captures and
amplifies the signal using branched DNA, such that the gene expression can be easily quantified
by measuring fluorescence using a Luminex instrument following the addition of streptavidin
phycoerythrin.
The screen used siRNA pools from the Dharmacon siGenome library that were predicted
to target a single genetic target to individually knockdown 14,355 unique genetic targets. This
was robotically performed simultaneously in biologic triplicate on three 384-well plates. The
plates were processed in the following groups: #1: 1-5, 20-22; #2 6-13; #3: 14-19, 23, 24; #4: 2532; #5: 33-40; #6: 41-44; #7: 66-67.
Data Preprocessing
Data preprocessing consisted of acquiring all the original data files and ensuring they
were formatted consistently so they could be processed in an automated fashion. R scripts were
used to read and integrate the data. Then the data was reformatted and scrubbed so that it could be
computationally analyzed. Once the data was fully integrated and formatted, the values were
background subtracted using “blank” wells (40 μl of water and 30 μl of hybridization solution),
and geometric mean normalized to the housekeeping genes (PPIB and HPRT). Negative numbers

27

were set to the probe minimum on each plate. All processing was completed for each biological
replicate individually and on the average of the three biological replicates. At each stage,
intermediate data files were generated and saved for future review if needed.
Outlier Detection
Control wells were excluded if their raw PPIB value was less than 1000. Outliers from
the repeated wells (i.e., control and KSR1 depleted wells) were identified using the grubbs.test
algorithm in R. Minimum number for control wells per plate was set to 6 and for KSR1-depleted
targets per group was set to 20. Outlier wells for all individual gene depletions were identified
based on variability between replicates and excluded from results based on the biological
replicate precision filter described in Chapter 3: FUSION.
Accuracy, Precision, and Scalability
To assess the validity of the screen algorithms, three measures were used: accuracy,
precision, and scalability. To measure the accuracy, the previously biologically validated hits was
used. Since these have already been validated and been shown to be KSR1-like, they are expected
to be in the top results (cutoff was top 5% of results). To measure precision, the ability for
siKSR1 replicates to cluster was evaluated visually by plotting the siKSR1 positive control values
by Euclidean distance and Pearson correlation similarity metrics. Scalability refers to the
consistency between results regardless of the number of plates used. For example, the results
should be relatively consistent if 25%, 50% of all the plates are included in the analysis. This was
evaluated by plotting the Euclidean distance similarity metric for the data from the kinome plates
for each normalization method after processing and normalizing the data using only the three
plates from the kinome or the entire genome-scale dataset. The correlation between the results
from the kinome-only processing/normalization compared to the results from the genome-scale
dataset processing/normalization was calculated.
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Normalization
Each normalization method was completed and evaluated on a per plate, group, or whole
assay basis. Normalization was completed based on the reporter median, plate position, or
negative controls. Normalization to reporter median is completed by finding the median value for
each individual gene within the KSR1-depletion signature from each plate, group, or across the
whole assay. Each gene reading is then divided by the median value for that given gene. For plate
position normalization, the same method is employed, but the median is determined for each row,
column, or both (if more than one plate is being evaluated). Normalization to negative controls is
performed by finding the median value for each gene within the KSR1-depletion signature from
the negative control (non-targeting siRNA/siControl) wells. After normalization, the data
underwent log base 2 transformation.
Calculate Similarity
The positive control (siKSR1) target was the average of the KSR1-depleted wells from
each experimental group/batch after outliers were excluded. Euclidean distance and Pearson
correlation metrics were calculated using the rdist and cor functions in R.
Calculate Viability Filter
The viability filter is based on the decrease in PPIB with a given gene depletion relative
to the average PPIB in the control wells. Based on the geomean normalized values for each
replicate individually and for the average of the three replicates, the PPIB decrease was calculated
as follows:
PPIB Decri = 1 - PPIBi/PPIBCONT

Cell Culture
Colorectal cancer cell lines HCT116, LoVo, RKO, HCT15, SW480, SW620, T84, and
Caco2 were purchased from American Type Culture Collection (ATCC). Cells were grown in
Dulbecco’s Modified Eagle’s Medium (DMEM) containing high glucose and L-glutamine with
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10% or 20% (Caco2) fetal bovine serum (FBS). All colorectal cancer cells were grown at 37°C
with ambient O2 and 5% CO2. Immortalized non-transformed human colonic epithelial cell lines
(HCEC) and HCEC exogenously expressing G12V mutant H-Ras (HCECs + Ras) were a gift
from J. Shay (UT Southwestern) 102. HCECs and HCECs + Ras were grown in medium composed
of 4 parts DMEM to 1 part media 199 (Sigma-Aldrich) with 2% cosmic calf serum (GE
Healthcare), 25 ng/mL EGF, 1 μg/mL hydrocortisone, 10 μg/mL insulin, 2 μg/mL transferrin, and
5 nM sodium selenite. HCECs were grown in a hypoxia chamber with 2% O2 and 5% CO2 at
37°C. In some cases, additional supplementation with l-glutamine/gluta-max (1%), non-essential
amino acids (1%), penicillin-streptomycin (1%), gentamicin (final concentration of 50 μg/mL),
and/or Fungizone (amphotericin B solution final concentration of 0.25-2.5 μg/mL) was used.
When used the additional reagent and concentration used are specified in the respective methods
sections.

siRNA Reverse Transfections
Pooled or individual (Table D.1) ON-TARGET plus siRNAs (DharmaconGE) were
introduced into the cell lines listed above following the Lipofectamine RNAiMAX (Invitrogen)
reverse transfection protocol and as described: 5 μL of RNAiMax was added to 2 mL of cells in
normal culture media (150,000 cells/mL), 500 μL Opti-MEM media in 6-well plates with a final
RNAi concentration of 40 nM. HCECs were transfected following the RNAiMax reverse
transfection protocol using 5 μL RNAiMax transfection reagent per 3-5 mL of media and 100,000
cells/mL with a final RNAi concentration of 20 nM in 6 cm plates (CorningTM, PrimariaTM) or on
6-well plates. After a 72-hour transfection, cells were lysed in RIPA lysis buffer with protease
and phosphatase inhibitors as described in the Western Blot Analyses section.

cDNA Forward Transfections
200,000-500,000 cells were plated on 6-well plates with one well for each forward
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transfection or experimental condition. When cells were 50-90% confluent (usually 24 hours after
plating) depending on your experiment/timeline, add transfection reagents. Transfection reagents
are made in two parts, first 2.5-10 μg of plasmid is added to OptiMem to a final volume of 250
μL. Second, 5-12.5 μL of Lipofectamine 2000 is added to OptiMem again to a final volume of
250 μL. The contents of the first tube (containing plasmid) was added to the second tube
(Lipofectamine 2000 and OptiMem) and were inverted 3 times to mix and incubated for 5
minutes. The entire 500 μL mixture was added dropwise to the cells on the 6-well plate. Cells
were collected 24-72 hours after transfection.

Circadian Rhythm Cell Synchronization
Cells were circadianly synchronized by treating with 50% horse serum for 2 hours, 10
μM forskolin for 30 minutes, or 100 nM dexamethasone for 30 minutes. Cells were then collected
at the end of the treatment (0 hr) and every four hours for the next 24-48 hours. For each
collection, the media was collected, cells trypsinized and pelleted. The cell pellet was rinsed with
PBS and repelleted. The pellet was then snap frozen in liquid nitrogen and stored at -80C until all
samples could be lysed in RIPA lysis buffer with protease and phosphatase inhibitors (described
in Western Blot Analysis section) and analyzed by western blot.

Anchorage-independent growth on poly-2-hydroxyethyl methacrylate (polyHEMA)-coated plates
10 mg/ml polyHEMA stock solution was made by dissolving polyHEMA in 95% ethanol
and shaking at 37°C until fully dissolved (6 hours to overnight). 96-well plates were coated with
polyHEMA by evaporating 100-200 μl of the 10 mg/ml stock polyHEMA solution in each well.
Cells were plated in complete medium on polyHEMA-coated wells at a concentration of 1.5-2 x
104 cells/100 µl 48 hours post-transfection (as described above). Cell viability was measured per
the manufacturer’s protocol using the CellTiter-Glo® Luminescent Cell Viability Assay
(Promega). Specifically, this was done by adding 90 µl of CellTiter-Glo® reagent, shaking for
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two minutes to lyse the cells, incubating at room temperature for 10 minutes, and measuring
luminescence (POLARstar OPTIMA).

Cell growth assay
5,000-10,000 (HCEC, LoVo, T84, Caco2) cells/well were transfected on white or clear
96-well plates. Transfections were done as described above but at a ratio of 1:25 for all of the
reagents. At 72 or 96 (start with half as many cells) hours post-transfection, 10 μL of
alamarBlue® (ThermoFisher Scientific) was added to each well (100 μL) or 100 μL of
alamarBlue® was added per mL of media and media was removed from the 96-well plate and
replaced with the alamarBlue®/media mixture. Plates were incubated at 37°C for 1-3 hours and
fluorescence was measured (POLARstar OPTIMA). Results were background subtracted (well
with media + alamarBlue® without any cells) and normalized with the control being set to 1. In
other instances, cell viability was measured per the manufacturer’s protocol using the CellTiterGlo® Luminescent Cell Viability Assay (Promega). Specifically, this was done by adding 90 µl
of CellTiter-Glo® reagent, shaking for two minutes to lyse the cells, incubating at room
temperature for 10 minutes, and measuring luminescence (POLARstar OPTIMA).

Cell Count
Adherent cells were counted by removing the media, washing the cells gently with PBS,
and trypsinizing the cells. The total volume of trypsin and media cells were resuspended in was
kept consistent across samples and noted for total cell number calculations. At each time point,
cells were then counted either manually using a hemocytometer or using a Coulter Counter to
obtain a concentration of cells. This was then multiplied by the total volume of suspended cell
mixture to obtain a total cell count.

Sensitization Studies with IR or 5-FU
2,500 (or 5,000 for slower growing cell lines: HCEC, LoVo, T84, Caco2) cells/well were
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plated or transfected on white or clear 96-well plates or 200,000 cells were plated/transfected on
6-well plates. Transfections were done as described above but at a ratio of 1:25 for 96-well plates.
At 24 hours, drug was added if included in the experiment. At 48 hours, 3-5 Gy gamma IR was
applied to the cells in a single dose (RS-2000 Irradiator). At 96 hours after plating, alamarBlue®
(ThermoFisher Scientific) was added to each well (100 μL alamarBlue/1 mL media) or cells were
collected for western blot analysis. Plates were incubated at 37°C for 1-3 hours and fluorescence
was measured (POLARstar OPTIMA).

Colony Forming Assay
250-500 (HCEC, LoVo, T84, Caco2) cells were plated on 12-well or 24-well plates. Drug
was added 24 hours later and replaced as needed. Media containing Fungizone (Amphotericin B –
2.5 µg/mL final conc.) and gentamicin (50 µg/mL final conc.) was used. 10-14 days later, cells
were rinsed with PBS, and methanol for 20 minutes to fix the cells. Cells were rinsed with water
and incubated in Giemsa Stain (diluted 1:10-1:20) for 5 minutes. Cells were washed with gently
running water. Plates were laid upside down and dried overnight. Images were taken of the
colonies using the LI-COR Odyssey imager. Cell colony number and size were quantified using
an ImageJ macro and the built-in analyze particles function.

Carboxyfluorescein succinimidyl ester (CFSE) Cell Proliferation/Division Assay
Cells were stained with CFSE by resuspending 2 million HCT116 or SW480 cells in 10
μM CFSE in PBS (1 mL total volume) in a 1.5 mL Eppendorf tube. Resuspended cells were
incubated at 37oC in the hot water bath for 15 minutes, washed once with 5 mL media, and
resuspended in 13 mL media. Two mL of cells/media (approximately 300,000 cells/well) were
added to each well on a 6-well plate on top of the siRNA transfection reagents as described
previously. After 96 hours, cells were trypsinized, pelleted, and resuspended in PBS for flow
cytometry analysis to measure CFSE staining. Remaining cells, after flow cytometry analysis,
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were used in western blot evaluation to confirm target gene depletion.

Propidium Iodide
Cells were assessed for apoptosis using the sub-G1 peak and percent of cells in each
phase of the cell cycle as measured by flow cytometry following propidium iodide (PI) staining.
Prior to staining, all media in the sample well was collected and placed in a 12 x 75 mm round
bottom polystyrene tube (BD Falcon, 352054). Cells were washed once with PBS, the PBS was
saved, and cells were subsequently treated with 0.25% trypsin for 5 minutes. Media was then
used to resuspend the trypsin-treated cells, which were collected and placed in the polystyrene
tube. Cells were pelleted by centrifugation for 5 minutes at 2800 RPM using an Immunofuge II.
The media was aspirated, and the cells were fixed in 1 mL of ice cold 70% ethanol overnight at 20°C. Cells were then warmed to room temperature (~15 minutes on bench), pelleted by
centrifugation for 5 minutes, then rehydrated in 1 mL of room temperature PBS and incubated at
37°C for 15 minutes. Cells were then pelleted, the PBS aspirated, and the cells were resuspended
in PI stain overnight. Data was acquired using a Becton-Dickinson FACSCalibur flow cytometer
and analyzed using FlowJo Cell Cycle analysis to detect the percentage of cells in the sub-G1
peak, 2N peak/G1 phase, S phase, and 4N peak/G2 phase.

RT-qPCR
RNA was harvested using 1 mL TriReagent (MRC, TR118) and stored at -80C until
extraction. RNA was extracted per manufacturer’s protocol and final RNA was eluted with
nuclease-free water. RNA was quantified using the NanoDrop 2000 (Thermo Scientific). Reverse
transcription was performed using iScript™ Reverse Transcription Supermix for RT-qPCR (BioRad, 170-8840) with 1 μg of total RNA per 20 μL reaction. RT-qPCR was performed using the
primers and conditions listed in Table 2. All targets were amplified using SsoAdvanced™
Universal SYBR Green Supermix (Bio-Rad) with 40 cycles of a 2-step program (95°C x 5 sec,
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Tm x 45 sec). Primer sequences used are specified in Table D.2.

TCGA
mRNA expression was analyzed based on the FPKM-UQ normalized RNASeq values of
normal solid tissue samples and primary tumors from within The Cancer Genome Atlas (TCGA)
Breast Invasive Carcinoma (BRCA)(Number of Samples from Normal N=113 and Primary
Tumor N=1102), Colon Adenocarcinoma (COAD) (N=41 and N=478 samples with 456 unique
patients), Lung Adenocarcinoma (LUAD)(N=59 and N=533), Lung Squamous Cell Carcinoma
(LUSC)(N=49 and N=502), Glioblastoma (GBM)(N=5 and N=156), Prostate Adenocarcinoma
(PRAD)(N=93 and N=498), Pancreatic Ductal Adenocarcinoma (PAAD)(N=4 and N=177),
Sarcoma (SARC)(N=2 and N=259) datasets and primary tumors only from Ovarian Serous
Cystadenocarcinoma (OV)(N=374) and Cervical Squamous Cell Carcinoma (CESC)(N=304)
datasets. Results were analyzed for statistical significance using unpaired (unmatched samples)
and paired (patient-matched samples) Student’s t tests.

Western Blot Analysis
Whole cell lysate extracts were prepared in radioimmunoprecipitation assay (RIPA)
buffer comprised of 50 mM Tris-HCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% Na dodecyl
sulfate, 150 mM NaCl, 2mM EDTA, 50 mM NaF, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 2
mM EDTA, 1 mM PMSF. Nuclear and Cytoplasmic lysates were obtained using the
ThermoFisher NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (78835, ThermoFisher
Scientific) based on the manufacturer’s protocol and the 100X Halt Protease and Phosphatase
Inhibitor Cocktail (ThermoFisher Scientific 78440). Protein concentration was determined using
the Promega BCA protein assay. SDS-PAGE was performed, membranes were blocked in
Odyssey PBS blocking buffer (LI-COR Biosciences, 927-40000), and incubated in primary
antibody (listed below) overnight at 4°C. LI-COR secondary antibodies (IRDye 800CW, 680LT,

35

or 680RD) were diluted 1:10,000-1:50,000 in 0.1% TBS-Tween (for nitrocellulose). Membranes
were imaged using the LI-COR Odyssey.

In vitro kinase assay
AMPK assays were performed by diluting 20 ng of AMPKα1β1γ1and 60 ng of
AMPKα2β1γ1 in 5 µl of 10 mM MOPS (pH 7.2), 5 mM β-glycerophosphate, 10 mM MgCl2, 2
mM EGTA, 0.8 mM EDTA and 0.1 mM DTT, 80 ng/µl BSA and 8% glycerol and placing them
on ice. 5 µl of AMP (480 µM final in water), drug or DMSO diluted in water (1:10,000 nM final),
1 mg/ml SAMS substrate (in water) and -32P-ATP (40-500 µM final dilution in 25 mM MOPS
pH 7.2, 12.5 mM β-glycerophosphate, 25 mM MgCl2, 5 mM EDTA, 2 mM EGTA and 0.25 mM
DTT) was added. Standard assay included a 50 µM final ATP concentration. Samples were
mixed and incubated in 30C water bath for 15 minutes with gentle rocking and then returned to
ice. 20 µl of samples were spotted on P81 paper and allowed to dry. Papers were washed three
times each with 200 ml 0.1% phosphoric acid, allowed to dry, placed in a vial with scintillation
cocktail, and counted. One sample without enzyme was used to correct for non-specific binding
to the P81, which was determined to be equal to using no SAMS peptide in a mock assay.

Anchorage-independent growth in soft agar
Cells were seeded at 5 x 103 cells/35 mm dish in 1 ml of top agarose consisting of
Iscoves’s Dulbecco Modified Growth Medium (DMEM) mixed with 0.4% NuSieve GTG
agarose, 4 mM L-Glut, 1% NEAA and 1% penicillin/streptomycin suspended over a bottom layer
consisting of 2 ml of DMEM with 0.8% Nu-Sieve GTG agarose, 4 mM L-Glut, 1% NEAA and
1% penicillin/streptomycin. DMSO or 5-OH-S was placed in both top and bottom layers at a
concentration of 10 µM. Colonies over 100 microns were counted and representative
photomicrographs were taken after 14 days of incubation in 37C and 5% CO2.

Antibodies
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Primary antibodies were diluted as follows:
P-4EBP1 (T70 9455, Cell Signaling) 1:1000; T-4EBP1 (53H11, 9644, Cell Signaling)
1:1000; pACC (#3661, Cell Signaling) 1:2000; tACC (#3676, Cell Signaling) 1:2000; B-Actin
(C-4, 47778, Santa Cruz) 1:2000; pAKT S473 (9271, Cell Signaling) 1:1000; pAKT T308
(9275, Cell Signaling) 1:1000; tAKT (9272, Cell Signaling) 1:1000; pAMPKα1α2 (#2531, Cell
Signaling) 1:1000; AMPKα1α2 (#2532, Cell Signaling) 1:1000; AMPKα2 (#AF2850, R&D
systems) 1:1000, and AMPKα1 (#2795, Cell Signaling) 1:1000; AMPKβ1 (#12063, #4182,

Cell Signaling) 1:1000, and AMPKβ2 (#4148, Cell Signaling) 1:1000; AMPKγ1
(#ab32382, Abcam) 1:2000; Beclin 1 (3495, Cell Signaling) 1:1000; CDC25C (4688, Cell
Signaling) 1:1000; P-CDC25C (S216, 9528, Cell Signaling) 1:1000; P-CDC25C (T48, 9527, Cell
Signaling) 1:1000; P-CDK1 (Y15, 9111, Cell Signaling) 1:1000; T-CDK1 (77055 and 9112, Cell
Signaling) 1:1000; P-CHK1 S345 (2348, Cell Signaling) 1:1000; T-CHK1 (G-4, 8408, Santa
Cruz) 1:1000; eIF4A (C32B4, 2013, Cell Signaling) 1:1000; eIF4E (9742, Cell Signaling)
1:1000; peIF4E (S209, 9741, Cell Signaling) 1:1000; pERK (9106, Cell Signaling) 1:1000; ERK
(9102, Cell Signaling) 1:1000; ERRa (V-19, 32971, Santa Cruz) 1:1000; P-GSK3B (S9, cs55585, Cell Signaling) 1:1000; Phospho-Histone H2A.X (Ser139)(2577, Cell Signaling) 1:1000;
H2A.X (2595, Cell Signaling) 1:1000; H3K4Me3 (ab8580, Abcam) 1:1000; H3K4Me1 (ab8895,
Abcam) 1:1000, Histone 3 (ab1791, Abcam) 1:2500; HDAC2 (ab7029, Abcam) 1:5000; KSR1
(H-70, Santa Cruz) 1:1000; pMEK (4694, Cell Signaling) 1:1000; MEK (9122, Cell Signaling)
1:1000; MYC (5605, Cell Signaling) 1:1000; MDM2 (sc-965, Santa Cruz) 1:500; p53 (6243,
Santa Cruz) 1:1000; P21 (ab7903, Abcam) 1:1000; PARP (9542, Cell Signaling) 1:1000; PDCD4
(D29C6, #9535, Cell Signaling) 1:1000; PP2ACa/B (1D6, sc-80665, Santa Cruz) 1:1000; PUMA
(3041, ProSci, gift from Xu Luo lab) 1:1000; pRAPTOR (#2083, Cell Signaling) 1:1000;
tRAPTOR (#2280, Cell Signaling) 1:1000; RBBP5 (A300-109A, Bethyl) 1:1000; P-RSK (S380,
cs-9341, Cell Signaling) 1:1000; T-RSK (601225, BD Biosciences) 1:1000; TIMELESS (A300-
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961A, Bethyl) 1:5000; α-tubulin (B-5-1-2, Santa Cruz) 1:2500; ULK1 (#4773, Cell Signaling)
1:1000; P-ULK1 (S317, #12753, Cell Signaling) 1:1000; WDR5 (ab22512, Abcam) 1:1000, and
P-Wee1 (S642) (4910, Cell Signaling) 1:1000. The PGC1β antibody was a generous gift from Dr.
Ching-Yi Chang and Dr. Donald McDonell (Duke University) and was used at 1:5000 dilutions.
Anti-mouse, and anti-rabbit secondary antibodies conjugated to Alexa Fluor 680
(Invitrogen, Carlsbad, CA) or IRDye800, and IRDye680LT were used at 1:5000-1:10,000
dilutions.

Reagents
Additional reagents included recombinant AMPKα1β1γ1 (#P47-10H, SignalChem) and
AMPKα2β1γ1 (#P48-10H, SignalChem), SAMS peptide (S07-58, Cquential Solutions), and
radioactive -32P-ATP (64014, MPBIo). Poly-2-hydroxyethyl methacrylate (polyHEMA, P3932),
cycloheximide (CHX, C7698), Wright-Giemsa stain (WG16), the MYC inhibitor 10058-F4
(F3680), and propidium iodide (PI, P4170) were purchased from Sigma-Aldrich. OICR-9429 was
purchased from Caymen Chemical (1801787-56-3). WDR5-C47 was purchased from Xcessbio
(M60118-2). The RSK inhibitor BI-D 1870 was purchased from Axon MedChem (1528). The
mTOR inhibitor AZD8055 (HY_10422), Wee1 inhibitor MK-1775 (HY-10993) and CHK1
inhibitor AZD-7762 (HY-10992) were purchased from MedChem Express. The ERK inhibitor
SCH772984 was purchased from SelleckChem (S7101). Z-Leu-Leu-Leu-al (MG132, S2619) and
5-flurouracil (5-FU, AC228440010) were purchased from Fisher. The AKT inhibitor MK2206
was a gift from the Black Lab.
Constructs purchased from Addgene include: pcDNA4-Flag-TIM (22887, Addgene) and
WDR5 plasmid (#15552). Other constructs include an GIPZ WDR5 shRNA (Thermofisher
RHS4531-EG11091), pTRIPZ inducible WDR5 shRNA (Dharmacon/Fisher RHS4696200696686 Clone: V2THS-140181), and pTRIPZ inducible TIMELESS shRNA
(Dharmacon/Fisher RHS-4696-200685318 Clone: V2THS-47526).
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STR PCR Profiling for Cell Line Validation
The DNA Forensic Lab Core Facility within MMI was utilized to verify cells lines using
STR PCR Profiling. A PBS washed cell pellet (can be frozen) is needed to perform the analysis.
The results were evaluated using the ATCC tool: https://www.atcc.org/STR%20Database.aspx

Statistical Analyses
P values were calculated using Prism Software (GraphPad, La Jolla, CA). A P value of
less than 0.05 was considered statistically significant. Values presented as bar plots are shown as
mean +/- standard deviation (SD) unless otherwise noted.
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Chapter 3: Evaluation of a Functional Signature Ontology
genome-scale screen to identify novel targets in cancer
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Introduction
Tumors acquire vulnerabilities due to oncogene-driven changes in cell signaling
pathways, which promote uncontrolled proliferation and suppress apoptosis. These vulnerabilities
provide opportunities to develop selective cancer therapeutics that lack the side effects
accompanying current therapies. Previously, Kinase Suppressor of Ras 1 (KSR1), a scaffold for
the Raf/MEK/ERK kinase cascade, has been shown to be required for maximal ERK activation
and Ras-driven transformation 3,24,32,38,41,56. Depletion of KSR1 by RNA interference (RNAi) kills
malignant, Ras-driven cancer cells, but not immortalized, non-transformed human colon
epithelial cells (HCECs) 3. Additionally, KSR1-/- mice are viable and fertile 24 suggesting KSR1 is
not required for normal cell survival making it a prime therapeutic target; however, drug
development targeting KSR1 has had limited success.
Using screening approaches to identify KSR1-like targets that are selectively required for
cancer cell survival has proven fruitful. In fact, Gene Set Enrichment Analysis (GSEA) of gene
expression alterations discovered through microarray analysis in HCT116 colon cancer cells with
and without KSR1 led to the discovery that PGC1β and ERR were key downstream effectors of
KSR1 in cancer 3. Further analysis revealed that PGC1β and ERR were overexpressed in cancer
and required for cancer cell survival as shown in both cell line-based and tumor xenograft studies.
These findings led us to hypothesize that novel vulnerabilities in cancer could be identified using
an unbiased genetic depletion screen.
RNA interference (RNAi) screens can be performed using multiple techniques. The two
most common techniques involve using either a pooled gene depletion method or an arrayed
single gene depletion method (Fig. 3.1). In pooled approaches, an entire library of shRNA
(RNAi) or sgRNA (CRISPR-based screens) is added to a single dish of cells. This method is
typically performed for longer periods of time, which allows a few cells with the desired
phenotype to outgrow other cells and become overrepresented at the end of the study. Cells can
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Fig. 3.1: RNAi-mediated screening overview. High-throughput screening can be completed by
applying siRNA, shRNA, or CRISPR-Cas9 to alter gene expression or genetically manipulate cells
in either an arrayed or pooled approach.
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then be examined for the presence of shRNA barcodes or genetic mutations through sequencing
to determine the genetic alteration that induced the phenotype of interest or is overrepresented in
a population. Recently, several groups have utilized the pooled method to perform CRISPR-based
screens seeking to identify mechanisms of drug resistance. In these instances, a pool of sgRNA
targeting the entire genome are added to cells stably expressing Cas9 that are sensitive to a given
therapy. Shortly after the addition of sgRNA, the drug of interest is added and clones that develop
drug resistance to the therapy survive. These are then evaluated by sequencing to determine the
genetic alterations that were responsible for the development of resistance. In the arrayed, single
well screen, siRNA or shRNA targeting a single gene is added to each well. The result of the
individual gene depletion is then evaluated in each well typically using high content microscopy,
cell viability, or other reporter assays such that each gene depletion examined in the screen yields
a quantifiable effect. One vital aspect in arrayed screening is identifying the optimal readout.
Assessing cell viability is cheap and informative; however, it is a crude approach and does not
distinguish between numerous downstream effects of gene depletion. This approach was therefore
not sensitive enough for this study since the goal was to identify genetic targets that are
functionally similarly to KSR1 such that they are selectively required only in cancer cells. Other
common readout assays evaluate the state or effect of individual gene depletions on a specific
downstream target of interest. KSR1 promotes phosphorylation of ERK, therefore, evaluating the
phosphorylation status of ERK with each gene depletion could have been applied as the screen
readout. However, this approach suffers from a significant weakness in that it would fail to detect
targets that acted either downstream or tangentially to ERK. Additionally, the activation of ERK
has been well-studied and using phosphorylation of ERK would be likely to just reinforce the
already identified interactions without revealing significant novel effectors in cancer. Recent
studies have also demonstrated that it is likely KSR1 has functions that are independent of its
effects on ERK, further necessitating the use of a different readout for this function-based screen.
In 2004, Stegmaier et al. published a study describing the successful implementation of
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gene expression-based high-throughput screening to identify chemical compounds that induce
differentiation of acute myeloid leukemia cells. This method used a gene expression-based
signature as a marker for the differentiation phenotype, which can be quantifiably compared
between known differentiating agents and the tested compounds. In this implementation, they
screened 1,739 compounds using RNA extraction, RT-PCR, then performing mass spectrometry
to assess gene expression of five genes that demonstrated altered expression following cell
differentiation. This screen ultimately identified eight compounds that induced the differentiation
signature and demonstrated morphological and functional evidence of differentiation upon
follow-up analysis 103. This study definitively demonstrated that a gene expression-based
signature could be used as a proxy for a phenotype of interest such that one could effectively
assess the functional effect of a chemical or genetic perturbation without having to examine or
even knowing all the intermediate steps allowing for an unbiased, rapid identification of novel
potential therapeutic targets in cancer.
Therefore, a gene expression-based screening approach termed Functional Signature
Ontology (FUSION) 3 was utilized to identify other genes that are functionally similar to KSR1,
such that they are required for colon cancer survival, but not normal colonic epithelial cell
survival. To do this, a gene signature representing the downstream effects of KSR1 depletion in
HCT116 colon cancer cells was established. This was based on gene expression changes in
HCT116 cells with and without KSR1 measured using a microarray. Based on this analysis, six
reporter probes (BNIP3, NDRG1, ALDOC, LOXL2, ACSL5, BNIP3L), which decreased in
expression following KSR1 depletion were chosen for the KSR1-depletion gene expression-based
signature (Table 3.1). Since these six genes demonstrated consistent downregulation upon KSR1
depletion, their expression was measured following individual gene depletions to identify genes
that had a similar effect on their expression, and, theoretically, the same overall effect on cancer
cells (Fig. 3.2). Two additional reporters, cyclophilin B (PPIB) and hypoxanthine-guanine
phosphoribosyltransferase (HPRT) that did not change with KSR1-depletion were included as
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Gene

Gene Details

BNIP3

BCL2/Adenovirus E1B 19 kDa Interacting Protein 3: Encodes a
mitochondrial protein with a BH3 domain, pro-apoptotic

NDRG1

N-Myc Downstream Regulated 1: alpha/beta hydrolase
superfamily, involved in stress response, hormone response, cell
growth and differentiation

ALDOC

Aldolase C: Fructose-bisphosphate:Glycolytic enzyme that
catalyzes F1,6BP and F1P  DHAP, G-3-P

LOXL2

Lysyl Oxidase-Like 2:Biogenesis of connective tissues,
crosslinkage of collagen and elastin

BNIP3L

BCL2/Adenovirus E1B 19 kDa Interacting Protein 3-Like:
Protein with a BH3 domain, binds Bcl-2, pro-apoptotic

ACSL5

Acyl-CoA Synthetase Long-Chain Family Member 5: Converts
free fatty acids into fatty acyl-CoA esters  lipid biosynthesis
and fatty acid degradation

Table 3.1: Genes comprising the KSR1 depletion gene expression-based signature.

45

Fig. 3.2: Representative diagram of the FUSION analysis.
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control reporters and were used to account for well-to-well cell number variation. This allowed
for the relative change in gene expression to be evaluated without being confounded by cell
proliferation or viability changes. In contrast to the study performed by Stegmaier et al. that
measured gene expression using RT-PCR followed by mass spectrometry, the gene expressionbased signature was measured using the Affymetrix Quantigene 2.0 Multiplex assay. This
allowed for a much easier evaluation of gene expression during high throughput screening as
gene expression was easily quantified for each gene in the KSR1-depletion signature by
measuring fluorescence. The identification of the KSR1-depletion gene expression signature
(BNIP3, NDRG1, ALDOC, LOXL2, ACSL5, BNIP3L) and validation of the Affymetrix
Quantigene 2.0 Multiplex assay laid the foundation for the preliminary kinome (791 kinases,
phosphatases, and related genes) screen, which was robotically performed simultaneously in
biologic triplicate on three 384-well plates. Each gene within the kinome portion of the siGenome
library (Dharmacon) was individually knocked down using pooled siRNA sequences and gene
expression of BNIP3, NDRG1, ACSL5, ALDOC, BNIP3L, PPIB, and HPRT were measured
(Fig. 3.3). Data underwent quality control and data preprocessing (see Chapter 2: Materials and
Methods), then was normalized based on the median gene expression for each of the six genes in
the KSR1-depletion signature (Fig. 3.3). Positive control outliers (siKSR1 wells) were identified
using Grubbs algorithm as described in Chapter 2: Materials and Methods. The positive control
target was the average of all remaining siKSR1 wells. Euclidean Distance and Pearson
Correlation similarity metrics were used to evaluate the effects on the gene expression-based
signature following each individual gene depletion. Five (AMPKγ1, EPHB4, ERK5, DYRK1A,
and LATS1) of the top ten hits from the kinome screen were biologically validated with three of
these hits (AMPKγ1, EPHB4, DYRK1A) being examined extensively and two being the subject
of published manuscripts from the Lewis lab 3,42 (Fig. 3.4).
The current work expands upon this early success with FUSION and applies this analysis
to the full genome-scale RNAi screen that interrogated 14,355 genes (siGenome library from
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Fig. 3.3: FUSION relies on the identified KSR1 depletion gene expression-based signature to
evaluate the functional similarity between KSR1 and other genes.
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Fig. 3.4: Biologically validated hits from the preliminary kinome screen. (A) Scatter plot of the
kinome screen results based on Euclidean distance and Pearson correlation. KSR1-depleted wells are
shown in red and the remaining gene depletions from the kinome library are shown in black. (B)
Expanded view of the Euclidean distance and Pearson correlation metrics for each gene depletion. KSR1depleted wells are shown in red, validated hits in blue, and the remaining gene depletions in black. (C)
Table of validated hits with Pearson correlation and Euclidean distance metrics.
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Dharmacon) and was adapted to evaluate 1,200 natural product fractions in the K-RasG13D-driven
human colorectal cancer cell line HCT116. However, the scale of the expanded experiment
dramatically increased the experimental and computational complexity required to elucidate
promising targets while limiting false positives. First, the size of the genome-scale screen forced
it to be processed in batches. This caused a certain degree of unavoidable variability between
individual runs that must be accounted for in order to preserve the unbiased nature of the screen.
These batch-wise variances need to be identified and accounted for prior to analysis. This was
completed through normalization of the data. Additionally, in any experiment with more than
50,000 measurements there is bound to be a certain number of faulty wells that generate outliers
in the data that should be excluded from analysis. Following the data preprocessing and
normalization, the functional similarity between KSR1 and each gene screened was quantified in
the same manner that was employed in the kinome screen using Euclidean distance and Pearson
correlation similarity metrics. However, this led to the identification of nearly 800 potential target
genes. To prioritize the identified hits, filters were applied to the 788 identified genes and
bioinformatic analyses were performed to identify common pathways or related proteins that
were identified in an attempt to limit false positives and prioritize the identified targets.

Results
FUSION Screen: Experimental Background
Each 384-well plate consists of 24 vertical columns and 16 horizontal rows. On every
plate, 10 control wells with non-targeting siRNA (siCont) and 10 wells containing siRNA
targeting KSR1 (siKSR1) are split evenly between columns 3 and 22 along with other control
gene depletions (PPIB and PLK1) in the same columns above and below the siCont and siKSR1
wells as shown in the plate layout diagram (Fig. 3.5). The screen was performed in experimental
batches because of the limitations in the size of the incubating shaker such that only eight plates
could be processed at a time.
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Fig. 3.5: FUSION screen 384-well plate layout. (A) Plate layout with control and KSR1-depleted wells
in columns 3 and 22 shown in black and red, respectively. (B and C) Plate diagram heatmap with PPIB
values from a representative individual plate (B) and average of all plates (C).
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Quality Control: Probe Correlations
Ideally, the probes included in the gene expression-based signature will move
independently and will not co-vary. To evaluate the covariation of probes, a pairwise comparison
between each of the probes was performed. BNIP3 and NDRG1 had a correlation value of 0.84,
while the remaining pairwise comparisons demonstrated correlations less than 0.7 (Fig. 3.6).
Quality Control: Experimental Consistency
Experimental variability was examined and visualized using the raw HPRT and PPIB
gene expression. Replicate and plate consistency were evaluated using PPIB expression (Fig.
3.7). There was a high level of correlation between replicates (Fig. 3.7). Interestingly even though
the same number of cells were plated in each experiment, there was significant variation between
the PPIB ranges on different plates particularly between experimental batches (Fig. 3.7B). These
differences were consistent between the three replicates (Fig. 3.7B). These effects are seen in the
expression of all of the genes examined, but to differing degrees (Fig. 3.8). This could be due to
different gene depletions being placed on each plate; however, this is highly unlikely as nontargeting siRNA and lethal controls appear on every plate and a large number of unique gene
depletions are found on each plate. Examining the raw PPIB gene expression relative to the well
type clearly demonstrates the ranges for the PPIB values fluctuate between plates and batches
(Fig. 3.9). Reassuringly, background control wells and lethal controls have minimum PPIB
values, while the non-targeting siRNA negative controls consistently have some of the highest
PPIB levels. The positive control, KSR1-depleted wells sit between these two groups and
demonstrate intermediate PPIB values and are intermixed within the other screened gene
depletions (Fig. 3.9). Other possibilities that could explain the different PPIB ranges include the
experimental cell growth being altered or probe signal intensity varying between plates or
processing groups. Follow-up analysis demonstrated that the PPIB value was highly variable
depending on the confluency or density of the cells on the stock plate prior to plating for the
experiment. This suggests that the confluency of the cells was affecting whether the cells were in
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Fig. 3.6: Pairwise evaluation of gene expression-based signature probes. Correlation between gene
expression for the six genes within the KSR1-depletion reporter genes BNIP3L, NDRG1, ALDOC,
LOXL2, BNIP3, and ACSL5. Correlation values are designated in the top/right half above the diagonal
and plots comparing the values are shown one the bottom/left half below the diagonal. Dot colors within
the correlation plots represent the experimental group or batch.
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Fig. 3.7: Replicate and Plate Consistency. (A) Scatter plot and correlation between biological replicates.
(B) Raw PPIB values for each replicate by plate.
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Fig. 3.8: Probe consistency across plates. Boxplot of BNIP3L, NDRG1, ALDOC, LOXL2,
BNIP3, ACSL5, HPRT, and PPIB expression represented by plate. (Continued on the following
pages).
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Fig. 3.8 Continued: Probe consistency across plates.
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Fig. 3.8 Continued: Probe consistency across plates.
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Fig. 3.9: Scatterplot of Raw PPIB values by well type. Average raw PPIB for the three
biological replicates. Dot color represents the well type: BKGD control in yellow; Lethal control
in orange; Negative control (non-targeting siRNA) in blue; positive control (KSR1-depleted) in
pink; and siRNA library gene depletion in green.
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a log growth phase or becoming senescent and highlights the importance of careful replication of
all aspects of the experiment particularly when completing large-scale screens. Additionally, the
reporters within the Quantigene system reported differently with different types of serum, which
unfortunately was changed between groups of experimental plates.
The potential effect of plate position (i.e. plate row and column) was evaluated. PPIB
showed a slight trend for increased values on edge rows and HPRT demonstrated an offsetting
slight decrease in these rows resulting in no differences being seen in gene expression for any of
the genes within the KSR1-depleted signature panel after PPIB- and HPRT-based geomean
normalization (Fig. 3.10). More dramatic effects were seen in gene expression based on column
(Fig. 3.11). Columns 1 and 24 were excluded from this analysis because they only contained
background controls (Fig. 3.5 and Chapter 2: Materials and Methods). Columns 3 and 22 have
lower readings in PPIB, NDRG1, and ACSL5, as well as a substantially increased range of values
for BNIP3 (Fig. 3.11). This can be attributed to the effect of non-random plating in these columns
(Fig. 3.5) as these two columns contained five non-targeting negative control wells, five KSR1depleted wells, and six additional lethal controls.
Quality Control: Outlier Detection
Outliers were identified among the positive control (KSR1-depleted) wells and negative
control (non-targeting siRNA-treated) wells (Fig. 3.12 and Fig. 3.13). Prior to algorithmic
identification of outliers, visual examination of the PPIB expression in negative and positive
control wells demonstrated a cluster with PPIB values less than 1000 on plates 20 and 21 (Fig.
3.12). This led to further examination of these wells, which revealed that they were blank wells
and not negative or positive control wells despite being labeled as such. These wells were
therefore no longer included as positive and negative controls. Algorithmic identification of
outliers was performed for each plate individually for the negative controls and across each
experimental batch for the positive control, KSR1-depleted wells using a Grubbs algorithm
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Fig. 3.10: Plate position effects evaluated by row. Boxplots of BNIP3L, NDRG1, ALDOC,
LOXL2, BNIP3, ACSL5, HPRT, and PPIB expression represented by row.
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Fig. 3.11: Plate position effects evaluated by column. Boxplots of BNIP3L, NDRG1, ALDOC,
LOXL2, BNIP3, ACSL5, HPRT, and PPIB expression represented by column.
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Fig. 3.12: Relationship between raw PPIB values of negative control (siControl) and positive
control (siKSR1) wells by plate. Negative control wells are shown in black and positive control
wells are shown in red. Circles designate outliers in plates 20 and 21 and a highly variable third
biological replicate in plates 38, 43, and 44.
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Fig. 3.13: Outliers identified in positive control wells using the Grubbs algorithm.
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(described in Chapter 2: Materials and Methods). The Grubbs algorithm is based on minimizing
the distance between samples, therefore, outliers were preferentially excluded if they had a higher
Euclidean distance more so than a reduced level of correlation (Fig. 3.13).
Seventy-five outliers in control wells that were transfected with non-targeting siRNA
were identified out of a total 452 negative control wells. Fifteen outliers were identified from the
average of the three biological replicates for the KSR1-depleted wells. Examining each biological
replicate individually, 30, 25, and 31 outliers were identified for the first, second, and third
biological replicate respectively. This is out of a total 456 KSR1-depleted wells on 46 plates, such
that each plate averages less than one KSR1-depleted well outlier and represents a 7% or less
outlier detection rate for these repeated wells.
Outliers for each individual RNAi-mediated gene depletion were visualized based the
standard deviation between the three biological replicates using a heatmap shown by plate
position (Fig. 3.14). These were not immediately excluded from further analysis, but their
presence identified the need for a filter based on consistency in results between the three
biological replicates.
FUSION Normalization
The genome-scale screen represented a substantial increase in complexity over the
original kinome-only screen, and the original method of normalization was not designed to handle
this complex, variable data set. Therefore, over 100 algorithmic variations following the same
general pattern of data validation and initial processing, normalization, outlier identification of
non-targeting control and KSR1-depleted wells and removal, generation of the siKSR1 target, and
similarity evaluation were evaluated. Several of these steps could be completed across all of the
data, by experimental batch, or on a plate-by-plate basis, which contributed to the high number of
algorithmic variations evaluated.
Normalization methods typically include normalizing to the mean/median of all samples
for a given probe based on the Z-score or variation of this method, normalizing to plate position,
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Fig. 3.14: Identification of outliers was performed by evaluating the standard deviation
between the PPIB values on the three biological replicate plates. Plate layout heatmap
representing the standard deviation for each knockdown between the three biological replicates.
Green depicts a lower standard deviation and red depicts a larger standard deviation. (Continued
on the next pages).
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Fig. 3.14 Continued: Identification of outliers was performed by evaluating the standard
deviation between the PPIB values on the three biological replicate plates.
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Fig. 3.14 Continued: Identification of outliers was performed by evaluating the standard
deviation between the PPIB values on the three biological replicate plates.
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or normalizing to positive or negative controls. Each of these methods has pros and cons and
should be selected for utilization based on the specific biologic question being asked and the
experimental design being employed. The methods of normalization that were examined included
normalizing based on plate median values, by plate position, or to control wells all with log base
2 transformation. Each of these methods were evaluated using the ranking of the previously
validated kinome hits (accuracy), evaluating the effects of analyzing the kinome vs the entire
genome-scale screen (scalability), and confirming the KSR1 depletion wells demonstrated high
similarity based on Euclidean distance and Pearson correlation similarity measures (precision).
FUSION Normalization: Reporter Median
First, normalization to reporter median was evaluated (Fig. 3.15). This was the method
originally used to analyze the pilot kinome screen data that successfully identified multiple genes
that were biologically validated and shown to be selectively required for colon cancer cell
survival. To assess the validity of the screen algorithms, three measures were used: accuracy,
precision, and scalability, which are fully described in Chapter 2: Materials and Methods.
Unfortunately, the previously validated hits dropped dramatically demonstrating a low accuracy
(Fig. 3.15A). To measure precision, the ability for siKSR1 replicates to cluster was evaluated,
which in this algorithm was satisfactory (Fig. 3.15B). Last, scalability was examined. In this case,
the scalability is low because the analysis depends on all plates being on the same range and
assumes the median on each plate is and should be the same (Fig. 3.15C). However, based on the
experimental setup (non-random plate assignments based on the siGenome library), there is no
expectation that all of the plates should be the same (i.e. the median on one plate could be the
minimum or max for another). Based on the poor performance of this normalization method,
additional methods were evaluated.
FUSION Normalization: Plate Position
Our collaborators initially chose to pursue normalization based on plate position based on
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Fig. 3.15: Evaluation of median reporter normalization based on accuracy, precision, and
scalability. (A) Table containing the Euclidean distance and Pearson correlation rank and values for three
previously biologically validated hits: DYRK1A, PRKAG1 (AMPKγ1), and EPHB4. (B) Scatterplot of
positive control (KSR1-depleted) wells shown in red and individual gene depletions from the siGenome
library shown in black based on Euclidean distance and Pearson correlation similarity metrics. (C)
Scatterplot and correlation of the Euclidean distance metrics for the kinome data after normalizing only
the kinome or analyzing the entire genome.
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the plate positional effects they were seeing particularly in regard to the column assignment. This
was prior to the recognition that these effects could largely be attributed to the non-random
plating (i.e. control wells being assigned to the same column on each plate) (Fig. 3.5).
Unfortunately, this normalization method also demonstrated very low accuracy (Fig. 3.16A) and
almost no precision (i.e. there was no correlation between the KSR1-depleted wells) (Fig. 3.16B),
which was very concerning as the identification of hits is predicated upon their similarity to
KSR1-depleted wells. If the repeated KSR1-depleted wells were not similar to each other, it
would be very difficult, if not impossible, to identify additional genes that could be described as
KSR1-like. In retrospect, the distribution of KSR1-depleted wells could have been predicted
based on this normalization scheme in conjunction with the knowledge that the KSR1-depleted
wells all reside in one column. Therefore, normalizing in any way based on column position,
forces these wells to be evenly assigned across a normal distribution, which pushes them to have
very little similarity with each other. This method does have nearly perfect scalability between
the kinome- and genome-scale screens. This is expected as normalization based on plate position
for each individual plate, is not affected or altered by the addition of more plates resulting in the
outcomes from each plate being completely independent from the other plates analyzed resulting
in perfect scalability (Fig. 3.16C).
FUSION Normalization: Normalize to Controls
Finally, the method of normalizing to control wells was evaluated (Fig. 3.17). This
method intuitively makes sense in the context of the biological experiments because it is
consistent with how the reporters were initially chosen (represents a difference between an
siControl well and siKSR1 or other individual gene knockdown), it takes into account
experimental differences (plate to plate or group to group), and it does not require any
assumptions be made about randomness of plating. Normalization based on the median of the
negative control (non-targeting siRNA) wells for each individual plate demonstrated high
accuracy, precision, and scalability (Fig. 3.17). Therefore, it was selected for future analysis.
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Fig. 3.16: Evaluation of plate position normalization based on accuracy, precision, and scalability.
(A) Table containing the Euclidean distance and Pearson correlation rank and values for three previously
biologically validated hits: DYRK1A, PRKAG1 (AMPKγ1), and EPHB4. (B) Scatterplot of positive
control (KSR1-depleted) wells shown in red and individual gene depletions from the siGenome library
shown in black based on Euclidean distance and Pearson correlation similarity metrics. (C) Scatterplot
and correlation of the Euclidean distance metrics for the kinome data after normalizing only the kinome
or analyzing the entire genome.
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Fig. 3.17: Evaluation of negative control normalization based on accuracy, precision, and
scalability. (A) Table containing the Euclidean distance and Pearson correlation rank and values for
three previously biologically validated hits: DYRK1A, PRKAG1 (AMPKγ1), and EPHB4. (B)
Scatterplot of positive control (KSR1-depleted) wells shown in red and individual gene depletions from
the siGenome library shown in black based on Euclidean distance and Pearson correlation similarity
metrics. (C) Scatterplot and correlation of the Euclidean distance metrics for the kinome data after
normalizing only the kinome or analyzing the entire genome.
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FUSION Output
The positive control target was established by averaging the positive control (KSR1depleted) wells after the exclusion of outliers. Based on this target, the FUSION analysis provides
a ranked list of genes based on two similarity metrics, Euclidean Distance (ED) and Pearson
Correlation (PC). Empirically, other targets with both a high correlation and a low distance were
the most likely to validate. Therefore, linear regression analysis was used to establish a cutoff (PC
> 0.25 X ED + 0.5) for KSR1 similarity based on the ED and PC values of KSR1- positive
controls (Fig. 3.18A). Using this linear regression cutoff, 788 hits were identified from the
genome-scale screen (Fig. 3.18B). Unfortunately, this is too many for follow-up biological
validation (Table 3.2). One approach that could have been employed would have been to
complete a follow-up screen comparing viability changes in HCEC and HCT116 cells with
genetic knockdown using individual oligos. This would have limited off-target effects because
the effect could be confirmed for multiple siRNAs as well as evaluating the selective toxicity to
cancer as compared to normal cells. This approach, while commonly practiced and effective, is
also very expensive and likely would still yield numerous promising targets. Instead, further
bioinformatic analysis was applied to limit the hits.
Bioinformatic Analysis
In this screen, eliminating false positives was prioritized over reducing false negatives
leading to a high degree of specificity, but lower sensitivity. Stringent criteria were established in
an attempt to reduce wasted time and resources following up on false positives. To do this, the
following factors were used as limiting criteria: viability (hits remaining = 662), precision (189),
seed sequence off-target potential (157), and target expression level in HCT116 cells (81) and
colon adenocarcinoma samples within The Cancer Genome Atlas (40) (Fig. 3.19). This was
paired with gene set enrichment analysis (GSEA), Database for Annotation, Visualization, and
Integrated Discovery (DAVID)-based KEGG pathway and GO term association, and Cytoscape
pathway analysis.
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Fig. 3.18: FUSION identified 788 targets. (A) Scatterplot of positive control (KSR1-depleted) wells
shown in red and individual gene depletions from the siGenome library shown in black based on
Euclidean distance and Pearson correlation similarity metrics. The linear regression-based cutoff to
specify hits based on Euclidean distance and Pearson correlation metrics is shown as a line in blue. (B)
Flow chart of the FUSION screen that identified 788 targets.
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NCOR2

UBASH3B

NPEPL1

NPL

ABTB2

KIAA0100

FPR1

PPT1

DACH2

TEN1-CDK3

MYCBPAP

CHRNA5

ZCCHC9

ADRA1D

APOL6
TXK

TACR3

CHCHD2

RAB21

HSPA9

NAP1L1

PTPN4

TCHH

CLPB

RGS19

ADIPOR1

CPB2

IFFO1

ZC3H14

CISH

ATP2A3

SPNS1

STK32A

PIP4K2C

NIM1K

HIAN2

GLIPR1L1

LPAR3

ABHD1

PODXL

SEMA7A

S100B

SFSWAP

CADM3

RNASEH2C

HCRT

TH

TMPRSS13

RGS12

CDH1

DEDD

TRO

ACAD11

PTCD2

DNAJC5

ST5

GPRC5B

PIGL

GIPC1

DLX3

PIK3CG

PLA2G12B

TMEM204

OR2B2

WDR5B

LPAR4

PPP1R16B

MRPL38

CSRNP2

THAP2

MRGPRX3

GLIPR1

TAS2R13

BAZ2B

JAM3

HSPH1

RGS4

ZBTB37

ATP5G2

HLA-DMA

LDOC1L

SRCT1

AKAP6

MYH9

ETV6

NFYA

CCDC136

PRODH

PAIP2

VN1R2

FYCO1

ADGRL3

NEK3

LDHC

PRR5L

IRX1

FAM172A

C15orf48

DYM

FLJ13105

PPP4R1L

AHNAK

OR51B4

KIN

LGALS2

RBM5

LPO

PI4K2A

FOSL2

NOS3

OR10H2

SELE

OR1E2

EVA1A

C19orf44

RGS2

ACSS3

CHIA

FGFBP2

P2RY8

LINC01547

NUDT4

ADGRE5

NSUN7

FOS

KRT84

FIBP

SH3D21

AADAC

PDCD2L

EPHB4

ADORA2B

TKTL2

RNASE7

MMAA

TMEM126A

PTGFR

VWA7

C4orf17

RNF128

HTR5A

TATDN1

CELSR2

AMELX

ACADM

ADGRL1

NKTR

HNF1A

ZBTB45

SIPA1

OR2C1

NPY5R

ZNF385D

TCFL5

ACKR4

APOC1

LPAR5

RHOH

AFTPH

VN1R1

TXNDC2

DLX6

NTNG2

RIOK3

MYH14

FGF9

EN2

NPIPA1

ZNF566

CNTNAP4

OR51E2

LRIG2

EFCAB1

SIGLEC11

ADO

SOD2

TAAR9

OR52A1

LPAR1

CCDC183

DMWD

AKIRIN2

BDKRB1

HK1

GPR183

PINK1

FKSG17

CCDC142

RHOXF2

ACYP2

PAX1

MARVELD1

FAR1

ZRANB3

OR1J2

DCAKD

RAB34

FAM136A

HOXC11

ANG

TNS1

GPR143

ATG12

MAS1L

OR2T1

ZNF394

ATP8B4

FRY

CARS2

LRRC27

EIF4EBP2

ADRA2B

OR3A2

ZNF541

MAGI1

MMP19

PTGER1

VIP

RHBDD1

SH3GL2

NPY2R

ZMYND8

TIMELESS

FAM167B

ADGRG1

MAF1

RIN1

IP6K1

NPVF

HSP90AA1

SYP

PLXNC1

PSG7

IL22RA1

JRKL

TCF19

OR7A17

FAM207A

TMEM156

APOPT1

ECE2

SDPR

ACTR10

MUC2

PCNA

NR3C1

CXCL8

KLF16

OPRM1

SEPP1

AARS

LRRC19

NEK6

SDCBP

COG8

CARD11

ZGPAT

SYT15

TAAR1

3-Sep

DHRS9

GABBR2

CLPTM1L

RPE65

MC1R

CERS1

VPS25

H3F3B

ZNF702P

RBM48

GPR162

CYSLTR2

TTTY5

NUDT16L1

SLC35G5

GNB1

OTX1

LGR5

MSMO1

KDM2B

CRIP1

RGP1

C14orf151

DDB2

ZMYND15

TAS2R4

UGT1A3

ESYT3

HTATIP2

OR2H1

NUBPL

GPR75

CDC42BPB

CLEC11A

FRMPD3

SEPT1

ENDOU

C12orf49

ARHGAP10

MEX3B

OR5V1

OR3A1

ARHGAP11A

HAS2

CSF3R

ASCL1

NRP1

DDX47

PDE1C

NEURL1

YIPF4

GABARAP

OR51E1

PRKAG1

BAALC

ALDH18A1

TCF7L2

APLNR

HBZ

GADD45B

TPM2

PTPRT

FYTTD1

NFIC

SLC7A6

GZMA

HNRNPD

TXNDC15

DUSP2

CYORF15B

HOXD1

PRDM13

RHOBTB1

MAP4K4

ETV4

PCDHB12

MAPK10

DYRK1A

APLF

PRSS27

BAD

OXTR

ALLC

ABLIM3

OR5P3

CRY1

GRWD1

TOMM40L

PPP1R14D

FARP1

RHNO1

FUBP3

OR2W1

MFSD7

CXorf36

ELAVL3

SLC25A2

ARFGAP2

KIAA1024

GLI1

PCDH17

TMEM222

TAAR8

SOCS1

CRHR1

DMXL1

SCO2

CKS1B

MC2R

FRS3

ZNF28

OR2A4

BACH1

DGAT1

RASL11B

RSPH6A

CDKN1A

TTLL2

PKN3

CIRBP

PARM1

MTCH1

TAAR2

ADRA1B

CDH19

VCAM1

ITIH5

MND1

ZNF557

SYTL1

RFK

C3orf20

TRPM7

MTNR1A

CXCL13

MAP2K7

SPIC

TAS2R14

ZSWIM5

DRD4
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OR13A1

PSENEN

TCERG1

NPPB

TBRG1

ITGA10

GATAD2B

CPSF7

ERLIN1

SPATC1L

BATF

RAB27B

TFB2M

TBX22

GTF2I

ABCC4

TBX2

HN1L

GRM2

PCOLCE

TUSC3

FGFBP1

RPRM

PRLHR

TPK1

SPINK7

GUCA2B

ZNF559

NLRP12

GPR1

CELF1

HORMAD1

ZNF528

HIST1H2AC

FGFR1

MMEL1

PEBP1

ANGPTL6

CTC1

SVEP1

NONO

DNAJC9

LGALS13

VIPR1

ARF6

ANKRD20A1

ADGRE1

EZR

LATS1

PIK3C2G

ABCG4

FAM126A

IL1B

ALKBH5

SND1-IT1

SLC35E2

PLCB4

PDZD7

GRK1

PCDHA3

SNED1

ZNF484

SNTA1

CD3E

NPTX2

FAM167A-AS1

PTP4A1

C7orf50

FSCB

C9orf78

SCD5

AMD1

NME3

RAB33B

GPR61

VBP1

CPT1B

KLHL22

GPR101

TM2D1

ADCYAP1R1

HPCAL1

PRH2

ABCG8

ADGRF3

SRY

TESK2

TAZ

DLX2

SNX2

C10orf76

POF1B

CDR2L

PTDSS2

FLJ10246

MEST

STXBP3

NMBR

PRSS1

ADRM1

SYCP1

FOXC2

ITFG3

KIRREL2

FOXP3

ARMC2

IGSF9

TMEM43

PTH1R

PROZ

CLMP

PNKP

FAAP100

MVK

PROP1

LGALS3BP

SLC22A16

LY6G5C

STAG3L4

CNFN

DLX1

LHCGR

HIST1H4I

RNF208

OR8B8

VGLL4

MS4A2

FGF13

FOXD1

HPR

PARD6G

MAPK8IP2

ASB13

CDKN1B

BTRC

EFNA2

SSBP1

TAS2R46

TAX1BP1

TMEM25

TNNC2

UBA5

GMPPA

WDR78

MON1A

IMMP2L

KRTAP9-3

CDKN3

MUS81

LRRTM4

SORT1

GTF2A1L
USP48

CFAP69

OXER1

BMP4

IGFBP5

KRCC1

ZDHHC8

ACTRT3

FER

RASGRF2

KLF13

PSG9

ECHDC3

KLK10

NFATC3

TNIP1

CMSS1

HOOK3

CHD6

ULK4

TSPYL5

SRSF4

FNDC1

NPFFR2

SLITRK2

RGS5

ZNF382

GSK3A

LRRC8D

MORN1

SLC10A7

TMEM185A

RALB

BMP2

TEAD3

CHKA

ARL3

LRRC37A2

PUM1

SPIRE2

METTL25

PIK3CG

DDA1

DDHD1

TAS2R16

HSPA1B

PAPD5

IFNG

PRKY

SHC1

ZNF397

PI4KA

ITPKB

C1orf115

LTBP2

CYP2A13

GARNL3

MAGT1

FLJ12595

CHRM1

TAS2R39

TEC

PKD2

PTGDR

ADIPOQ

RAP1A

ADGRA2

HSPB8

GRK7

GPR17

SPINK1

LUM

MT4

LY6K

SPATA16

TGM2

PDE4B

GCGR

FCAMR

CCNL1

B3GNT9

TNNI2

AATK

DRP2

WDR24

PHC2

HNF1B

GABRG1

HFE

FSCN2

QDPR

GNAZ

TEKT2

GPR6

EMC6

TBCK

MAPK7

TSEN2

TRAF7

GNG11

PRICKLE3

CHST15

VRK1

FZD1

BCO2

RGS9

S1PR5

RGS1

TSN

PAQR8

MDS1

IRX3

GNRH1

FAM155B

HKDC1

EIF4G2

ARPP19

RPP30

DEFB4A

CDH5
ADORA3

MATK

ZNF395

NODAL

HSH2D

LRRC61

CD40

KCNIP3

SPIRE1

MRI1

RASD1

ZFYVE21

CCR4

FRMD8

ZNF124

GFI1B

ZNF84

RFXANK

CDK20

PECR

FAM184A

C10orf2

MFSD5

FLJ14054

OR3A3

PIK3R1

L3MBTL3

HAND1

GPR82

GP2

MEFV

PSD2

KLHL1

RHOBTB2

ZXDC

MPV17L2

ACSF2

SPARC

FAM134B
POLR3GL

NUDT2

TBL1XR1

SSTR4

SCTR

FAM167A

RPL7A

TRABD

NR1D1

CDC2L2

QRICH2

EGR4

SPATA9

LPAR2

OR6A2

ENTPD7

GFM2

IL17RB

PTPRJ

STRN

GABPA

CHCHD5

BBC3

ADORA3

NEK4

ADGRB2

KISS1R

MICA

IQCG

FZD10

ARSJ

PAX5

ROM1

AMIGO1

MACC1

XCL2

TAAR6

GPR160

MYH11

DRC7

PCDHB10

MMRN2

GARS

PLEKHA1

ZNF182

UQCR10

CXCL3

NR4A2

IL27RA

SCN9A

AMMECR1L

NTSR1

LY6H

ZBTB22

SLC46A2

MINA

GNG3

MRGPRX4

PKN1

MTERF2

POLE

NPHS1

TNFSF15

DRD1

FAM118B

CSTF3

C11orf63

PPP1R14C

BMX

INPP5E

GPR55

P2RY14

TMEM11

GNAI3

LAT1-3TM

PQLC1

RAC1
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Fig. 3.19: Flow chart of prioritizing targets using bioinformatic filters
that limited the FUSION-identified 788 to 40 hits.
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This approach was based on the idea that the FUSION analysis suggests these genes relate, so
gene set enrichment analysis or the evaluation of pathways and functionally related genes that are
enriched at the top of the results allows us to focus on the most promising hits.
Bioinformatic Analysis: Filtering the Results
The viability filter cutoff was a PPIB decrease of greater than 20% in the average of the
replicates. This reduced the number of hits approximately 15% or from 788 to 662. Based on the
earlier identification that in a few cases significant variability occurred between the three
biological replicates within the screen (Fig. 3.14), precision, or consistency of results was added
as a metric to filter out potentially false positive results. The criteria used that the maximum
difference between the three biological replicates of an identified hit must be less than 0.6 for
Euclidean distance and 0.2 for Pearson correlation to be considered further. This reduced the
number of hits dramatically from 662 to 189.
The results were then evaluated for the presence of enrichment of certain seed sequences
within the siRNAs targeting the top results from the screen (Fig. 3.20). This was completed using
two independent algorithms: Common seed analysis (CSA)104 and Genome-wide enrichment of
seed sequences (GESS)105. Criteria were imposed such that results that were identified using
either method as potentially being hits due to seed sequence effects were excluded. This reduced
the number of hits from 189 to 157.
Finally, the expression of the identified hits was evaluated in HCT116 cells based on
microarray analysis and in colon tumors based on TCGA. To pass the microarray expression
filter, the gene had to be designated as being “Present”. The TCGA-based filter required that
genes had greater than 150 RSEM expression. These cutoffs reduced the number of hits to 83 and
then to 40, respectively (Table 3.2).
Bioinformatic Analysis: Gene Set Enrichment Analysis (GSEA)
The Gene Set Enrichment Analysis (GSEA)106-108, maintained by the Broad Institute of
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Fig. 3.20: Seed sequence off-target effect diagram.
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Symbol
PPT1
ECE2
CRIP1
TPM2
CHCHD2
TCFL5
DEDD
EPHB4
ACTR10
AARS
GRWD1
HSPH1
TCF19
GNB1
CIRBP
MAP2K7
NEK3
KIAA0100
SDCBP
MAP4K4
ATP5G2
TIMELESS
PODXL
NONO
GARS
ZNF395
TAX1BP1
ZNF397
ADGRA2
TRAF7
GPR160
LGALS3BP
HSPB8
HSH2D
ASB13
PQLC1
GMPPA
LTBP2
MMRN2
TAZ

Gene Name
palmitoyl-protein thioesterase 1 [HGNC:9325]
endothelin converting enzyme 2 [HGNC:13275]
cysteine-rich protein 1 (intestinal) [HGNC:2360]
tropomyosin 2 (beta) [HGNC:12011]
coiled-coil-helix-coiled-coil-helix domain containing 2 [HGNC:21645]
transcription factor-like 5 (basic helix-loop-helix) [HGNC:11646]
death effector domain containing [HGNC:2755]
EPH receptor B4 [HGNC:3395]
actin-related protein 10 homolog (S. cerevisiae) [HGNC:17372]
alanyl-tRNA synthetase [HGNC:20]
glutamate-rich WD repeat containing 1 [HGNC:21270]
heat shock 105kDa/110kDa protein 1 [HGNC:16969]
transcription factor 19 [HGNC:11629]
guanine nucleotide binding protein (G protein), beta polypeptide 1 [HGNC:4396]
cold inducible RNA binding protein [HGNC:1982]
mitogen-activated protein kinase kinase 7 [HGNC:6847]
NIMA-related kinase 3 [HGNC:7746]
KIAA0100 [HGNC:28960]
syndecan binding protein (syntenin) [HGNC:10662]
mitogen-activated protein kinase kinase kinase kinase 4 [HGNC:6866]
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) [HGNC:842]
timeless circadian clock [HGNC:11813]
podocalyxin-like [HGNC:9171]
non-POU domain containing, octamer-binding [HGNC:7871]
glycyl-tRNA synthetase [HGNC:4162]
zinc finger protein 395 [HGNC:18737]
Tax1 (human T-cell leukemia virus type I) binding protein 1 [HGNC:11575]
zinc finger protein 397 [HGNC:18818]
adhesion G protein-coupled receptor A2 [HGNC:17849]
TNF receptor-associated factor 7, E3 ubiquitin protein ligase [HGNC:20456]
G protein-coupled receptor 160 [HGNC:23693]
lectin, galactoside-binding, soluble, 3 binding protein [HGNC:6564]
heat shock 22kDa protein 8 [HGNC:30171]
hematopoietic SH2 domain containing [HGNC:24920]
ankyrin repeat and SOCS box containing 13 [HGNC:19765]
PQ loop repeat containing 1 [HGNC:26188]
GDP-mannose pyrophosphorylase A [HGNC:22923]
latent transforming growth factor beta binding protein 2 [HGNC:6715]
multimerin 2 [HGNC:19888]
tafazzin [HGNC:11577]

Table 3.3: List of 40 FUSION-identified hits after bioinformatic filtering.
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MIT and Harvard, is a tool developed to look for the presence of the selective enrichment of
genes at the top of a result set compared to the rest of the data based on the annotated gene sets in
the Molecular Signatures Database (MSigDB) 106,108. This analysis demonstrates if any of the
known gene sets have more members ranking higher than they would if their members were
distributed randomly throughout the results, and if any sets are likely to represent a common
pathway or function that is required for survival in HCT116 cells. Even though GSEA is limited
by the gene sets that are already known, it still has the potential to identify known gene sets that
have a previously unrecognized role in Ras-driven, KSR1-dependent tumorigenesis.
A ranked list of genes based on the Pearson correlation similarity metric was used as the
input and compared against the Hallmark Gene Sets and identified multiple gene sets whose
members were enriched in the top results with a nominal p-value less than 5% and a false
discovery rate of less than 25%. Enriched Hallmark gene sets included KRAS_Signaling_Up,
PI3K_AKT_MTOR_Signaling, UV_Response_UP, P53_Pathway, Hypoxia,
IL2_Stat5_Signaling, IL6_JAK_STAT3_Signaling, Interfereon_Gamma_Response,
Inflammatory Response, TNFA_Signaling_Via_NFKB, and Adipogenesis (Fig. 3.21).
Bioinformatic Analysis: Database for Annotation, Visualization, and Integrated Discovery
(DAVID)
Instead of analyzing a ranked list of genes from the FUSION analysis for enrichment of
gene sets within the top results, DAVID analysis provides gene annotation and assignment to
functional groups or pathway mapping for a list of hits. Therefore, the 788 hits identified from
FUSION analysis were supplied to DAVID for GO term annotation (biological processes and
molecular function) and KEGG pathway mapping. Of the 788 hits that were supplied for DAVID
analysis using Entrez IDs, 779 were identified and included in the results. The missing IDs were
83459 (DKFZP761H1710/NM_031297), 79765 (HIAN2/NM_024711), 84234
(DKFZP547F072/NM_032274), 55104 (FLJ10246/NM_018038), 80068
(FLJ13105/XM_376325), 57413 (AD026/NM_020683), 985 (CDC2L2/NM_024011), and
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Fig. 3.21: Gene Set Enrichment Analysis (GSEA) Hallmark Gene Sets positively associated with
hits from FUSION.
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84800 (C14orf151/NM_032714). KEGG pathway mapping identified neuroactive ligand-receptor
interaction, calcium signaling pathway, taste transduction, chemokine signaling pathway,
leukocyte transendothelial migration, inositol phosphate metabolism, colorectal cancer, and
melanoma terms were identified with a p-value of less than 0.1. Identified GO terms for
molecular function included G-Protein coupled receptor activity, transmembrane receptor
activity, signal transducer activity, receptor activity, peptide receptor activity, G-protein coupled,
peptide receptor activity, neuropeptide receptor activity, neuropeptide binding, and kinase activity
with a Bonferroni corrected p-value of less than 0.01 and FDR < 5%. Identified GO terms for
biological processes included G-protein coupled receptor protein signaling pathway, cell surface
receptor linked signal transduction, signal transduction, regulation of cellular process, regulation
of biological process, biological regulation, second-messenger-mediated signaling, cyclicnucleotide-mediated signaling, intracellular signaling cascade, regulation of cyclic nucleotide
metabolic process, G-protein signaling, coupled to cyclic nucleotide second messenger,
regulation of nucleotide metabolic process, regulation of nucleotide biosynthetic process,
regulation of cyclic nucleotide biosynthetic process, MAPKKK cascade, regulation of catalytic
activity, regulation of cAMP metabolic process with a Bonferroni corrected p-value of less than
0.01 and FDR <5%. The presence of a large number of GO terms surrounding GPCR signaling,
signal transduction, kinase activity, and MAPKKK cascade were reassuring; however, the list of
KEGG pathways and GO terms that were found to be associated with the FUSION hits were
difficult to interpret and did not reveal new information as was anticipated. Therefore, additional
methods including graphical representations of the associated cellular functions were employed.
Bioinformatic Analysis: Cytoscape App Reactome and Reactome Pathway Browser
In collaboration with Dr. Nicholas Woods, evaluation using hits that had a PC greater
than 0.7 and an ED less than 1 (197 targets queried, 47 returned) using the Reactome Cytoscape
App 109,110 demonstrated pathway enrichment of GPCR ligand binding (CX3CR1, ADCYAP1R1,
LPAR4, CXCL13, TAS2R4, P2RY14, TAS2R13, HTR5A, MTNR1A, MC1R, ADORA2B,
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GNRH1), neuroactive ligand-receptor interaction (ADCYAP1R1, LPAR4, TAAR8, P2RY14,
HTR5A, MTNR1A, MC1R, ADORA2B), Rap1 signaling (RAP1A, YWHAZ, SIPA1),
Calcineurin-regulated NFAT-dependent transcription in lymphocytes (EGR4, NFATC3, FOS,
RNF128), Heterotrimeric G-protein signaling pathway Giα and Gsα mediated pathway (RGS19,
GNG3, RAP1A, HTR5A, MTNR1A, ADORA2B), Neurotrophic factor-mediated Trk receptor
signaling (TGS19, RAP1A, FRS3, GIPC1), PDGFRβ signaling pathway (RAP1A, FOS,
YWHAZ, MAPK10, SIPA1), and Circadian Rhythm pathway (TIMELESS, NR1D1, CRY1) with
an FDR < 1% (Fig. 3.22). One of our previously validated hits, AMPKγ1 was integrated in this
figure clustering with the circadian rhythm pathway, which led us to investigate these three
targets further. Only one of the three circadian rhythm pathway genes, TIMELESS, also passed
all of the bioinformatic filters making it a prioritized hit for further evaluation.

Conclusions
Using a gene expression-based signature as a proxy or readout for our phenotype of
interest (effect of KSR1 depletion in cancer cells), Functional Signature Ontology (FUSION) was
applied to a genome-scale genetic depletion screen to identify genes that are selectively required
in colon cancer cells, but dispensable in normal cells. Hits that were biologically shown to be
preferentially required in colon cancer cells represent cancer-specific vulnerabilities that can
often be tied back to driving oncogenic signaling, reinforcing the idea that oncogenes corrupt or
hijack certain cellular pathways or functions to promote tumorigenesis. This, however, can leave
the cells susceptible or vulnerable to targeted therapies that disrupt the required downstream
effectors.
The scale of this screen dramatically increased the complexity for computational analysis
as compared to the preliminary kinome screen. The sheer size of the data being analyzed made it
difficult to perform initial quality control checks on the data as issues were not readily apparent
until R scripts were written to aid in data visualization. Additionally, experimental limitations
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Fig. 3.22: Pathway enrichment analysis performed using the Reactome Cytoscape App.
Functionally related genes are grouped by color.
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forced the screen to be performed in batches further compounding the biological variability
between plates. The batched processing also created a lapse in time between when the initial and
last plates were processed. Unfortunately, only rudimentary quality control checks were evaluated
as each plate was completed, such that additional issues were painstakingly identified and
corrected after all of the data was generated and was being compiled.
Another confounding issue that arose was the lack of random plating both due to control
wells being plated in the same two columns on each plate as well as the functionally grouped
library being assayed in the groups assigned by the manufacturer. This eliminated the possibility
of normalizing the results based on plate position or median probe value as either technique
would experience confounding due to the non-random plating.
After these issues were identified, they were addressed using multiple computational
approaches. R scripts were generated to take the raw reads that were manually validated,
complete the geomean normalization, and integrate the data for further analysis. Negative and
missing values were set to the plate minimums for each probe. Outliers were identified and
excluded in an attempt to eliminate variability in the positive and negative controls due to faulty
wells. Numerous methods of normalization were considered and evaluated with a normalization
method based on the negative control wells (treated with non-targeting siRNA) outperforming the
other methods based on accuracy, precision, and the potential for scalability. In retrospect, it is
logical that this method would be preferable when the experimental conditions are considered. It
is vital that experimental conditions be considered when performing the quality control evaluation
and computational processing of biologic experimental data. A robust understanding of how the
screen was performed prior to computational processing could have reduced the amount of time
required and limited wasted efforts to computationally process the screen data. For this to occur,
strong collaborations must be formed between the individuals performing the biologic assay and
the individuals performing the computational analysis such that both of these groups can work
closely together to ensure the experiments are performed in a robust manner that will allow for
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direct computational-mediated assessment after completion. This requires both biologists and
computer or data scientists to learn about the other field at least to an extent such that they can
effectively communicate.
Several modifications or additions could be employed to improve upon the current
computational analysis of FUSION. Further evaluation of the six genes within the KSR1-depleted
gene signature to delineate those that preferentially identified hits that were biologically validated
could lead to a refinement of the KSR1-depletion signature gene set. This could then lead to
dropping one or more probes from the signature or weighting the probes to give more
discriminatory power to certain probes. Since the dynamic ranges of the probes varied, the genes
within the gene expression signature were inherently given different levels of impact on the
similarity metrics used to identify other KSR1-like genes. This effect is much more pronounced
on Euclidean distance, but is seen to a lesser extent on the Pearson correlation similarity metric.
A FUSION screen was also performed on a library of microRNA, natural products, and
commercially available drugs. The results from the microRNA screen were computationally and
biologically validated by our collaborators in Dr. Michael White’s lab at UT Southwestern 101.
Genetic targets and natural product compounds identified at multiple time points during the
computational analysis of FUSION are the subject of the subsequent chapters contained herein.
These include TIMELESS (Chapter 4), a circadian gene that was identified in the 40 hits listed in
Table 3.3, WDR5B/WDR5 (Chapter 5), a highly ranking gene within the 788 initially identified
hits listed in Table 3.2, and AMPKγ1/5-OH-S 1 (Chapter 6), a genetic target initially identified in
the preliminary kinome screen depicted in Fig. 3.4 and a compound that inhibits AMPK that was
identified in the natural product screen. Preliminary biological validation data is also provided for
ECE2 (Table 3.3), HAS2, DYRK1A, and BMP4 (Table 3.2) in Appendix A.
Out of the prioritized 40 hits (Table 3.3), other targets that are of particular interest
include MAP2K7 and MAP4K4, two highly druggable kinases that share JNK as a direct
downstream target, and two heat shock proteins, HSPH1 and HSPB8.
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Chapter 4: TIMELESS promotes colon cancer cell
proliferation by limiting the accumulation of DNA damage

Portions of the material covered in this chapter are the subject of a manuscript
submitted for publication by Neilsen BK et al.
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Introduction
Data indicate that the FUSION screen provides a platform for identifying novel
therapeutic targets and demonstrates the potential to identify oncogene-specific vulnerabilities in
an unbiased manner. Based on the similarity between gene expression signatures, Timeless
Circadian Clock (TIMELESS) was identified as being KSR1-like and a potential therapeutic
target in cancer (Fig. 4.1).
TIMELESS Protein Structure
Mammalian TIMELESS is a protein that was named for its similarity to the TIMELESS
protein in Drosophila with which it shares four homologous regions, nuclear localization signals
(NLS), short stretches of glutamate-rich regions, and a conserved DEDD sequence on the Cterminus 111,112 (Fig. 4.2). However, later studies revealed that a different gene in Drosophila,
TIMEOUT, shares greater sequence similarity to mammalian TIMELESS 113. TIMELESS is also
a member of an evolutionarily conserved family of orthologs that are conserved all the way back
to yeast and are implicated in DNA synthesis, S-phase dependent checkpoint activation, and
chromosome cohesion 114,115. Mammalian TIMELESS is highly conserved, as mouse and human
TIMELESS share greater than 80% identity in both the nucleotide and amino acid sequences
111,116

. The human form of TIMELESS contains a TIMELESS domain on the N-terminus, which

is required for homodimerization and interactions with TIPIN, CHK1, and CRY1 proteins
111,112,116,117

. On the C-terminus, TIMELESS has the TIMELESS C-terminal domain that is

predicted to be required for nuclear localization. Between these two regions, is the glutamic acidrich region and a region predicted to contribute to DNA binding (Fig. 4.2).
Circadian Rhythm
TIMELESS was initially identified in Drosophila where TIMELESS is a circadian gene
that serves as a negative circadian regulator. Initial studies of TIMELESS function in mice, failed
to demonstrate circadian expression or function 118; however, several mouse strains have been
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Fig. 4.1: FUSION identified TIMELESS as a functional analogue of KSR1 based on
Pearson correlation and Euclidean distance similarity metrics.
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Fig. 4.2: TIMELESS protein structure diagram.
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shown to have abnormal circadian rhythms, which casts some doubt as to the applicability of
these findings to human TIMELESS. In early studies, TIMELESS mRNA did not oscillate in the
suprachiasmatic nucleus (SCN) or the retina and was not altered with light exposure at night in
mice 111,112,116. However, soon thereafter another group demonstrated constitutive, high expression
of TIMELESS in the SCN, but oscillatory expression of TIMELESS in the retina with light/dark
cycles 119. Further studies using a different probe against TIMELESS observed diurnal variation
of TIMELESS mRNA in the SCN with peak levels at the day-to-night transition in light-entrained
animals and demonstrated light pulse-induced elevation in TIMELESS mRNA in mice 120. In rat
models, TIMELESS expression demonstrated clear 24-hour oscillations and physically interacted
with the PERIOD circadian proteins (PER1/2/3). Conditional knockout of TIMELESS in the
SCN disrupted SCN neuronal activity rhythms and altered levels of other known core clock genes
121

, which provided strong evidence for a role for TIMELESS in the mammalian circadian clock.
Canonical circadian signaling is driven by CLOCK:CYCLE/BMAL1 binding to E-boxes

(CACGTG sequences) within promoters thereby initiating transcriptional activation of circadian
genes, including PER and TIMELESS 122. PER and TIMELESS then inhibit
CLOCK:CYCLE/BMAL1 activity forming a negative feedback loop. Mutations of the canonical
E-box sequence of TIMELESS reduces mRNA cycling and circadian locomotor activity rhythms
demonstrating the necessity of the E-box sequences and the transcriptional regulation of circadian
cycles 122,123.
In both Drosophila and mammalian models, TIMELESS has been shown to interact with
other circadian genes, most notably the family of PERIOD proteins. This interaction promotes
protein stability and nuclear localization of both interacting partners 111,119,124-128. When the
PER:TIMELESS complex is in the nucleus, it inhibits CLOCK:CYCLE/BMAL1 DNA binding at
E-boxes, which dramatically decreases circadian gene transcription (including PER and
TIMELESS transcription), without affecting CLOCK:CYCLE/BMAL1 heterodimer formation
122,129-133

. In addition, complex formation between PER:TIMELESS and
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CLOCK:CYCLE/BMAL1 induces hyperphosphorylation of CLOCK by DBT/CK1 leading to
CLOCK degradation 133. TIMELESS has also been shown to interact with CRY proteins. While
CRY proteins support light-dependent degradation of TIMELESS in Drosophila, CRY1/2 inhibits
CLOCK:CYCLE/BMAL1 and interacts with PER1/2 and TIMELESS in a light-independent
manner in mice 134.
An additional layer of regulation exists through post-translational modifications.
Phosphorylation of PER by DBT/CK1 targets PER for degradation, and phosphorylation of
TIMELESS by Sgg/GSK3 promotes the PER:TIMELESS complex translocation to the nucleus,
both of which significantly alter the circadian period 135-144. Additionally, GSK3-mediated
phosphorylation of PER-bound TIMELESS initiates a CK2-mediated phosphorylation cascade.
Mutations in TIMELESS that block this phosphorylation cascade delay its nuclear accumulation
and affect rhythmic behavior 145. Data suggest that PER:TIMELESS complex formation prevents
PER phosphorylation and subsequent degradation revealing the mechanism by which TIMELESS
promotes PER stability 136,146.
TIMELESS is rapidly degraded through a ubiquitin-proteasome mechanism that is
preceded by tyrosine phosphorylation and generally triggered in response to light. This
contributes to light-mediated circadian cycle entrainment 127,128,130,147-151. Alternative mechanisms
do exist to maintain the circadian rhythms in the absence of light as evidenced by the continued
phosphorylation and degradation of TIMELESS through a ubiquitin-proteasome mechanism even
in the absence of light. However, this mechanism is mediated by different kinases than those that
promote light-induced degradation 152. Specific kinases have been identified that regulate the
stability of mammalian TIMELESS including multiple individual Src-family tyrosine kinases that
direct the degradation (Fyn or Hck) or protection of TIMELESS (c-Src and c-Yes) based through
changes to phosphorylation-dependent ubiquitylation 153. Recent screens have also revealed
several protein phosphatases that alter the circadian cycle suggesting possible additional
mechanisms by which the circadian rhythm is regulated through phosphorylation changes 154.
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Development
TIMELESS is essential for development 118,155-157 and has been shown to be highly
expressed in the developing lung, liver, kidney, and neuroepithelium 156,158. The definitive
requirement for TIMELESS has been shown as TIMELESS depletion causes defects in kidney
development and evidence suggests TIMELESS may be an immediate early gene that is required
for kidney morphogenesis 156, lung development 157, and neural development 158. Further, mouse
embryonic stem cells lacking TIMELESS formed embryoid bodies that failed to cavitate due to a
lack of programmed cell death and differentiation, which ultimately arrested development 159.
DNA synthesis
During normal DNA replication, TIMELESS depletion decreased DNA replication
efficiency and caused genomic instability demonstrated by increased γH2AX, Rad51, and Rad52
foci formation 114,160. TIMELESS localized to replication forks and limited ssDNA accumulation
as well as fork rotation during DNA replication to prevent DNA damage and chromosomal
instability 114 161-164. This is particularly important at sites of physical barriers including
centromeres, telomeres, ribosomal DNA repeats, and termination sites 165. Specifically at
telomeres, TIMELESS promoted efficient DNA replication, and TIMELESS depletion caused
telomere shortening independent of telomerase, increased DNA damage leading to telomere
aberrations, and slowed telomere replication 166. As a component of the replication fork barrier,
TIMELESS also coordinated transcription and S-phase DNA replication thereby reducing DNA
damage 167.
TIMELESS interacted with DNA helicases 168-170 and stimulated their unwinding activity
by enhancing DNA binding 171. Additionally, TIMELESS coupled the replicative helicase
complex to DNA polymerases for efficient DNA synthesis 172. TIMELESS also stimulated the
activity of DNA polymerases , δ, and ε 169, and without TIMELESS, replication fork
progression was dramatically decreased 171,173. TIMELESS promoted chromosome cohesion, and
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TIMELESS depletion caused a 100-fold increase in sister chromatid discohesion and induced
significant chromosome fragmentation 114,163,165,174,175.
These combined mechanisms demonstrate how TIMELESS promotes high fidelity,
efficient DNA synthesis. These mechanisms also likely contribute to the maintenance of viral
genomes as TIMELESS has been shown to promote viral episome maintenance in two cancerassociated viruses: Herpes Simplex virus (HSV, Kaposi’s sarcoma) and Epstein-Barr virus (EBV,
Burkitt’s lymphoma)176,177.
Cell Cycle
The cell cycle is under circadian regulation 178-181, and TIMELESS could be the mediator
that coordinates this connection 182. TIMELESS expression is regulated both by the circadian
rhythm and cell cycle with the highest expression occurring at night and during S and G2 phases
in normal human fibroblasts, respectively 182. TIMELESS depletion has been shown to limit the
ability of cells to trigger DNA damage-associated checkpoint arrest at intra-S checkpoints and the
G2/M checkpoints 173,182,183, which further sensitized cells to DNA damaging agents 183. Loss of
TIMELESS caused defects in mitotic progression 163,165 because TIMELESS synchronizes
replication termination and subsequent mitotic kinase (CDK1, Auroras A and B, PLK1)
activation 165.
DNA Damage
Further, in addition to causing genomic instability, DNA damage, and subsequent
checkpoint activation, TIMELESS is involved in the DNA damage signaling cascade, DNA
damage repair, and cell cycle arrest 114,173.
RPA binds to ssDNA during replication fork advancement and intermediate ssDNA that
is created during homologous recombination following double stranded breaks and chewing back
of the ends. RPA binding recruits the ATR-ATRIP complex, which then phosphorylates and
activates CHK1 at S345. Activated CHK1 prevents CDK1 activation and mitotic entry, thereby
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triggering the G2/M DNA damage checkpoint 184,185. In this pathway, TIMELESS, along with its
binding partner TIPIN (Timeless interacting protein) physically interacts with RPA, claspin, and
CHK1 and mediates both ATR- and claspin-mediated phosphorylation of CHK1 114,168,173,182,186-190.
Independent of ATR, CHK1 and TIMELESS are also required for efficient PCNA ubiquitination
after DNA damage 191,192.
Similar to other synthetically lethal combinations in DNA damage repair pathways,
TIMELESS depletion increased reliance on homologous recombination for continued DNA
synthesis 160, and TIMELESS depletion dramatically increased cell sensitivity to ATR depletion.
Cells deficient in ATR and TIMELESS have dramatically reduced nucleotide incorporation in S
phase and experience replication failure as a result of synergistic increases in γH2AX and DNA
double stranded breaks 162. TIMELESS has also been shown to be required for ATM-mediated
CHK2 activation following DNA double strand breaks 183.
TIMELESS physically interacts with PARP-1 193,194 and this interaction is required for
TIMELESS to accumulate at sites of DNA damage 193,194. TIMELESS does not affect PARP-1
enzyme activity 193,194, but is required for recruitment of other complex components to sites of
DNA damage 194. Loss of TIMELESS reduces homologous recombination193 as well as DNA
double strand break repair 194 suggesting a role for TIMELESS in DNA damage repair. PARP
inhibition prevents DNA damage repair by trapping PARP-1 at sites of DNA damage 193. PARP
inhibitors also trap TIMELESS at sites of DNA damage, but the effect of the sequestration of
TIMELESS is unknown 193.
Cancer
Significant evidence now suggests that cancer may be a circadian-related disorder as
several studies have demonstrated circadian rhythms are dysregulated in cancer cells 195,196.
Concerningly, large studies have correlated a substantial history of shift work and jet lag or
altered sleep/wake patterns with increased cancer incidence and higher mortality rate 197-201. This
suggests circadian rhythm dysregulation is not merely a downstream effect of oncogenic
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signaling, but also plays a pro-tumorigenic role. Recent work has started to elucidate the
relationship between the development of cancer and circadian rhythm dysregulation as well as
demonstrate the functional benefits of circadian dysregulation in cancer cells.
Oncogenes can drive the expression of certain circadian genes effectively hijacking the
circadian cycle, such as when MYC drives the expression of REV-ERB, which decreases
BMAL1 expression thereby releasing the cell from its tumor suppressive effects and alters cell
metabolism 202. Recent work has also shown that restoring circadian rhythmicity in vitro
decreased proliferation of cancer cells and circadian dosing of certain chemotherapeutics
increased their efficacy 203.
TIMELESS was not mutated in cancer 204, but was significantly overexpressed in both
patient tumors and cancer cell lines relative to normal adjacent tissue and normal cell lines,
respectively in multiple cancer types including acute lymphocytic leukemia, breast, cervical,
hepatocellular, and lung cancer (both non-small cell lung cancer and small cell lung cancer) 204210

.
Generally, TIMELESS has been shown to promote proliferation and metastasis in cancer

cells 204,207,208; however, the demonstrated mechanisms have varied greatly. In breast cancer,
TIMELESS upregulated the expression and activity of MYC, and inhibition of MYC blocked the
effects of TIMELESS 207. In hepatocellular carcinoma, TIMELESS depletion decreased cell
viability via increased apoptosis and G2 arrest following CHK2, but not CHK1, phosphorylation
and reduced ribosomal protein biosynthesis by decreasing EEF1A2 levels 208. TIMELESS
conferred cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/β-catenin
signaling pathway and promoting epithelial-mesenchymal transition 211. Increased TIMELESS
expression also correlated with tamoxifen resistance in breast cancer 212, and subsequent analysis
demonstrated that 17β-estradiol promoted TIMELESS expression in vitro in cells sensitive to
tamoxifen, but in tamoxifen-resistant cells, TIMELESS expression was independent of 17βestradiol 212. Clinically, increased TIMELESS expression was associated with a poorer prognosis
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in breast, cervical, bladder, and lung cancer 204-207,210,212,213. This suggests that TIMELESS likely
has a conserved, protumorigenic role that is present in many types of cancer. Determining the
mechanism behind its overexpression and further elucidating its functional role in tumorigenesis
is likely to increase our understanding of cancer and may reveal opportunities for the
development of new therapeutics.

Results
Preliminary biological validation of TIMELESS
Initial biological validation of targets identified using FUSION was performed by
assessing cancer cell growth or viability in anchorage-independent conditions following RNAimediated target depletion by measuring cell ATP levels on polyHEMA-coated plates 214,215 using
CellTiter-Glo® Luminescent Cell Viability Assay, as previously described 3. The smartPool of
four siRNA oligos (Dharmacon) targeting KSR1 or TIMELESS was used to deplete cells of the
target. Growth in anchorage-independent conditions was reduced substantially with KSR1 or
TIMELESS depletion in HCT116 colon cancer cells (Fig. 4.3A).
Immortalized, yet non-transformed human colon epithelial cells (HCECs)102 are unable to
proliferate in an anchorage-independent environment and were therefore not assayed in
anchorage-independent culture conditions. To compare the effects of TIMELESS depletion in
colon cancer cells to immortalized, yet non-transformed HCECs, RNAi-mediated depletion of
TIMELESS was completed under normal plating conditions and viability was measured using
alamarBlue. TIMELESS depletion for 72 hours reduced viability in HCT116 cells, but not
HCECs (Fig. 4.3B). TIMELESS depletion was validated by western blot in HCECs and HCT116
cells (Fig. 4.3C).
TIMELESS is overexpressed in cancer
TIMELESS is upregulated at the RNA level in several types of tumors compared to solid
normal tissue (TCGA) (Fig. 4.4A) and is upregulated at the mRNA (Fig. 4.4B) and protein level
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Fig. 4.3: Preliminary biological validation of TIMELESS. (A) Viability of HCT116 colon
cancer cells measured using CellTiter-Glo® following RNAi of KSR1 or TIMELESS that were
replated on polyHEMA-coated plates 48 hours following transfection to simulate anchorageindependent conditions. Cell viability is measured immediately after replating (Hrs: 0) and 24
hours later. (N=6). (B) Viability of HCECs and HCT116 cells measured using alamarBlue®
following RNAi-mediated TIMELESS depletion for 72 hours in normal culture conditions. (N=6)
(C) Immunoblot confirmation of TIMELESS depletion from B. Data are shown as mean ± SD.
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Fig. 4.4: TIMELESS is overexpressed in cancer. (A) TIMELESS gene expression (RNASeq)
data from TCGA for unpaired primary colon tumors and normal solid tissue samples. The results
published here are in whole or part based upon data generated by the TCGA Research
Network: http://cancergenome.nih.gov/. (B) Immunoblot and (C) RT-qPCR of TIMELESS levels
in a panel of colon tumor cell lines and immortalized, non-transformed HCECs. RT-qPCR data is
shown as mean ± SD. (N=3) (Experiment 4.4C was completed in collaboration with Jamie
McCall and Danielle Frodyma).
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(Fig. 4.4C) in a panel of human colon cancer cell line (HCT116, LoVo, RKO, HCT15, SW480,
SW620, T84, and Caco2) compared to HCECs.
Previous reports suggested altered promoter methylation on circadian genes was
associated with their altered expression in cancer 216. Specifically, TIMELESS promoter
hypomethylation was present with TIMELESS overexpression in breast cancer 217. Examining the
Beta value of TIMELESS-associated sites included on the Illumina Infinium Human DNA
Methylation 27 and Illumina Infinium Human DNA Methylation 450 beadchips from solid tissue
normal and primary tumor samples from the TCGA COAD dataset revealed the methylation of
TIMELESS is nearly identical between normal and colon tumor samples (Fig. 4.5A and B).
Comparing TIMELESS methylation state in HCECs as compared to HCT116s demonstrated no
difference in methylation (Fig. 4.5C) suggesting promoter hypomethylation is not contributing to
TIMELESS overexpression in colon cancer.
TIMELESS loses circadian expression in cancer.
In normal cells and tissues, TIMELESS expression has a circadian pattern 119-121.
However, TIMELESS demonstrated a loss of circadian rhythmicity in protein expression in colon
cancer cell lines. Following 50% horse serum shock for two hours, HCECs demonstrate cyclical
expression of TIMELESS over a 24-hour period that is consistent with a normal circadian pattern
with the highest level of expression being seen approximately 16-18 hours following serum shock
(Fig. 4.6A). Conversely, in HCT116 colon cancer cells, TIMELESS is constitutively expressed at
a high level, with very little cyclic alterations in expression (Fig. 4.6B). TIMELESS also
demonstrated circadian expression, with an earlier peak in expression, ~ 12 hours, following cell
synchronization by forskolin treatment (Fig. 4.6C).
Mutant Ras through downstream ERK signaling contributes to TIMELESS expression
To evaluate if oncogenic Ras contributes to increased TIMELESS expression in colon
cancer, TIMELESS expression was examined in HCECs following exogenous expression of
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Fig. 4.5: TIMELESS overexpression is not due to methylation changes at the
promoter. (A and B) TIMELESS methylation data from Illumina Infinium Human DNA
Methylation 27 (A) and Illumina Infinium Human DNA Methylation 450 (B) beadchips
data from TCGA for unpaired primary colon tumors and normal solid tissue samples. The
results published here are in whole or part based upon data generated by the TCGA
Research Network: http://cancergenome.nih.gov/. (C) Percent methylation for CpG sites
near or within the TIMELESS DNA sequence in HCECs and HCT116 cells. (Experiment
4.5C was completed in collaboration with Dr. Dave Klinkebiel and the Epigenomics Core).
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Fig. 4.6: TIMELESS is circadianly-expressed in HCECs, but constitutively overexpressed in
HCT116 colon cancer cells. (A and B) Immunoblot of TIMELESS expression over 24 hours
following circadian synchronization via 2 hour 50% horse serum treatment in HCECs (A) and
HCT116 cells (B). (C) TIMELESS mRNA expression over 24 hours following circadian
synchronization via 2 hour 50% hourse serum treatment in HCEC and HCT116 measured with RTqPCR. (N=1). (D) Immunoblot of TIMELESS expression over 24 hours following circadian
synchronization via 30 minute 10 µM foskolin treatment. (Experiment 4.6C-D were completed in
collaboration with Danielle Frodyma).
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mutant Ras and in HCT116 cells following ERK inhibition or RNAi-mediated ERK1/2 depletion.
HCECs expressing exogenous RasG12V have increased TIMELESS expression relative to HCECs
albeit not to the levels seen in the colon cancer cell lines tested. Following serum shock-induced
cell synchronization, HCECs with Ras maintain circadian expression of TIMELESS, but at an
increased level of expression (Fig. 4.7A). Comparing TIMELESS expression 16 hours following
serum shock in HCECs with Ras to HCECs (far right lane) demonstrates RasG12V promoted
TIMELESS expression. This increase in expression was abrogated with ERK inhibition with
1µM SCH772984 (Fig. 4.7B). In asynchronous HCECs, HCECs exogenously expressing RasG12V,
and HCT116 colon cancer cells, ERK inhibition with 1 μM SCH772984 decreased TIMELESS
expression (Fig. 4.8A) demonstrating the vital role ERK activation plays downstream of activated
Ras to promote TIMELESS expression. RNAi-mediated depletion of ERK demonstrates a similar
effect, but to a lesser degree (Fig. 4.8B). ERK inhibition for 24 hours prior to cell synchronization
by serum shock and collection over the next 24 hours demonstrated partial restoration of the
circadian expression of TIMELESS; however, the levels of TIMELESS remain elevated as
compared to the non-transformed HCECs (Fig. 4.9).
In HCECs, TIMELESS expression decreases with increasing cell confluency (Fig.
4.10A). In HCT116 cells, TIMELESS expression is constitutively high regardless of cell
confluency (Fig. 4.10A). However, changing the HCEC media daily dramatically reduces this
decrease in TIMELESS expression. This maintained TIMELESS expression occurs coordinately
with maintained levels of ERK phosphorylation and activation suggesting the possibility that
replacing the media daily refreshes the EGF levels (a normal additive in the HCEC as described
in Chapter 2: Materials and Methods), which then promotes ERK activation.
To evaluate how consistently ERK signaling promotes TIMELESS expression in colon
cancer, multiple colon cancer cell lines were treated with 1 μM SCH772984 for 48 hours and
assessed for cell viability with alamarBlue and TIMELESS expression via immunoblot. ERK
inhibition decreased cell viability and TIMELESS expression in HCT116 and SK-Co-1 cancer
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Fig. 4.7: HCECs expressing mutant RasG12V have increased, but circadianly regulated
TIMELESS expression. (A) Immunoblot of TIMELESS expression over 24 hours following
circadian synchronization via 2 hour 50% horse serum treatment in HCEC with RasG12V.
Lysates from HCECs 16 hours after 50% horse serum shock is included for reference. (B)
Immunoblot of TIMELESS in HCECs, HCECs with RasG12V, and HCECs with RasG12V
treated with 1 µM SCH772984 (ERK inhibitor) 24 hours prior to synchronization with 50%
horse serum shock and for the 16 hours after serum shock prior to collection.
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Fig. 4.8: Activated ERK promotes TIMELESS expression. (A) Western blot of TIMELESS in
HCECs, HCECs that stably express H-RasG12V, and HCT116 colon cancer cells with and without 1 µM
SCH772984 (ERK inhibitor) treatment for 48 hours. (B) Western blot of TIMELESS following RNAimediated ERK1/2 depletion for 72 hours in HCT116 cells. (Experiment 4.8B was done in collaboration
with Clara Rich)
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Fig. 4.9: ERK inhibition decreases TIMELESS expression and restores circadian expression of
TIMELESS in HCT116 cells. (A) Immunoblot of TIMELESS expression over 24 hours following
circadian synchronization via 2 hour 50% horse serum treatment in HCECs (top), HCT116 treated
with DMSO (middle), and HCT116 cells treated with 1 µM SCH772984 (ERK inhibitor) (bottom)
for 24 hours prior to synchronization and following synchronization throughout the time course until
collection. (B) Densitometry quantification of TIMELESS levels in A. (N=1).
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Fig. 4.10: TIMELESS expression correlates with phospho-ERK and is higher in less
confluent cells. (A and B) Immunoblot of TIMELESS expression and phosho-ERK in HCEC
and HCT116 cells at different stages of confluency without changing media daily (A) or
changing media daily (B). Note: In both figures, the lysates from both cell lines were run on
single blot and are shown at the same intensities.
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cell lines, but did not affect viability or TIMELESS levels in HCT15 and FET cancer cell lines
(Fig. 4.11).
TIMELESS is known to be degraded via the ubiquitin-proteosome system. ERK
inhibition by 1 μM SCH772984 or MEK inhibition by 1 μM PD0325901 decreases TIMELESS
expression, which was not rescued by 6-hour treatment with MG132 (Fig. 4.12A). Unfortunately,
the half-life of TIMELESS appears to be extended in cancer such that a 6-hour treatment with
MG132 may not have been long enough for TIMELESS expression to be rescued. Conversely,
TIMELESS mRNA levels were not affected by ERK inhibition suggesting that ERK is not
affecting TIMELESS transcription or mRNA stability (Fig. 4.12B).
ERK inhibition decreases cell viability and TIMELESS expression in HCT116 and SKCo-1 cells, but not HCT15 or FET cells (Fig. 4.11). In a similar pattern, ERK inhibition reduces
MYC expression in HCT116 and SK-Co-1 cells, but not in HCT15 and FET cells (Fig. 4.13A). In
normal cells, protein translation is largely regulated by PI3K and mTOR signaling, but recently it
has been shown that in some colon cancer cell lines PI3K and mTOR does not regulate MYC
translation 218. This led to the hypothesis that ERK may be regulating translation in these cell
lines. Previous work has shown that KSR1 regulates MYC expression in HCT116 cells by
promoting its translation via regulation of P-4EBP1 (T70) and PDCD4 42. Similarly, ERK
inhibition regulates P-4EBP1 (T70) and PDCD4 in HCT116 and SK-Co-1 cells, but not HCT15
and FET cells. This opens the possibility that ERK regulates TIMELESS expression via
translation in HCT116 and SK-Co-1 cells. To ascertain if the cell lines that are not affected by
ERK inhibition are instead dependent on mTOR signaling for increased translation, the effect of
mTOR inhibition on PDCD4, P-4EBP1 (T70), and TIMELESS was examined. mTOR inhibition
with 1 μM AZD8055 decreased TIMELESS expression in HCT15 and FET cells, while
TIMELESS expression in RKO and SW480 cells decreased with ERK or mTOR inhibition (Fig.
4.13B). P-4EBP1 (T70) decreased in all four colon cancer cell lines tested following mTOR
inhibition, with a slight decrease in expression following ERK inhibition in HCT116 cells. ERK
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Fig. 4.11: ERK inhibition decreases TIMELESS expression in colon cancer cell lines that
are sensitive to ERK inhibition. (A and B) Viability (A) and paired immunoblot analysis of
TIMELESS expression (B) following treatment with 1 uM SCH772984 for 48 hours in a panel of
colon cancer cells. (N=6). (Experiment 4.11A-B was done in collaboration with Danielle
Frodyma)
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Fig. 4.12: ERK does not promote TIMELESS expression by increasing its protein stability or
mRNA levels. (A) Immunoblot of TIMELESS and MYC levels (MG132 rescue control) following
treatment with 1 µM SCH772984 (ERK inhibitor), or 1 µM PD0325901 (MEK inhibitor) with and
without 10 µM MG132 treatment for 6 hours. (B) TIMELESS mRNA following 48 hour ERK
inhibition with 1 µM SCH772984. (N=3). (Experiment 4.12B was performed in collaboration with
Jamie McCall).
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Fig. 4.13: ERK and mTOR inhibition regulates inhibitors of translation in a subset of colon
cancer cell lines. (A) Immunoblot of downstream ERK targets (phospho- and total-RSK)
regulators of translation (PDCD4, phospho- and total-4EBP1), and MYC following ERK
inhibition with 1 µM SCH772984 for 48 hours in HCT116, HCT15, LoVo, SK-CO-1, and FET
cells. (B) Immunoblot of PDCD4 and P-4EBP1 (T70) following ERK or mTOR inhibition with 1
µM SCH772984 or AZD8055 for 24 hours in HCT116, HCT15, RKO, FET, and SW480 cells.
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inhibition increased PDCD4 expression in the cell lines tested, but this effect was modest in
HCT15 and FET cells (Fig. 4.13B).
Using polysome profiling, the translational efficiency of TIMELESS was examined
following ERK or mTOR inhibition in HCT116 and HCT15 colon cancer cells, respectively.
Translational efficiency is defined as the ratio of polysome-bound mRNA to total mRNA. Total
TIMELESS mRNA was unchanged, but polysome-bound TIMELESS mRNA was significantly
decreased following ERK inhibition with 1 μM SCH772984 in HCT116 cells or mTOR inhibition
with 1 μM AZD8055 in HCT15 cells for 24 hours resulting in an overall decrease in TIMELESS
translational efficiency (Fig. 4.14).
To further evaluate the requirement for ERK or mTOR in colon cancer cells, cell viability
was examined following single agent treatment with either 1 μM SCH772984 or 1 μM AZD8055
as well as combination treatment with both SCH772984 and AZD8055 either 500 nM or 1 μM
doses for 48 hours. Consistent with previous results, HCT116, SW480, and RKO cells were
sensitive to both the ERK inhibitor and mTOR inhibitor and underwent a substantial decrease in
cell viability with either individual treatment; however, no additional effects were seen with
inhibition of both ERK and mTOR together (Fig. 4.15). HCT15 and FET cells were more
sensitive to mTOR inhibition than ERK inhibition, but also demonstrated very little additional
effect of treating with both inhibitors simultaneously (Fig. 4.15).
The mechanism by which ERK or mTOR regulates translation is thought to be at least in
part through RSK; however, RSK inhibition via 1 μM BI-D 1870 treatment only reduced
TIMELESS expression in HCT15 cells, but not HCT116 or RKO cells (Fig. 4.16). RSK
inhibition in HCT15 cells did not affect PDCD4 levels; however, the effect of RSK inhibition on
P-4EBP1 (T70) in these cells is still unknown and could still be mediating an effect of RSK on
TIMELESS translation. Additionally, the interpretation of these results is limited by the lack of
positive controls that demonstrate the effects of the inhibitors on downstream targets of ERK,
mTOR, and RSK. Regardless, the preliminary evidence that RSK may not be mediating the effect
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Fig. 4.14: Translation of TIMELESS is decreased following ERK inhibition in
HCT116 cells and mTOR inhibition in HCT15 cells. Translational efficiency (TE) of
TIMELESS in HCT116 cells (top) following ERK inhibition with 1 μM SCH772984
and in HCT15 cells (bottom) following mTOR inhibition with 1 μM AZD8055 for 24
hours. (N=3). (Experiment 4.14 was completed by Eyerusalem Lemma and Danielle
Frodyma.).
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Fig. 4.15: Effects of ERK and mTOR inhibition on cell viability in a panel of colon
cancer cell lines. (N=6).
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Fig. 4.16: RSK does not mediate the effect of ERK on TIMELESS. Western blot of
TIMELESS and PDCD4 following ERK, mTOR, or RSK inhibition for 24 hours with 1
μM of SCH772984, AZD8055, or BI-D 1870 treatment, respectively.
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of ERK on TIMELESS expression raises questions about whether this interaction is truly
mediated through changes in translation.
TIMELESS is required for cancer cell proliferation
Preliminary biological validation demonstrated that HCT116 colon cancer cells were
substantially more sensitive to TIMELESS depletion than HCECs (Fig. 4.3). To determine the
prevalence of the requirement for TIMELESS in colon cancer cells, cell viability was measured
in a panel of colon cancer cell lines following RNAi-mediated TIMELESS depletion for 96 hours
using alamarBlue®. TIMELESS depletion decreased cell viability by more than 20% in HCT116,
SW480, SW620, and RKO colon cancer cells (Fig. 4.17A). HCT15 colon cancer cells were not
sensitive to TIMELESS depletion (Fig. 4.17A). To determine if this decrease in cancer cell
viability was a result of cells undergoing apoptosis, PARP cleavage following TIMELESS
depletion for 72 hours was assessed by western blot. TIMELESS depletion induced only a very
slight increase in PARP cleavage in HCT116, SW480, and SW620 colon cancer cells and did not
affect PARP cleavage in HCT15 or RKO cells (Fig. 4.17B). Therefore, the effect of TIMELESS
depletion on cell viability cannot be attributed to an increase in apoptosis.
Comparing the effect of TIMELESS depletion on PARP cleavage in HCECs and
HCT116 cells confirmed that TIMELESS depletion induces a small amount of PARP cleavage in
HCT116 cells; however, TIMELESS depletion reduced levels of PARP in HCECs without
increasing PARP cleavage (Fig. 4.18). Previous reports have clearly demonstrated that
TIMELESS physically interacts with PARP 193,194. This interaction was not required for PARP
enzymatic activity, but loss of this interaction reduced the level of DNA damage repair
suggesting a functional role for the TIMELESS PARP interaction. This data suggests the
possibility that TIMELESS could promote PARP stability.
TIMELESS depletion induces G2/M arrest
A previous study demonstrated that TIMELESS knockdown in HCT116 cells did not
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Fig. 4.17: TIMELESS is required for colon cancer cell viability, but does not induce cell
death. (A) Cell viability in a panel of colon cancer cells following RNAi-mediated depletion of
TIMELESS. Viability was measured by alamarBlue® assays 96 hours after transfection. (N=6).
(B) Western blot of TIMELESS and PARP following RNAi-mediated TIMELESS depletion for
72 hours in HCT116, HCT15, SW480, SW620, and RKO colon cancer cells. Data are shown as
mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
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Fig. 4.18: TIMELESS depletion selectively induces low levels of cleaved PARP in
HCT116 cells, but not HCECs. Immunoblot of TIMELESS and PARP following RNAimediated TIMELESS depletion for 72 hours in HCECs and HCT116 cells.
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affect the cell cycle 183. However, in a panel of colon cancer cell lines, TIMELESS depletion
reduced metabolic capacity based on the alamarBlue® viability assay, but did not increase
apoptosis based on very little, if any, increase in PARP cleavage (Fig. 4.17B). Additionally,
TIMELESS has been shown to play a role in triggering cell cycle checkpoints 163,165,173,182,183.
Therefore, cell cycle analysis was performed using propidium iodide staining and flow cytometry
evaluation. In HCT116, SW620, and SW480 colon cancer cell lines a very small increase in subG1 peak was induced with TIMELESS depletion (Fig. 4.19). This is consistent with the very
minor induction of PARP cleavage in these cell lines following TIMELESS depletion (Fig.
4.17B). All five colon cancer cell lines underwent a decrease in percent of cells within G1 and an
increase in percent of cells within G2 (Fig. 4.19).
TIMELESS depletion reduces cancer cell proliferation
To confirm that TIMELESS depletion reduced cell proliferation, or specifically cell
division, a carboxyfluorescein succinimidyl ester (CFSE) assay was completed. CFSE is a cellpermeable, fluorescent dye that covalently binds to intracellular molecules, particularly lysine and
other amine-containing molecules. The covalent integration of CFSE is highly stable such that the
fluorescence is sustained for long periods of time, and the dye is not leached to other cells. With
each cell division, approximately half of the integrated CFSE is passed on to each daughter cell,
such that the degree of CFSE staining can be used as a marker for cell division. Therefore,
HCT116 and SW480 cancer cells were stained with CFSE dye prior to RNAi-mediated
TIMELESS depletion for 96 hours. Flow cytometry analysis was then employed to measure
CFSE fluorescence levels (Fig. 4.20). Both HCT116 and SW480 cancer cells that lacked
TIMELESS had increased mean levels of CFSE demonstrating they underwent fewer cell
divisions (Fig. 4.20).
TIMELESS depletion does not affect ERK activation or MYC expression
One previous study demonstrated TIMELESS supports cancer cells by increasing MYC
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Fig. 4.19: TIMELESS depletion induces a G2/M arrest in a panel of colon cancer cells. (A)
Quantification of the percent of cells in each phase of the cell cycle following RNAi-mediated
TIMELESS depletion in HCT116, HCT15, SW480, SW620, and RKO colon cancer cells from 3
biological replicates. Apoptosis (% of cells in the sub-G1 peak) and cell cycle were evaluated using
propidium iodide staining followed by flow cytometry analysis. (N=3). (B) Representative cell cycle
histograms from (A). Data are shown as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001

121

Fig. 4.20: TIMELESS depletion decreases cell proliferation. (A) Overlay histogram for three
biological replicates of flow cytometry analysis of CFSE staining following RNAi-mediated TIMELESS
depletion in CFSE-stained HCT116 (top) and SW480 (bottom) cells for 96 hours. Control replicates are
shown in gray, and TIMELESS-depleted replicates are shown in black. (N=3). (B) Quantification of mean
CFSE staining from (A). (C) Western blot confirming TIMELESS depletion in all three biological
replicates of CFSE-stained cells from (A). **** p < 0.0001
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expression and activity 207. Another report proposed that TIMELESS could support cancer by
supporting Ras signaling as Ras mRNA expression was downregulated following TIMELESS
depletion 205. Therefore, the potential for TIMELESS to support Ras or MYC to promote cell
cycle advancement and proliferation was evaluated by examining the effects of TIMELESS
depletion on MYC expression and ERK activation/phosphorylation. RNAi-mediated TIMELESS
depletion for 72 hours did not affect ERK phosphorylation in HCEC or HCT116 cells (Fig.
4.21A) or MYC expression in HCT116 cells (Fig. 4.21B). However, serum shock (50% horse
serum for 2 hours) reduced phosphorylation of ERK and induced MYC expression (Fig. 4.21B),
which could be contributing to or confounding the results from the in vitro examination of the
circadian expression of TIMELESS (Fig. 4.6).
TIMELESS depletion decreases AKT phosphorylation
Preliminary experiments demonstrated that TIMELESS reduced AKT phosphorylation
and activation (Fig. 4.22). Several previous studies have demonstrated the strong role AKT plays
in cell cycle advancement and have shown that expression of activated AKT can drive cells
through the G2/M checkpoint via AKT phosphorylation and inactivation of Wee1. When Wee1 is
active, it phosphorylates and inactivates CDK1. Therefore AKT-mediated inactivation of Wee1
releases its inhibition of CDK1 thereby preventing G2/M arrest 219,220.
AKT does not mediate the effect of TIMELESS on the cell cycle
Based on this information, the ability of exogenous expression of a mutant, constitutively
active form of AKT that had S473 and T308 replaced with aspartic acid (D), which was denoted
AKTDD, to rescue the G2/M arrest caused by TIMELESS depletion in HCT116 cells was
evaluated. Overall, TIMELESS depletion still induced a small increase in the sub-G1 peak,
decreased the number of cells in the G1 phase, and increased the number of cells in the G2 phase
in cells transfected with the control eGFP or the eGFP-AKTDD (Fig. 4.23A). However, separating
the cells that received the eGFP-AKTDD construct with and without TIMELESS depletion based
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Fig. 4.21: TIMELESS depletion does not affect ERK activation or MYC levels, but serum shock
decreases P-ERK and induces MYC expression. (A) Western blot of TIMELESS, phospho- and totalMEK, phospho- and total-ERK following RNAi-mediated TIMELESS depletion for 72 hours in HCECs
and HCT116 cells. (B) Immunoblot of TIMELESS, MYC, phospho-ERK, and phospho-MEK following
RNAi-mediated TIMELESS depletion with and without 50% horse serum shock for two hours in
HCT116 cells.
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Fig. 4.22: TIMELESS depletion decreases AKT activation. Western blot of
phospho- and total-AKT (S473 and T308) following RNAi-mediated TIMELESS
depletion for 72 hours in HCT116 cells.
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Fig. 4.23: AKT can drive cells through G2/M, but AKT inhibition does not mimic TIMELESS
depletion and cause G2/M arrest. (A) Cell cycle analysis by PI stain following TIMELESS
depletion for 72 hours and exogenous expression of AKTDD for 48 hours prior to collection. (N=1).
(B) Re-evaluation of data from A separating the eGFP-AKTDD based on GFP positivity. (N=1). (C)
Cell cycle analysis following inhibition of AKT with 500 nM MK2206 for 48 hours. (GFP-AKTDD
and the AKT inhibitor MK2206 were a kind gift from the Black Lab at UNMC).
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on GFP positivity revealed that the cells expressing the eGFP-AKTDD no longer underwent G2/M
arrest following TIMELESS depletion (Fig. 4.23B). This suggested that activated AKT was able
to push the cells through the G2/M cell cycle checkpoint. However, inhibition of AKT with
MK2206 did not induce a G2/M arrest, but instead triggered S phase arrest (Fig. 4.23C). This
suggests that TIMELESS depletion is not inducing G2/M arrest through AKT despite the
potential for activated AKT to rescue cells from this arrest.
TIMELESS depletion causes G2/M arrest through increasing levels of DNA damage and
subsequent phosphorylation of CHK1 and CDK1
In normal cells, TIMELESS has been shown to promote DNA synthesis and DNA
damage repair 114,160. In a panel of five colon cancer cell lines, RNAi-mediated TIMELESS
depletion for 72 hours ubiquitously caused an increase in γH2AX, a marker of DNA damage (Fig.
4.24). Downstream of γH2AX, all five cancer cell lines demonstrated increased phosphorylation
of CHK1 and CDK1 (Fig. 4.24), which provides a mechanism for the G2/M arrest following
TIMELESS depletion. The increase in γH2AX, P-CHK1, and P-CDK1 was recapitulated using
four individual oligos targeting TIMELESS in HCT116 cells (Fig. 4.25). This mechanism appears
to also be present in HCECs, but is triggered to a lesser degree likely as a result of intact DNA
repair mechanisms, high fidelity DNA replication, and a slower cell proliferation rate in the
normal HCECs compared to colon cancer cells (Fig. 4.26).
ERK inhibition increases γH2AX, which cannot be rescued with exogenous TIMELESS
expression
Since ERK inhibition decreases TIMELESS expression, and TIMELESS depletion
dramatically increased the level of γH2AX, the effect of ERK inhibition on DNA damage was
examined, which demonstrated that ERK inhibition also substantially increased the
phosphorylation of H2AX (γH2AX) (Fig. 4.27). To determine if this increase in γH2AX was an
effect of decreased TIMELESS levels following ERK inhibition, TIMELESS was transiently
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Fig. 4.24: TIMELESS depletion induces G2/M arrest via CHK1 phosphorylation,
which leads to Cdk1 phosphorylation and inactivation. Immunoblot of phospho- and
total-H2AX, phospho- and total CHK1 (S345), phospho- and total- CDK1 (Y15) and AKT
targets phospho-GSK3B (S9) and phospho-Wee1 (S642) following RNAi-mediated
TIMELESS depletion for 72 hours in a panel of colon cancer cells. Note: The primary
antibody used for the T-CDK1 blot was 77055 cell signaling antibody. All other T-CDK1
blots used the 9112 cell signaling antibody.
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Fig. 4.25: Individual oligos induce TIMELESS depletion, which causes increased
γH2AX, CHK1 phosphorylation, and CDK1 phosphorylation in HCT116 cells.
Western blot of phospho- and total-H2AX, phospho- and total CHK1 (S345), phosphoand total- CDK1 (Y15) following RNAi-mediated TIMELESS depletion for 72 hours
using four individual oligos or a pool of all four oligos in HCT116 cells.
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Fig. 4.26: TIMELESS depletion induces increased γH2AX, CHK1 phosphorylation,
and CDK1 phosphorylation in HCT116 cells and to a lesser extent in HCECs.
Western blot of phospho- and total-H2AX, phospho- and total CHK1 (S345), phosphoand total- CDK1 (Y15) following RNAi-mediated TIMELESS depletion for 72 hours in
HCEC and HCT116 cells.
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Fig. 4.27: Exogenous TIMELESS expression does not prevent the accumulation of γH2AX
following ERK inhibition. (A and B) Western blot of ERK and its downstream targets including
γH2AX following moderate (A) or high (B) exogenous expression of TIMELESS for 72 hours
with or without ERK inhibition with 1 µM SCH772984 for 48 hours.
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exogenously expressed in HCT116 cells prior to treatment with SCH772984 for 48 hours. Low
levels (Fig. 4.27A) and high levels (Fig. 4.27B) of exogenous TIMELESS were unable to prevent
the increase in γH2AX or restore MYC expression in HCT116 cells following ERK inhibition
(Fig. 4.27) suggesting the induction of γH2AX following ERK inhibition is not solely due to a
decrease in TIMELESS expression.
Of note, while ERK inhibition decreased endogenous TIMELESS expression, it did not
affect the exogenous expression (Fig. 4.27). This demonstrates that ERK does not affect
TIMELESS protein stability, and must instead affect either transcription, mRNA stability, or
translation.
ERK inhibition prevents the phosphorylation and activation of CHK1 and CDK1 in
response to DNA damage.
Paradoxically, ERK inhibition with 1 μM SCH772984 for 24 hours in HCT116 cells
dramatically reduces the total and phosphorylated levels of CHK1 and CDK1 despite an increase
in γH2AX (Fig. 4.28). This is consistent with previous reports that ERK is activated in response
to DNA damage, and this activation contributes to DNA damage-induced cell cycle arrest or
apoptosis depending on the level of DNA damage induced 221. This effect may be coordinated by
RSK as RSK has been shown to phosphorylate CHK1 at S280, which is a prerequisite for nuclear
localization that is required for DNA-damage induced ATR-mediated phosphorylation of CHK1
at S345 222. Thus, Ras signaling ensures high DNA fidelity during DNA replication to allow for
increased cell proliferation, which explains the loss of CHK1 and CDK1 phosphorylation with
ERK inhibition.
Combination therapy with TIMELESS depletion and DNA-damaging chemotherapies
TIMELESS depletion caused an increase in γH2AX, a marker of DNA damage; however,
it is unclear whether this increase is due to an increase in the induction of DNA damage or a
reduced capacity to repair DNA damage. Regardless of the mechanism, the potential exists for
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Fig. 4.28: ERK inhibition increases γH2AX, but decreases phospho- and
total- CHK1 and CDK1. (A) Western blot of TIMELESS, phospho- and
total- RSK, phospho- and total- CHK1, and phospho- and total- CDK1 after
ERK inhibition for 24 hours with 1 μM SCH772984.
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TIMELESS depletion to synergize with other DNA-damaging therapies as the combination could
further induce damage or the increased induction of damage could be amplified by a decreased
ability to repair it. Therefore, the effect of TIMELESS depletion with other DNA damaging
agents including mitomycin C (MMC), 5-fluoruracil (5-FU), and oxaliplatin (OXAL) was
examined. The induction of γH2AX following TIMELESS depletion was modestly increased
with the addition of MMC (Fig. 4.29). Treatment with 5-FU further decreased viability compared
to TIMELESS depletion alone, but the effect was small and likely was not even additive (Fig.
4.30A). OXAL treatment reduced the effect of TIMELESS depletion (Fig. 4.30A). Interestingly,
treatment with 5-FU did not increase and may have in fact reduced the level of γH2AX following
TIMELESS depletion, while OXAL treatment caused a slight increase in γH2AX following
TIMELESS depletion (Fig. 4.30B). Even though these are largely negative results, they may
provide hints towards the mechanism behind the requirement for TIMELESS in cancer cells. The
principal mechanism by which 5-FU affects cancer cells is by inhibiting DNA replication through
depletion of thymidine that is required for DNA synthesis. If TIMELESS is limiting the induction
of DNA damage during DNA synthesis by supporting replication fork stability, slowing DNA
synthesis through 5-FU treatment, may, in fact, reduce the level of DNA damage induced by
TIMELESS depletion, while serving to reduce cell proliferation. On the other hand, OXAL
directly induces double-stranded DNA breaks and blocks DNA replication following the
formation of platinum-DNA adducts or cross-linking DNA. This could explain the increased level
of γH2AX, while also reducing the effect of TIMELESS depletion by again limiting DNA
synthesis.
Combination therapy with TIMELESS depletion and ionizing radiation
Examining TIMELESS depletion in combination with ionizing radiation (IR) treatment in
a panel of colon cancer cell lines revealed variable effects with HCT116, SW480, SW620, and
T84 cells showing some increased effects with combination treatment, while HCT15, RKO, and
LoVo cells did not (Fig. 4.31A). However, even in the cell lines that demonstrated some effect of
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Fig. 4.29: TIMELESS depletion induces DNA damage as evidenced by increased
phosphorylation of H2AX. (A) Western blot of phospho- and total H2AX following RNAimediated TIMELESS depletion for 72 hours with and without MMC treatment for 48 hours in
HCT116 cells. (Fig. 4.26A was completed in collaboration with Danielle Frodyma).

135

Fig. 4.30: TIMELESS depletion in conjunction with DNA damaging agents (5-FU and
oxaliplatin). (A and B) Cell viability (A) as measured by alamarBlue and western blot (B) of
γH2AX in HCT116 cells following 72-hour TIMELESS depletion in combination with 1 μM 5FU or OXAL treatment for 48 hours. (C) Dose-response curves for 5-FU and oxaliplatin (OXAL)
in HCT116 cells treated for 48 hours.
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combination treatment, the effect of the combination demonstrated less than additive effects.
Specifically, in HCT116 cells, both TIMELESS depletion or IR treatment alone dramatically
reduced cell viability; however, the combination barely outperformed either of these treatments
individually based on viability (Fig. 4.31A). The combination of TIMELESS depletion with IR
did increase the level of γH2AX further than either TIMELESS depletion or IR treatment alone
(Fig. 4.31B). Taken together these results suggest there may be limiting returns for inducing more
and more DNA damage or a longer assay may be needed for the full effects of these combination
treatments to be realized.
Combination therapy with TIMELESS depletion and cell cycle checkpoint inhibitors
Since TIMELESS depletion induces G2/M arrest, the potential for TIMELESS depletion
to synergize with checkpoint inhibition was examined. With individual drug treatment, CHK1
inhibition was more lethal than Wee1 inhibition in all cell lines except HCT15 cells, which were
more sensitive to the Wee1 inhibitor (Fig. 4.32). Cell viability was decreased with TIMELESS
depletion in HCECs, but combination treatment with Wee1 or CHK1 inhibitors reduced this
effect (Fig. 4.32). In contrast, TIMELESS depletion in combination with Wee1 or CHK1
inhibition further decreased cell viability than either perturbation alone in all the colon cancer cell
lines tested except for HCT15 cells (Fig. 4.32). Inhibition of Wee1 or CHK1 actually increased
the percentage reduction in viability following TIMELESS depletion suggesting at least additive,
if not synergistic, effect with this combination in all of the colon cancer cell lines tested, but an
inhibitory effect in HCECs (Fig. 4.32B). Interestingly, TIMELESS depletion has no effect in
HCT15 cells with no drug treatment or Wee1 inhibition; however, CHK1 inhibition sensitized
HCT15 cells to TIMELESS depletion.

Conclusions
This and previous studies have demonstrated that TIMELESS is highly expressed in
multiple types of cancer 204,206,207,210,216,217. Despite the high prevalence of TIMELESS
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Fig. 4.31: TIMELESS depletion in conjunction with ionizing radiation in a panel of colon
cancer cell lines. (A and B) Viability (N=6) (A) and Western blot (B) of p53, phospho- and totalH2AX following RNAi-mediated TIMELESS depletion for 96 hours with and without a single
dose treatment of 5 or 3 Gy ionizing radiation 48 hours prior to collection in a panel of colon
cancer cells and HCT116 cells, respectively.
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Fig. 4.32: TIMELESS depletion sensitizes colon cancer cells to Wee1 and CHK1 inhibition. (A) Cell
viability in a panel of colon cancer cells following RNAi-mediated depletion of TIMELESS with Wee1
inhibition or CHK1 inhibition. Viability was measured by alamarBlue® assays 96 hours after
transfection. 300 nM of Wee1 (MK-1775) or CHK1 (AZD7762) inhibitor was added 48 hours after
transfection. Data are normalized to the DMSO treated control transfection (far left bar) and are shown as
mean ± SD. (N=6). The lower case letters denote a statistical significance (one-way ANOVA with
Bonferroni’s Multiple Comparison test for the specified comparisons) with a p value less than 0.001 for
the following comparisons: a – DMSO-treated siCont vs DMSO-treated siTIM; b – MK-1775-treated
siCont vs MK-1775-treated siTIM; c – AZD7762-treated siCont vs AZD7762-treated siTIM; d – DMSOtreated siTIM vs MK-1775-treated siTIM; e – DMSO-treated siTIM vs AZD7762-treated siTIM.
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Fig. 4.32 Continued: TIMELESS depletion sensitizes colon cancer cells to Wee1 and CHK1
inhibition. (B) Same data as A, but data are normalized to the control transfection for each drug
treatment to isolate the subsequence effect of TIMELESS depletion on top of the drug-mediated
effects. (N=6). The lower case letters denote a statistical significance (one-way ANOVA with
Bonferroni’s Multiple Comparison test for the specified comparisons) with a p value less than
0.001 for the following comparisons: a – DMSO-treated siCont vs DMSO-treated siTIM; b –
MK-1775-treated siCont vs MK-1775-treated siTIM; c – AZD7762-treated siCont vs AZD7762treated siTIM; d – DMSO-treated siTIM vs MK-1775-treated siTIM; e – DMSO-treated siTIM vs
AZD7762-treated siTIM.
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overexpression, there is a distinct lack of mutations in TIMELESS in cancer 204 suggesting that
individual mutations are unlikely to increase TIMELESS activity and instead TIMELESS
expression determines its level of activity. These results demonstrate oncogenic Ras promoted
TIMELESS overexpression in cancer. Downstream of Ras this effect is mediated by ERK or
mTOR depending on the colon cancer cell line and is possibly tied to the ability of ERK or
mTOR to modulate translation. However, TIMELESS expression has been shown to vary with
cell cycle, with the highest levels being seen in the S and G2 phases 182. Therefore, it is possible
that ERK or mTOR activation promote TIMELESS expression as a side effect of increasing cell
proliferation and subsequently increasing the percentage of cells in S and G2 phases. Consistent
with the hypothesis that proliferation rate affects TIMELESS expression levels, as HCECs
become more confluent, TIMELESS expression decreases; however, in HCT116 cells,
TIMELESS expression is constitutively high regardless of confluency. TIMELESS is also
aberrantly expressed in colon cancer as it is constitutively expressed in HCT116 cells and has lost
the circadian expression that is present in HCECs, which could also be a result of oncogenic
signaling overriding the normal regulation of TIMELESS expression to drive its constitutive
expression.
It is also likely that TIMELESS expression is increased through other mechanisms since
TIMELESS is overexpressed, at least at the mRNA level, in several cancers that are not
commonly driven by oncogenic Ras including breast, uterine, ovarian, and cervical cancers (Fig.
4.4A). Additionally, while the exogenous expression of mutant Ras in HCECs increased the level
of TIMELESS expression, the colon cancer cell lines still maintained a much higher level of
TIMELESS expression. Previous reports have hypothesized TIMELESS expression is increased
as a result of decreased DNA methylation in breast cancer 217, but this was not seen in colon
cancer. Alternatively, the TIMELESS promoter contains an E-box sequence such that CLOCK
and BMAL1, the driving circadian rhythm transcription factors, are likely to promote the
transcription of TIMELESS; however, this has not yet been demonstrated in mammalian cells.
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Additionally, the presence of this E-box opens the possibility that MYC could drive the
expression of TIMELESS as MYC has recently been shown to disrupt the normal circadianregulated expression of REV-ERBα and promote its constitutive expression by aberrantly binding
to the E-box within its promoter 202.
The increase in TIMELESS expression in multiple cancers suggests that TIMELESS may
ubiquitously promote cell proliferation by supporting high fidelity DNA synthesis, DNA damage
repair, and cell cycle advancement likely through numerous mechanisms as several potentially
contributing mechanisms have already been described 114,160,162-165,168,169,173,175,207. Interestingly,
TIMELESS has been shown to be required for the maintenance of cancer-associated viral
genomes as well 176,177, which could provide some rationale for its particularly high expression in
cervical cancer, which is almost always driven by human papillomavirus (HPV).
While TIMELESS depletion increased γH2AX and triggered the same downstream
activation of CHK1 and inhibition of CDK1 in HCT15 cells as it did in the other cell lines
examined (Fig. 4.24), TIMELESS depletion did not reduce HCT15 cell viability (Fig. 4.17). This
could be due to dramatically disrupted and non-functioning cell cycle checkpoint function in
these cells as HCT15 cells have a high basal level of P-CDK1 (Fig. 4.24), yet maintain a high
proliferative rate. HCT15 cells have an abundance of genetic alterations that disrupt DNA
damage repair and cell cycle checkpoint pathways including mutations in ATM, ATR, BRCA1,
BRCA2, CHK2, and FANCA. These or other alterations that promote cell cycle advancement in
the presence of DNA damage could allow cells to lose their dependency on TIMELESS.
Similarly, SW480 cells had high basal level of P-CHK1 and demonstrated a limited capacity to
phosphorylate and inactivate CDK1 even following a robust induction of γH2AX (Fig. 4.24)
suggesting these cells may also contain additional alterations that suppress DNA damage
checkpoint signaling cascades and subsequent cell cycle arrest. Elucidating the mechanisms by
which HCT15 cells promote cell cycle advancement even in the presence of phosphorylated and
inactivated CDK1 and SW480 cells limit CDK1 inactivation by CHK1 may reveal novel
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mechanisms with potential therapeutic implications.
Despite the potential for some cancer cells to be insensitive or develop insensitivity to
TIMELESS depletion, four of the colon cancer cell lines that were tested in this study
demonstrated a substantial requirement for TIMELESS in order to maintain a high level of
proliferation. G2/M arrest was particularly high in HCT116 and RKO cells, two colon cancer cell
lines with wildtype p53. Several previous studies have demonstrated there are both p53independent and p53-dependent pathways in cell cycle checkpoints following DNA damage. This
suggests the p53-wildtype cells may trigger both p53-independent and p53-dependent pathways
thereby inducing a more robust cell cycle arrest as compared to the mutant p53 cell lines (HCT15,
SW480, and SW620) that only trigger p53-independent pathways.
Interestingly, ERK inhibition increases γH2AX, but downstream CHK1 phosphorylation
does not occur. This could be the result of decreased RSK phosphorylation as RSK has previously
been shown to phosphorylate CHK1 at S280, which is required for CHK1 nuclear localization, a
prerequisite for ATM or ATR mediated phosphorylation at S345 in response to DNA damage.
Additionally, ERK inhibition increases γH2AX independent of TIMELESS as exogenous
expression of TIMELESS does not reduce γH2AX levels.
TIMELESS appears to have a highly conserved functional role in cells that could make it
difficult to target therapeutically with a reasonable therapeutic index. However, HCECs
expressed TIMELESS at lower levels and demonstrated less sensitivity to TIMELESS depletion.
This could be a result of a slower proliferation rate, a difference that could also be exploited in
vivo and that is the only means of cancer selectivity for several clinically approved
chemotherapeutics. Targeting TIMELESS directly may be particularly efficacious in tumors that
possess other defects in DNA damage repair pathways as they may be more dependent on
TIMELESS to prevent or repair DNA damage. Unfortunately, combination treatment with
TIMELESS depletion and DNA damaging chemotherapeutics or ionizing radiation had only
small incremental increases in efficacy over single treatments. This suggests there may be an
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upper limit for the efficacy of DNA damaging agents or a minimum amount of DNA damage that
is required for cell cycle arrest such that once this level is reached further induction of DNA
damage has little or no effect. Alternatively, the combinatory effects of TIMELESS depletion in
conjunction with DNA-damaging chemotherapeutics or ionizing radiation might only be seen
with longer treatment regimens to allow for the effects of DNA damage accumulation to be fully
realized. Additional studies using other DNA damaging agents and/or longer experimental
courses may reveal a potential for TIMELESS depletion to complement currently used cancer
therapies.
Combination therapy with TIMELESS depletion and either Wee1 or CHK1 inhibition
demonstrated at least additive effects in the colon cancer cell lines, but not in HCECs, suggesting
this combination may be an efficacious strategy for the treatment of colon cancer. Interestingly,
the CHK1 inhibitor AZD7762 did not decrease HCT15 viability alone, but sensitized the HCT15
cells to TIMELESS depletion.
Recent studies have also demonstrated increased efficacy and decreased side effects
when chemotherapeutics are dosed in a circadian fashion 195,203,223-225 suggesting a window of time
exists when cancer cells, but not normal cells are proliferating and therefore even more sensitive
to chemotherapeutics. TIMELESS has been shown to be circadianly expressed in normal tissue;
however, it is likely constitutively overexpressed in cancer due to oncogene-driven expression.
This opens the possibility that a circadian dosing scheme could increase the therapeutic index of
TIMELESS inhibition.
This may not be necessary, however, as TIMELESS has previously been shown to
physically interact with PARP at sites of DNA damage and PARP inhibitors trap TIMELESS
with PARP at DNA lesions 193 effectively sequestering and possibly preventing TIMELESS from
performing its other functions in the cell. Clinical trials with PARP inhibitors have demonstrated
favorable side effect profiles such that these inhibitors are clinically approved for the treatment of
multiple cancers, which provides optimism that, if developed, direct TIMELESS inhibitors may
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also be efficacious and have minimal side effects in patients. However, the effects of PARP
inhibitors on TIMELESS have not been evaluated, and the high level of TIMELESS expression
in cancer may mitigate any effect from sequestration of TIMELESS with PARP at sites of DNA
damage. Additional work is needed to evaluate if PARP inhibitors functionally inhibit
TIMELESS and if this mechanism also contributes to their efficacy.
To summarize, oncogenic Ras, through increased ERK activation, contributes to the
overexpression of TIMELESS in cancer. TIMELESS reduces the accumulation of DNA damage
thereby supporting cell proliferation by preventing cell cycle checkpoint-induced G2/M arrest.
These results demonstrate a clear role for TIMELESS in cancer and suggest that further
examination of the link between circadian rhythm and cell cycle regulation may reveal novel
approaches for the development of cancer therapeutics. TIMELESS represents only one of many
therapeutic targets and associated vulnerabilities identified from the FUSION screen. Future work
validating and characterizing additional targets will increase our understanding of oncogeneinduced vulnerabilities in cancer and provide viable, novel approaches for the development of
selective cancer therapeutics.
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Chapter 5: WDR5 supports colon cancer cells by promoting
methylation of H3K4 and suppressing DNA damage

Portions of the material covered in this chapter are the subject of a manuscript
submitted for publication by Neilsen BK et al.
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Introduction
WDR5 (WD-repeat containing protein 5) is a WD40-repeat containing seven-bladed
propeller protein. WDR5 was initially identified as being a BMP2 inducible gene and was
originally named BIG-3 (BMP2-induced 3-kb gene protein). Early studies demonstrated that
WDR5 dramatically increased osteoblastic differentiation and chondrocyte differentiation
downstream of BMP2 226,227. Several additional studies have further demonstrated the role WDR5
plays in skeletal development, but the role of WDR5 has been expanded since its identification,
and it has been shown to function ubiquitously in human tissues.
COMPASS Complex
Importantly, WDR5 serves as a core component of several complexes within the cell 228.
It has been most well-studied for its role in the SET/MLL COMplex of Proteins ASsociated with
Set1 (COMPASS), which serves to mono-, di-, and tri-methylate Histone 3 Lysine 4 (H3K4Me13), 229-231. WDR5 has been shown to contribute to recognition of specific H3K4Me3 targets,
which serves to promote increased transcription of select target genes as the H3K4 methylation
often occurs within enhancer or promoter regions 232. WDR5 has a significant role in
development as it regulates embryonic stem cell pluripotency, self-renewal, and reprogramming
by modulating the transcription of targets that promote stem cell-like states 233-236. In particular, as
part of the COMPASS complex, WDR5 has been shown to regulate several HOX genes as well
as SOX9 expression 235,237-239. Of note, WDR5 can also promote its own expression through a
positive feedback loop where increased H3K4Me3 within the WDR5 promoter increases its
transcription 239.
The SET/MLL COMPASS Complex consists of one of the KMT2/MLL proteins
(KMT2A/MLL1, KMT2B/MLL2 or MLL4, KMT2C/MLL3, KMT2D/MLL4 or MLL2,
KMT2F/SETD1A, or KMT2G/SETD1B) in addition to a common subcomplex that includes
WDR5, RBBP5, Ash2L, DPY30 (WRAD subcomplex) 240. Interestingly, the catalytic component
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of this complex, the KMT2/MLL proteins, have very little activity outside of the complex, and
thus require the common WRAD subcomplex and COMPSS complex formation to be
functionally active. COMPASS complex formation serves to dramatically increase the affinity of
the KMT2/MLL protein for DNA and increases its catalytic activity 241.
KMT2/MLL family proteins, while highly related, have both distinct and redundant
functions 242. In mammals, these six proteins form three pairs of paralogs: KMT2A/MLL1 and
KMT2B/MLL2; KMT2C/MLL3 and KMT2D/MLL4; and KMT2F/SETD1A and
KMT2G/SETD1B. While all KMT2/MLL proteins bind to the WRAD subcomplex, each pair
also has unique additional complex members, which may contribute to their unique functions and
specific target genes 241.
The COMPASS complex primarily functions to add methyl groups to H3K4, which
generally promotes transcription by recruiting transcription factors and coactivators to promoters
while also interfering with the addition of epigenetic modifications that would repress
transcription 241. However, the location of methylation (in promoters or enhancers) and degree of
methylation (mono-, di-, and tri-methylation) varies between KMT2/MLL proteins and can be
tissue-specific. In general, monomethylation is most often associated with enhancers and trimethylation with promoters and transcription start sites in genes that are actively being
transcribed 241.
KMT2A/MLL1 and KMT2B/MLL2 have specific or limited methylation activity and are
most commonly associated with di- or tri-methylation of H3K4. Specific target genes of
KMT2A/MLL1 and KMT2B/MLL2 include the HOX genes where increasing H3K4Me3
increases their transcription 241. KMT2A/MLL1 is commonly chromosomally translocated or
mutated in leukemia. In normal cells, KMT2A/MLL1 is required for hemopoietic stem cell
maintenance at least in part by promoting the expression of hemopoietic stem cell transcription
factors HOXA9, PRDM16, PBX1 by increasing H3K4Me3 and H4K16Ac in or near these target
genes, which increases their transcription. KMT2B/MLL2 is not chromosomally translocated in
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leukemia and cannot replace KMT2A/MLL1 in these cancers likely due to its lower affinity for
CpG sequences 243,244. However, a recent report has indicated that maintenance of
KMT2B/MLL2, and not KMT2A/MLL1, is required in KMT2A/MLL1-rearranged leukemia 245.
KMT2B/MLL2 is required for H3K4Me3 maintenance at promoters and may limit trimethylation
at Histone 3 Lysine 27 (H3K27Me3), which is inhibitory for transcription, thereby modulating
the expression of bivalent promoters 241.
KMT2C/MLL3 and KMT2D/MLL4 demonstrate redundancy and both maintain
H3K4Me1 levels on enhancers 241,246,247 and recruit CBP/p300 to enhancers 247,248; however, either
knockout alone is embryonic/perinatal lethal in mice suggesting that neither one is able to fully
compensate for the loss of the other. Traditionally, KMT2C/MLL3 and KMT2D/MLL4 have
been considered tumor suppressors in leukemia and have been implicated as such in solid tumors
as well 241. Knockdown of KMT2C/MLL3 or KMT2D/MLL4 impaired differentiation of
hematopoietic stem/multipotent progenitor cells and increased the prevalence of progenitor cells
249 250

. These defects may be caused by increased oxidative stress due to the reduced expression of

KMT2D/MLL4-dependent genes that protect cells from oxidative stress 250. However, deletion of
KMT2D/MLL4 in an Acute Myeloid Leukemia (AML) model system, as opposed to most studies
that are performed in lymphoma models, demonstrated limited effects suggesting there may be
context or tissue-specific effects of KMT2D/MLL4 250. Additionally, KMT2C/MLL3 and
KMT2D/MLL4 contribute to the mono-methylation of H3K4 in collaboration with hormone
receptors, and thus may play a pro-tumorigenic role in hormone-driven tumors 241 251 252-254.
KMT2F/SETD1A and KMT2G/SETD1B are highly related, but phenotypes from
KMT2F/SETD1A knockouts demonstrate global decreases in mono-, di-, and tri-methylation on
H3K4, while KMT2G/SETD1B knockouts do not suggesting KMT2F/SETD1A may be the
dominant allele and capable of compensating for the loss of KMT2G/SETD1B 255. Alternatively,
their functions may not be fully redundant with KMT2F/SETD1A preferentially affecting H3K4
methylation and KMT2G/SETD1B potentially contributing to a different, unrecognized function.
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Functionally, changes in methylation on H3K4 downstream of KMT2F/SETD1A affect target
gene expression, which has been shown to affect erythroid cell differentiation as
KMT2F/SETD1A conditional knockouts demonstrated decreased expression of Gata1 and Tal1
corresponding to decreased H3K4Me3 at their promoters 256.
While the significance of KMT2A/MLL1 rearrangements in leukemia has been
established for many years 257-259, the specific effects of unique rearrangements and mutations,
and the mechanisms behind their pro-tumorigenic behavior are still being elucidated and
characterized 259. Interestingly, examining four specific mutations within the catalytic SET
domain of KMT2A/MLL1 that were identified in cancer demonstrated that these mutations can
decrease or increase KMT2A/MLL1 baseline activity and can modulate the augmented effect of
complex formation on DNA binding affinity and enzymatic activity 260. However, the H3K4
methyltransferase domain in KMT2A/MLL1 is often excluded from KMT2A/MLL1 fusion
proteins, yet the fusion protein still modulates transcriptional elongation. This suggests a broader
role for KMT2/MLL proteins in addition to altering specific chromatin modifications 261.
KMT2A/MLL1 and KMT2A/MLL1-fusion proteins have also been shown to have distinct
chromatin target sites, which may be a consequence of the KMT2A/MLL1:WDR5 interaction 262.
This highlights the complexity and potentially tumor-specific effect of KTM2/MLL proteins in
cancer. More recently, the surprisingly high frequency of KMT2/MLL mutations in solid tumors,
including breast, prostate, pancreas, stomach, and colon has been recognized. In addition to being
commonly mutated, these proteins are often overexpressed in cancer, and their expression has
largely been associated with protumorigenic effects and worse patient outcomes (pancreatic
cancer) 263.
In general, within cancer KMT2/MLL proteins have been shown to promote
transcriptional reprogramming through increased methylation at H3K4 264 and through
interactions with commonly recognized oncogenic transcription factors. Specific targets of
KMT2/MLL epigenetic regulation have been shown to include hTERT (KMT2A/MLL1, in
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melanoma) 265 , several HOX genes (KMT2A/MLL1) 266, ER target genes in breast cancer
(KMT2D/MLL4) 254,267, and androgen receptor target genes in prostate cancer (KMT2A/MLL1
and WDR5) 268,269. Inhibition or depletion of KMT2D/MLL4 in breast cancer or KMT2A/MLL1
in prostate cancer decreased the expression of important transcriptional targets thereby inhibiting
cancer cell growth 254,269. In pancreatic cancer, KMT2C/MLL3 and KMT2D/MLL4 depletion
caused downregulation of genes related to cell cycle advancement and proliferation based on
microarray and gene set enrichment analysis 263. The variable effects of individual KMT2/MLL
family member inhibition or depletion in various types of cancer supports the idea that
KMT2/MLL proteins have distinct roles and targets that are context- and tissue-specific.
In colon cancer, KMT2D and KMT2C mutations are common and are present in 10% of
tumors (Table 5.1, 270, COSMIC v83). In contrast, the common components of the COMPASS
complex were rarely mutated (Table 5.1). Additionally, many of the commonly used colon cancer
cell lines harbor multiple mutations within KMT2/MLL family members (Table 5.2, COSMIC
Cell Lines Project,271). However, the effects of these mutations are still being debated. While
often labelled as tumor suppressors, evidence demonstrating a protumorigenic role for KMT2C
and KMT2D in solid tumors has recently been reported. For example, one study demonstrated
that KMT2D promoted global K3K4 monomethylation in transcriptional enhancers, and depletion
of KMT2D in two colon cancer cell lines (HCT116 and DLD-1) decreased cancer cell
proliferation and migration 264.
Recent studies have identified a correlation between H3K4Me3 enrichment,
transcriptional fidelity, and enhanced elongation rates 272,273. This suggests a potential role for the
COMPASS complex in promoting DNA synthesis while preventing DNA damage during
replication, which could ultimately support cell proliferation. Recent studies have specifically
demonstrated that KMT2A/MLL1 as well as WDR5 are required for proper chromosome
congression and spindle assembly during mitosis, which may affect chromosomal stability 274,
and a KMT2B/MLL2 mutation resulted in genome instability 275. In another report, AML driven
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Gene

Percent
Mutated

Samples
(Mutated/Tested)

KMT2C/MLL3

13%

323/2478

KMT2D/MLL2

11%

243/2209

KMT2A/MLL

7%

152/2178

KMT2B/MLL4

7%

150/2130

KMT2F/SETD1A

6%

116/2109

KMT2G/SETD1B

3%

67/2098

RBBP5

2%

32/2109

WDR5

1%

28/2109

ASH2L

1%

25/2109

DPY30

<1%

6/2098

Table 5.1: Frequency of KMT2/MLL Mutations in Colon Adenocarcinoma (COSMIC v83).
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Cell Line

KMT2A

KMT2B

KMT2C

2

D550fs
1
G1881fs
2
L2136fs

HCT116

KMT2D

KMT2F

KMT2G

WDR5

2

1

Q419R
1,2
I1344fs

V160M
1
R2173fs
1,2
R2443fs

G1578fs

2

Y260H

1,2

2

2

HCT15

T771fs
1,2
S1062Y
1
V2178A

2

R226W
2
R1125H
2
A1989T

1,2

G3438D
1,2
S3543N

P1152H
1
E1244D
1,2
E1517D
2
P1931H

2

D159N
2
Q780H

2

SW480

D1633N
2

G273S
1,2
G292V

SW620

1

2

2

RKO

T771fs
2
S873fs
1
D877fs

A905T
2
R1579H
2
D1819fs
1
P1823fs

G2636C
2
R3853W

1,2

1

1

R916H
1,2
R1189H
1
L1327P
1,2
L1600P
2
G1960fs
2
P2550fs
1,2
G3465*
1
L4516P
2
R4964fs
1,2
L5056P

A1325T

2

2

T1657A

V217Ins

1

1,2

R525W
2
P2255L

LoVo

C1013R
1
E1313K

H77fs
1,2
P647fs
1,2
P648fs
2
T3548I

V1404I

2

1,2

T84

None

Table 5.2: Frequency of KMT2/MLL and WDR5 Mutations in Colon Cancer Cell Lines.
1

=COSMIC
=Mouradov et al
Note: SW480 are not included in COSMIC
2

G277D

1,2
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by KMT2A/MLL1 fusions were shown to be proficient in DNA-damage response (DDR) leading
PARP inhibitor resistance. However, depleting or inhibiting cells of HOXA9, a downstream
target of KMT2A/MLL1, caused DDR impairment and PARP inhibitor sensitization 266. Together
these data suggest a role for this complex in supporting DNA replication and maintaining DNA
fidelity thereby promoting cancer cell survival and proliferation. Consistent with this hypothesis,
depletion of KMT2D/MLL4 in multiple pancreatic cancer cell lines increased their
responsiveness to 5-FU 263 suggesting a possible role for KMT2/MLL or COMPASS complex
inhibition in chemotherapy or radiation sensitization.
The role of WDR5 outside of the COMPASS Complex
In addition to serving as a required component of the COMPASS complex, new evidence
shows that WDR5 participates in several other protein complexes such as the CH8-containing
ATP dependent chromatin remodeling complexes 276, human acetyltransferase complexes such as
MOF (Males absent On the First) and ATAC (Ada Two-A Containing) 277-279, and NSL (NonSpecific Lethal) complex in Drosophila 228. WDR5, as a component of a CHD8-containing
complex, regulates the expression of β-catenin target genes 276. WDR5 has also been shown to
regulate genes that are expressed in a circadian manner by supporting PER-mediated
transcriptional repression through histone methylation within the promoter region of clockregulated genes 280. WDR5 also plays an important role in the self-renewal of embryonic stem
cells and the maintenance of active chromatin for pluripotency genes 235,281 and is required to
induce pluripotent stem cell generation from differentiated somatic cells 233. This may be the
result of WDR5 binding to RNA as further studies identified a RNA-binding pocket in WDR5
through which WDR5 interacts with more than a thousand RNA including several lncRNAs
known to be important for embryonic stem cell gene expression 234.
WDR5 has also been shown to physically interact with MYC and promote transcription
of a subset of MYC target genes 282-286 287. This synergistic increase in transcription following
MYC and WDR5 interaction is thought to contribute to tumorigenesis, particularly in
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neuroblastoma and other MYC-driven tumors. Interestingly, a study using patient-derived
xenografts of pancreatic cancer demonstrated the WDR5:Myc interaction in vivo and showed this
interaction prevented DNA damage accumulation 287. Additional reports have shown that WDR5
regulated DNA replication and chromosomal polyploidy 288 as well as abscission through
localization to the midbody 289. The induction of DNA damage following loss of WDR5 could be
independent of or a result of its role in the COMPASS complex as there are multiple reports
suggesting that depletion of KMT2A/MLL1 or KMT2B/MLL2 induce DNA damage 263,266,272-275.
WDR5 has also been shown to increase transcription of cyclins, which serve to promote cell cycle
progression and increase cell proliferation 290,291.
Cancer
Recent studies have also demonstrated a role for WDR5 in cancer based on its increased
expression and requirement for cancer cell survival. Specifically, expression of WDR5 is
increased in prostate cancer tissues 268, leukemia 292, and bladder cancer 293. WDR5 promotes
survival, proliferation, and chemoresistance in bladder cancer 293. WDR5 overexpression is
associated with worse patient outcomes in breast cancer and hepatocellular carcinoma 291,294. In
breast cancer, WDR5 promotes cell survival 295 and tamoxifen resistance 296. WDR5 has also been
shown to physically interact with MYC and promote target recognition contributing to
tumorigenesis 282,284. In pancreatic cancer, WDR5 promotes cell proliferation, survival, and
migration 297. As expected, WDR5 appears to play a role in leukemia as it is overexpressed,
promotes H3K4Me3, and depletion of WDR5 decreases cell proliferation, increases cell death,
and reduces H3K4Me3 on target gene promoters 292.
In general, the mechanism by which WDR5 supports cancer cells has been shown to be
through increased target gene expression. For example, WDR5 has been shown to promote
epithelial to mesenchymal transition (EMT) by interacting with HDA3 to promote hypoxiainduced EMT by promoting mesenchymal gene activation 298. WDR5 promotes colon cancer
metastasis by binding to ZNF407 299. WDR5 has also been shown to promote both ErbB2 and
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NOTCH expression and signaling through a H3K4Me3-dependent manner to promote mammary
tumorigenesis 295,300, and depletion of WDR5 reduced ErbB2 expression and cooperated with
trastuzumab or chemotherapy to reduce ErbB2-positive breast cancer cell growth 295. WDR5 has
been shown to cooperate with HOTTIP to promote HOXA9 in prostate and pancreatic cancer
301,302

and HOXA13 expression in esophageal and gastric cancer cells by increasing H3K4Me3 on

their promoters 303,304. Increased HOX protein expression promoted aggressive cellular
phenotypes as cells demonstrated increased invasion and migration 301. In bladder cancer, WDR5
promotes global transcription by increasing H2A.Z incorporation 305 and increases the
transcription of cyclin B1, cyclin E1, cyclin E2, UHMK1, MCL1, BIRC3 and Nanog via
increased histone H3 lysine 4 trimethylation 306 293,306. WDR5 promotes gastric tumorigenesis
through multiple mechanisms including upregulation of cyclin D1 290,307. Based on its widespread
overexpression and pro-tumorigenic role in cancer, inhibition of WDR5 has therapeutic potential
in multiple cancers.
Therapeutic Targeting of WDR5
After multiple reports characterizing the structure and binding domains of WDR5 that
included the crystal structure of WDR5 in complex with KMT2A/MLL1 Win motifs 308,309, MYC
Mb111b peptide 284, and histone H3K4 peptides 310, numerous groups have designed inhibitors of
WDR5. Successful inhibitors have largely targeted the WDR5:MLL protein:protein interaction
260,311-320

with some groups demonstrating selective targeting of KMT2A/MLL1:WDR5 318

interactions or KMT2F/SETD1A:WDR5 314 interactions. Further, use of a WDR5:MLL inhibitor,
OICR-9429 in C/EBP N-terminal acute myeloid leukemia cells inhibited proliferation and
induced differentiation 321. More recent attempts have largely focused on targeting other WDR5
protein interactions with the WDR5:MYC interaction being a primary target, but these have not
yet been successful.

Results

156

Preliminary Biological Validation of WDR5
Based on the screen results, the seven-bladed beta propeller protein WDR5B was
identified as a hit. Unfortunately, there is very little known about WDR5B. In contrast, the
highly-related protein WDR5 is well-established in the literature, has validated reagents, and
several inhibitors targeting this protein have been developed.
Initial biological validation of targets identified using FUSION was performed by
assessing cancer cell growth or viability in anchorage-independent conditions following RNAimediated target depletion by measuring cell growth on a polyHEMA-coated plate 214,215 using
CellTiter-Glo® Luminescent Cell Viability Assay, as previously described 3. The smartPool of
four siRNA oligos (Dharmacon) targeting KSR1, WDR5, or WDR5B was used to deplete cells of
the target. Growth in anchorage-independent conditions was reduced substantially with KSR1 or
WDR5 depletion, but not WDR5B depletion in HCT116 colon cancer cells (Fig. 5.1A).
Repeating the WDR5 knockdown in two colon cancer cell lines, HCT116 and HCT15,
demonstrated a robust decrease in HCT116 cell viability, but a relatively small decrease in
viability in HCT15 cells (Fig. 5.1B). HCECs are unable to proliferate in an anchorageindependent environment and were therefore not assayed in this manner. To compare the effects
of WDR5 depletion in colon cancer cells to immortalized, yet non-transformed HCECs, RNAimediated depletion of WDR5 was completed under normal plating conditions and viability was
measured using alamarBlue. WDR5 depletion in HCECs, HCT116, and HCT15 cells for 72 hours
reduced viability in all three cell lines, but did so to varying degrees with the HCT116 cells
decreasing viability by more than 80% and HCEC and HCT15 cells decreasing by 20% and 25%,
respectively (Fig. 5.1C). Additionally, apoptosis was significantly upregulated in HCT116 cells
depleted of WDR5 where nearly 40% of the cells resided in the sub-G1 peak following propidium
iodide staining and flow cytometry analysis (Fig. 5.1D). In contrast, the HCEC and HCT15 cells
demonstrated no increase in sub-G1 peak following loss of WDR5. HCT15 cells did demonstrate
a robust increase in G1 peak; however, representing a cell cycle arrest (Fig. 5.1E).
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Fig. 5.1: Preliminary biological validation of WDR5. (A) Viability of HCT116 colon cancer
cells measured using CellTiter-Glo® following RNAi of KSR1, WDR5, or WDR5B that were replated on polyHEMA-coated plates 48 hours following transfection to simulate anchorageindependent conditions. (N=6). (B) Viability of HCT116 and HCT15 colon cancer cells measured
using CellTiter-Glo® following RNAi of WDR5 that were replated on polyHEMA-coated plates
48 hours following transfection to simulate anchorage-independent conditions. (N=6). (C)
Viability of HCECs, HCT116, and HCT15 cells measured using alamarBlue® following RNAimediated WDR5 depletion for 72 hours in normal culture conditions. (N=6). (D) Apoptosis
(percent of cells in the sub-G1 peak) in HCEC, HCT116, and HCT15 cells after WDR5 depletion
by RNAi for 72 hours. (N=3). (E) G1 arrest (percent of cells in the G1 peak) in HCT15 cells after
WDR5 depletion by RNAi for 72 hours. Apoptosis and cell cycle were evaluated using propidium
iodide staining followed by flow cytometry analysis. Data are shown as mean ± SD. (N=3).
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A single oligo targeting WDR5 increases p53 stability in HCT116 cells
To elucidate the mechanism behind the massive increase in apoptosis in HCT116 cells
following WDR5 depletion that is not seen in HCECs or HCT15 cells, cells were depleted of
WDR5 using the smartPool oligos for 72 hours and assessed for expression of pro-apoptotic
proteins. PARP cleavage, p53, and downstream p53 effectors (p21, MDM2, PUMA) were
increased following WDR5 depletion in HCT116 cells, but not HCECs or HCT15 cells (Fig. 5.2).
Of note, HCEC and HCT116 cells have wild-type p53, but HCT15 cells have mutated p53, which
explains the constitutively high level of p53 expression in HCT15 cells and could explain why
WDR5 depletion in HCT15 cells does not reduce their viability.
A common mechanism by which p53 expression is increased in cells is by increasing
protein stability following DNA damage. Therefore, the effect of WDR5 depletion on p53 protein
stability was examined in HCT116 cells. Preliminary studies found the half-life of p53 was
approximately 2 hours in these cells in stable conditions, therefore cells were treated with
cycloheximide for four hours to allow for approximately 75% p53 protein degradation. HCT116
cells depleted of WDR5 using the smartPool oligos and treated with cycloheximide (100 μg/mL)
to prevent translation of new proteins, demonstrate p53 is significantly stabilized with WDR5
depletion (Fig. 5.3A). To confirm the effect of WDR5 on viability is p53 mediated, HCT116 cells
that lack p53 (HCT116 p53-/-) were utilized. HCT116 cells without p53 were less sensitive to
WDR5 depletion suggesting the effects of WDR5 knockdown in HCT116 cells are, at least in
part, p53-mediated (Fig. 5.3B-D).
Based on previous studies, known mechanisms by which WDR5 could be acting include
serving as part of the COMPASS complex to facilitate histone modifications that support tumor
maintenance or physically interacting with MYC to promote tumorigenesis. However, MYC
depletion decreased p53 expression (Fig. 5.4A) and OICR-9429, an inhibitor of
WDR5:KMT2/MLL interaction and COMPASS complex formation, had no effect on p53 (Fig.
5.4B).
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Fig. 5.2: WDR5 depletion Induces p53 expression and PARP cleavage in HCT116 colon
cancer cells. (A) Immunoblot of WDR5, PARP, p53, and downstream p53 targets (MDM2,
PUMA, and p21) following RNAi-mediated WDR5 depletion for 72 hours in HCECs, HCT116,
and HCT15 cells.
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Fig. 5.3: WDR5 depletion induces cell death in HCT116 colon cancer cells by stabilizing p53. (A)
Immunoblot and relative densitometry-based quantification (below) of p53 following RNAi-mediated
WDR5 depletion for 72 hours and 100 µg/mL CHX treatment for 4 hours prior to collection to inhibit
new protein translation. (B-D) Viability as measured with alamarBlue® (N=6) (B), immunoblot of PARP,
WDR5, p53, and p21 (C), and photomicrographs (D) of p53WT and p53-/- HCT116 cells following RNAimediated WDR5 depletion for 72 hours.
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Fig. 5.4: MYC depletion or OICR-9429 treatment does not induce p53 expression. (A)
Immunoblot of p53 following RNAi-mediated MYC depletion for 72 hours in HCECs, HCT116,
and HCT15 cells. (B) Immunoblot of p53 following WDR5 depletion (smartPool) or OICR-9429
treatment for 72 hours in HCT116 cells.
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Concerningly, WDR5 depletion in other colon cancer cell lines did not induce p53
expression (Fig. 5.5) even in another other cell lines with wildtype p53 (LoVo). Examining the
individual oligos from the smartPool of four oligos targeting WDR5 revealed that even though all
four dramatically decreased WDR5 levels, in HCT116 cells, oligo #6, the smartPool (a pre-mixed
pool of all four oligos in an undisclosed ratio), and 1:1:1:1 pool of all four oligos dramatically
decreased viability to a level substantially lower than the other three individual oligos (#5, #7,
and #8) even though the level of WDR5 depletion was comparable (Fig. 5.6A). Comparing oligo
#6 with #8, both oligos induced DNA damage, as evidenced by increased phosphorylation of
H2AX (γH2AX), yet only oligo #6 increased p53 expression and induced PARP cleavage in
HCT116 cells (Fig. 5.6B). This was concerning for the possibility of an off-target effect for oligo
#6. A blast search using the oligo #6 sequence demonstrated an 100% match to WDR5, but also
shared a high degree of similarity to ME1 sharing a 14-nucleotide substring within the 19nucleotide siRNA oligo: GUGGAAGAGUGACUGCUAA (large, bold letters were matches).
A substantial, previous publication demonstrated ME1 depletion induced p53 322, suggesting this
off-target could likely be causing the p53 induction in HCT116 cells. Reassuringly, all four
individual oligos and both pools reduced HCT116 viability as measured by alamarBlue following
WDR5 depletion by more than 30% in 72 hours suggesting WDR5 itself is playing a role
supporting colon cancer cells, but the mechanism of action remains to be revealed.
WDR5 is required for colon cancer cell survival
To determine whether WDR5 is required for cell survival in more than just HCT116
cells, cell viability in a panel of colon cancer cell lines and HCECs following transient depletion
of WDR5 by RNAi was measured. A pool containing all four oligos was used for all cell lines
except HCECs and HCT116s where oligo #6 was shown to induce p53. In HCECs and HCT116
cells a pool of oligos #7 and #8 was used. Cell viability was measured using CellTiter-Glo®
Luminescent Cell Viability Assay 72 hours after WDR5 depletion. WDR5 depletion reduced
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Fig. 5.5: WDR5 depletion does not induce p53 in other colon cancer cell lines.
(A) Immunoblot of WDR5, PARP, and p53 following RNAi-mediated WDR5
depletion for 72 hours in LoVo (p53WT), SW480 (p53MUT), and T84 cells
(p53NULL).
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Fig. 5.6: Evaluation of individual WDR5 siRNA. (A) Immunoblot of WDR5 and viability as measured
by alamarBlue® following RNAi-mediated knockdown with individual siRNA oligos in HCT116 colon
cancer cells. (N=6). (B) Immunoblot of WDR5, PARP, p53, and γH2AX following RNAi-mediated
WDR5 depletion using either oligo #6 or #8. (C) WDR5 #6 oligo sequence with nucleotides that match
the ME1 sequence shown in red.
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cell ATP levels by 15-30 percent in six colon cancer cell lines (Fig. 5.7A). These results were
largely confirmed using the alamarBlue® Cell Viability Assay after 96 hours of WDR5 depletion
(Fig. 5.7B) with the only change being WDR5 depletion having no effect on viability in LoVo
cells as measured by alamarBlue. In contrast, HCECs demonstrated only a 5% decrease in cell
ATP levels (Fig. 5.7A) and no difference in viability following WDR5 depletion as measured
using the alamarBlue assay (Fig. 5.7B).
COMPASS complex inhibition is detrimental to colon cancer cells
To evaluate the effect of WDR5 inhibition, the effect of OICR-9429 on colon cancer cells
and HCECs was examined. OICR-9429 is an antagonist of the interaction of WDR5 with peptide
regions of MLL and Histone 3, and disrupts COMPASS complex formation by blocking the
interaction between WDR5 and MLL1 and RBBP5 319,321. Treatment with 10 µM OICR-9429 for
72 hours also decreased cell viability (alamarBlue® Cell Viability Assay), but to a lesser extent
than seen with WDR5 depletion in some cell lines (Fig. 5.7C). Interestingly, OICR-9429
treatment had less of an effect in RKO and HCT116 cells, two cell lines that harbor WDR5
mutations that may reduce the affinity of OICR-9429 for WDR5. Two cell lines with wildtype
WDR5 and relatively few or no mutations in any COMPASS components (Table 5.2), SW620
and T84 cells, were more sensitive to both WDR5 depletion as well as OICR-9429 treatment with
approximately a 50% decrease in cells over 72 hours.
WDR5 is overexpressed in colon cancer cells
To evaluate the expression of the components of the required WRAD subcomplex within
the COMPASS complex in cancer, the mRNA levels of WDR5, RBBP5, ASH2L, and DPY30 in
tumors compared to solid tissue normal samples were examined based on RNASeq from the
colon adenocarcinoma (COAD) dataset within The Cancer Genome Atlas (Fig. 5.8A). WDR5,
RBBP5, and DPY30 are increased in tumors relative to normal tissue; however, WDR5 was
expressed at the highest level and showed the most dramatic increase in expression between
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Fig. 5.7: WDR5 depletion or disruption of the COMPASS complex limits cell proliferation
or viability in colon cancer cells. (A and B) Cell viability in a panel of colon cancer cells as
compared to HCECs following RNAi-mediated depletion of WDR5. Viability was measured by
CellTiter-Glo® (A) and alamarBlue® (B) assays 72 hours and 96 hours after transfection,
respectively. (C) Cell viability in a panel of colon cancer cells as compared to HCECs following
72 hour treatment with 10 uM OICR-9429 as measured by alamarBlue®. Data are shown as mean
relative light units or relative fluorescent intensity ± SD. (N=6). ** p < 0.01 *** p < 0.001 ****
p < 0.0001
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Fig. 5.8: WDR5 is overexpressed in colon cancer cells. (A) WDR5, RBBP5, ASH2L, and
DPY30 gene expression (RNASeq) data from the Colon Adenocarcinoma (COAD) dataset within
TCGA for unpaired primary colon tumors and normal solid tissue samples. Tumor includes 478
samples from 456 patients for each gene. Normal includes 41 samples from 41 patients for each
gene. The results published here are in whole or part based upon data generated by the TCGA
Research Network: http://cancergenome.nih.gov/. (B) RT-qPCR of WDR5 and (C) western blot
of WDR5 and RBBP5 in a panel of colon tumor cell lines as compared to immortalized, nontransformed HCECs. RT-qPCR data is shown as mean ± SD. (N=3).** p < 0.01 *** p < 0.001
**** p < 0.0001 (Figure 5.8B was performed by Danielle Frodyma and Jamie McCall).
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normal tissue and colon tumor tissue. WDR5 is also overexpressed at the mRNA (Fig. 5.8B) and
protein level (Fig. 5.8C) in a panel of colon cancer cells as compared to immortalized, yet nontransformed human colon epithelial cells (HCECs) 102. RBBP5 is similarly overexpressed at the
protein level (Fig. 5.8C) in a panel of colon cancer cells as compared to the HCECs.
OICR-9429 treatment dramatically decreases colony growth in colon cancer cell lines
Based on the assumption that WDR5 depletion or COMPASS complex inhibition is
altering histone modifications, it would be expected that the effects on proliferation would
increase with a longer treatment. Therefore, drug treatment with OICR-9429 for 10-14 days in a
colony forming assay was performed in a panel of colon cancer cell lines. Interestingly, OICR9429 treatment had variable effects between colon cancer cell lines. RKO, LoVo, SW480,
SW620, and T84 cell lines demonstrated dramatic decreases in colony formation; however,
HCT15 and HCT116 cell lines demonstrated no effect (Fig. 5.9) even after an effect in viability
was seen after 72 hours of treatment (Fig. 5.7C).
WDR5 depletion does not decrease AKT phosphorylation and activation
Preliminary data in the lab demonstrated that WDR5 depletion (pool of all four oligos)
decreased AKT phosphorylation at both S473 and T308 (Fig. 5.10A); however, later analysis
demonstrated the opposite effect (Fig. 5.10B). The misinterpretation of the preliminary results
could have been a result of uneven loading. Regardless, if a relationship exists between WDR5
and AKT activation, this relationship is likely indirect and context-specific. Therefore, the
mechanism or relationship between WDR5 and AKT phosphorylation was not pursued further.
WDR5 depletion increases DNA damage and decreases trimethylation of H3K4
To further examine the role WDR5 plays in cancer, the effect of WDR5 depletion (oligos
#7 and #8 only) and OICR-9429 treatment on H3K4Me3, H3K4Me1, and phosphorylation of
H2A.X (γH2AX) was examined in HCT116, SW620, and RKO cells. These cell lines were
chosen because HCT116 cells were highly sensitive to WDR5 depletion, but not OICR-9429
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Fig. 5.9: Disruption of the COMPASS complex decreases cell colonies in colon cancer cells.
(A and B) Representative pictures (A) and quantification of number and average size of colonies
(B) formed on 24-well plates in colon cancer cell lines following treatment with OICR-9429
treatment for 10-14 days. (N=3).
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Fig. 5.10: The relationship between WDR5 and AKT may be context dependent. (A)
Immunoblot of pAKT (S473), pAKT (T308), and tAKT following RNAi-mediated WDR5
depletion (smartPool of all four oligos) for 72 hours with insulin stimulation for 30 minutes
prior to collection in HCT116 cells. (B) Immunoblot of WDR5, pAKT (S473), pAKT (T308),
and tAKT following RNAi-mediated WDR5 depletion (smartPool of all four oligos) for 72
hours in HCECs, HCT116 (two independent replicates), and HCT15 cells.
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treatment; RKO cells were sensitive to both WDR5 depletion and OICR-9429 treatment, but to a
lesser extent; SW620 cells were highly sensitive to both WDR5 depletion and OICR-9429
treatment; and HCT15 cells were mildly sensitive to both WDR5 depletion and OICR-9429
treatment. In all four cell lines, WDR5 depletion induced γH2AX formation and decreased
H3K4Me3 (Fig. 5.11). In SW620 cells, WDR5 depletion also decreased H3K4Me1. OICR-9429
treatment was able to induce γH2AX in SW620 cells, but did not affect γH2AX in the other two
cell lines. OICR-9429 treatment decreased H3K4Me3 levels in HCT116 cells and to a less extent
in RKO and SW620 cells (Fig. 5.11).
These results suggest that WDR5 depletion induces damage in colon cancer, but the
OICR-9429 treatment is unable to fully replicate this effect in HCT116 and RKO colon cancer
cells. This could be due to the presence of WDR5 mutations in these cell lines that render them
less sensitive to OICR-9429 treatment. In contrast, SW620 cells that harbor wildtype WDR5
appear to be equally sensitive to WDR5 RNAi-mediated depletion and OICR-9429 treatment and
demonstrate increased γH2AX with either manipulation. The effect on H3K4 methylation appears
to be more consistently affected by OICR-9429 treatment. This could be due to the drugs ability
to not only directly interact with WDR5, but could be the result of generalized COMPASS
complex disruption. This leads one to wonder if the effect of WDR5 on γH2AX is a function of
its role within the COMPASS complex or another mechanism. In fact, RBBP5 depletion did not
affect cell viability suggesting that WDR5 may function outside of the COMPASS complex to
promote tumorigenesis (Fig. 5.12).
WDR5 depletion sensitizes colon cancer cells to IR-induced DNA damage
The increase in γH2AX with WDR5 depletion (Fig 5.11) and previous literature
demonstrating that WDR5 depletion induces DNA damage suggests that WDR5 depletion may be
able to sensitize cancer cells to DNA damage. To evaluate the potential that loss of WDR5
sensitizes cells to DNA damage, the effect of WDR5 depletion (oligos #7 and #8 only) on IRinduced γH2AX formation and PARP cleavage was assessed. HCT116, HCT15, SW620, and

172

Fig. 5.11: WDR5 depletion increases DNA damage and reduces H3K4Me3. (A) Immunoblot
of γH2AX, H3K4Me1, and H3K4Me3 following 96-hour RNAi-mediated WDR5 depletion
(oligo pool of #7 and #8 only) or 72 hour OICR-9429 treatment in HCT116, HCT15, SW620, and
RKO colon cancer cells.
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Fig. 5.12: RBBP5 depletion does not affect cell viability in a panel of colon cancer cell lines. (N=3).
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RKO cells were depleted of WDR5 for 48 hours prior to a single dose of irradiation (3 Gy). Cells
were allowed to recover for 48 hours after IR prior to collection and then were assessed for
γH2AX expression and PARP cleavage. In control cells, radiation increased γH2AX levels,
which were further increased with the loss of WDR5 in all cell lines tested (Fig. 5.13). SW620
and RKO cells demonstrated a step-wise increase in γH2AX levels with WDR5 depletion,
irradiation in control cells, with maximal γH2AX in the cells that received irradiation in
conjunction with WDR5 depletion (Fig. 5.13). In contrast, HCT116 and HCT15 cells
demonstrated substantial increased in γH2AX with WDR5 depletion that was not further
increased with the addition of IR (Fig. 5.13). This could be a consequence of the high level of
endogenous genomic instability and defects in DNA damage repair present in these cells.
Regardless, in all conditions, WDR5 depletion further increased γH2AX levels indicating
increased DNA damage.

Conclusions
The data presented clearly demonstrate that WDR5 is overexpressed and preferentially
required in colon cancer cells more so than in immortalized, yet non-transformed human colon
epithelial cells (HCECs); however, the mechanism behind its overexpression and requirement for
survival has not been fully revealed. WDR5 has previously been shown to promote its own
expression through a positive feedback loop where increased H3K4Me3 at the WDR5 promoter
increases its transcription 239. It is possible this positive feedback loop could be contributing to the
maintenance of the overexpression of WDR5 demonstrated here in both colon cancer cell lines
and human colon tumors, yet this cannot explain the initial increase in WDR5 expression and is
difficult to demonstrate experimentally. The overexpression of WDR5 is not unique to colon
cancer as several recent studies have demonstrated WDR5 is overexpressed in several cancer
types including breast, prostate, bladder, and pancreatic cancer. Of importance, WDR5
overexpression has been clinically associated with worse patient outcomes in breast cancer and
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Fig. 5.13: WDR5 depletion increases sensitivity to ionizing radiation. Immunoblot of γH2AX
and PARP following 96-hour RNAi-mediate WDR5 depletion (oligo pool with #7 and #8 only)
with 3 Gy gamma IR for 48 hours prior to collection.
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hepatocellular carcinoma 291,294. Our data demonstrate that colon cancer cells rely on WDR5 for
increased proliferation and cell survival as depletion of WDR5 reduces cell viability, but does not
substantially increase apoptosis. Other groups have demonstrated similar findings and
demonstrated that WDR5 is similarly required for cell survival and proliferation in various other
types of cancer including leukemia 292, prostate268, bladder 293 breast 295, and pancreatic cancer 297.
In general, the mechanism by which WDR5 supports cancer cells has largely been shown
to be through increased target gene expression. Consistent with these findings, our data
demonstrate that WDR5 depletion caused a decrease in global H3K4Me3 levels likely
suppressing target gene expression. However, our data demonstrated that WDR5 depletion
induced a robust increase in γH2AX levels representative of an increase in DNA damage that was
highly associated with decreased viability in colon cancer cells following WDR5 depletion.
Recently, WDR5 has been shown to physically interact with MYC to promote transcription of a
subset of MYC target genes. In addition, this interaction also prevented DNA damage
accumulation in patient-derived xenografts of pancreatic cancer 287. Other mechanisms by which
WDR5 may suppress the accumulation of DNA include regulating DNA replication,
chromosomal polyploidy 323 and abscission through localization to the midbody 289. Based on our
data demonstrating WDR5 depletion increases DNA damage accumulation, it is likely that
WDR5 is contributing to DNA fidelity possibly through one of the previously described
mechanisms thereby supporting cancer cell viability. The contribution of WDR5 to DNA fidelity
may or may not be independent of its role in the WRAD subcomplex, as RBBP5 did not affect
viability in a panel of colon cancer cells. However, there are multiple reports suggesting that
depletion of KMT2A/MLL1 and KMT2B/MLL2 induce DNA damage as well as WDR5
suggesting a potential connection between the increased DNA damage following WDR5
depletion and its role in the COMPASS complex 263,266,272-275.
Resolution of γH2AX is thought to occur through exchange of γH2AX with
dephosphorylated H2AX with subsequent dephosphorylation of the removed γH2AX by
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phosphatases. One mechanism that facilitates the dephosphorylation of γH2AX is through H3K4
and H3K36 methylation by metnase, a protein that contains a SET domain and is a potential
binding partner of WDR5. Metnase also promoted non-homologous end-joining, restart of stalled
replication forks, resolution of γH2AX, and knockdown increased sensitivity to ionizing radiation
324

. Alternatively, WDR5 could contribute to K3K4 methylation through the COMPASS complex

to facilitate γH2AX resolution. WDR5 itself has been shown to promote the incorporation of
H2A.Z to promote global transcription 305 suggesting a potential mechanism where WDR5
regulates cell cycle progression through increased transcription (H2A.Z incorporation) and
release of cell cycle checkpoints (removal of γH2AX). Future studies are needed to further
elucidate the individual contributions each of the multitude of functions WDR5 has on the
induction of DNA damage, and more importantly, on cancer cell viability.
Our data demonstrated increased sensitivity to radiation, particularly in SW620 and RKO
colon cancer cells. While the HCT116 cells demonstrated increased γH2AX following WDR5
depletion, WDR5 depletion alone was sufficient to increase γH2AX to the same level seen with
IR. Relative to the other cell lines, HCT116 cells demonstrated the highest induction of γH2AX
with WDR5 depletion alone. This could be a result of the high level of genomic instability in
these cells. This, in combination with the additive effect of WDR5 depletion following IRinduced DNA damage, suggests WDR5 is particularly required in cells following DNA damage.
Overall, WDR5 depletion demonstrated a more robust phenotype than OICR-9429
treatment. Several factors could contribute to this disparity, but likely either WDR5 plays a role
independent of the COMPASS complex that is not inhibited by OICR-9429 treatment or
mutations in WDR5 or other COMPASS components limited the affinity and therefore efficacy
of OICR-9429. Consistent with the second possibility, cells with limited mutations in WDR5 and
KMT2/MLL proteins had increased sensitivity to both WDR5 depletion and OICR-9429. This
could be because that without mutations in KMT2/MLL components, the KMT2/MLL have a
significant requirement for WDR5 in order to function to methylate H3K4 as they have very little
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enzymatic activity outside of the COMPASS complex. Cells containing WDR5 mutations could
be less sensitive to OICR-9429 as mutations could reduce the affinity of the drug for WDR5.
These results also suggest that it is unlikely that the reduced effect on cells following OICR-9429
treatment as compared to WDR5 depletion is simply due to the drug being unable to inhibit
WDR5 as some cell lines showed a similar response to WDR5 depletion and OICR-9429
treatment.
Additional studies on the effect of mutations in KMT2/MLL proteins and WDR5 will
provide further understanding of the role of WDR5 and the COMPASS complex in cancer and
will help delineate whether these proteins have tumor suppressive, oncogenic, or a combination
of both roles. Further studies are also needed to fully distinguish if the role of WDR5 is a result of
its contribution to the COMPASS complex, is due to an alternative mechanism, or a combination
of multiple mechanisms. Regardless, WDR5 is required for colon cancer cell proliferation and
sensitized cells to ionizing radiation demonstrating a clear role for WDR5 in cancer and revealing
its potential as a therapeutic target in cancer.
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Chapter 6: FUSION identified 5’-hydroxy-staurosporine as an
AMPK inhibitor that is selectively toxic in colon cancer cells

Portions of the material covered in this chapter are the subject of a manuscript
published in Scientific Reports by Das B*, Neilsen BK* et al. 1
* Denotes equal contribution
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Introduction
The Ras oncogene is activated in more than 40% of colon tumors 325 and 25%-30% of
human cancers overall 6,7. Despite substantial efforts to develop therapeutics targeting this
pathway 18,326, significant challenges still exist. We previously demonstrated that Kinase
Suppressor of Ras 1 (KSR1), a molecular scaffold for the Raf/MEK/ERK kinase cascade, is
required to maintain the transformed phenotype of Ras-driven colon cancer cell lines, but is
dispensable for the survival and proliferation of non-transformed human colon epithelial cells3.
Using KSR1 as a reference standard in a RNAi-based gene expression high-throughput screen
termed Functional Signature Ontology (FUSION) 101, we identified and validated the γ1 subunit
of AMP-activated protein kinase (AMPK) as a contributor to the survival of human colon tumor
cells 3.
AMPK belongs to a family of serine/threonine kinases that are highly conserved from
yeast to humans 327. AMPK functions as a heterotrimeric complex consisting of a catalytic  and
regulatory β and  subunits 328. Mammalian AMPK acts as an energy sensing kinase that is
activated by an increasing AMP/ATP ratio and by metabolic alterations, such as hypoxia, glucose
deprivation, decreased ATP production, or increased energy consumption. AMPK is a substrate
for kinases such as LKB1 and CAMKK2, which modulate its activity by phosphorylation of the
activation loop on both alpha subunits at threonine 172. During severe stress, AMP binding to the
 subunit allosterically activates AMPK, promoting phosphorylation of the  subunit at threonine
172, and protects it from dephosphorylation 329.
The role of AMPK in cancer is controversial and has been shown to both support and
inhibit tumor growth 3,328,330-340. Retrospective population-based studies suggest that AMPK may
act as a tumor suppressor because metformin, an inhibitor of mitochondrial electron transport
complex 1 and an indirect AMPK activator, appears to decrease the risk for cancer 341,342. While
the mechanism through which metformin lowers cancer risk is not fully understood, numerous
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studies demonstrate the value of metformin as an anti-cancer agent in vitro, in preclinical in vivo
models, and in patients 332,333,338,341,342. However, the link implicating AMPK as a contributor to
the metformin-induced anti-cancer effect is controversial.
One recent study demonstrated that some cancer cells have upregulated cancer-specific
ubiquitin ligases (MAGE-A3/6) that promote the degradation of AMPK to allow for increased
mTORC1 signaling 339. Peutz-Jeghers Syndrome, which is characterized by the formation of
numerous benign and malignant tumors, is characterized by loss of LKB1 kinase activity, a
known upstream kinase and activator of AMPK 343. However, LKB1 is not the only kinase that
phosphorylates AMPK, and LKB1 phosphorylates numerous additional downstream targets that
may contribute to its tumor suppressive role.
In contrast, AMPK activation was seen in early stages of glioblastoma tumor formation
344

, and AMPK activation was found to be critical for pancreatic cancer cell growth in anchorage-

independent conditions 345. Moreover, both AMPK1-/- and AMPK2-/- MEFs are resistant to
Ras-induced oncogenic transformation, arguing that Ras-driven transformation requires AMPK
. Based on the conflicting evidence, AMPK has been described as a “conditional tumor

334,337

suppressor and contextual oncogene” 338. The cause of these conflicting reports may be due to the
role of AMPK in stress response. In non-transformed cells, AMPK likely contributes to the
maintenance of a non-transformed phenotype by promoting a controlled stress response.
However, in transformed cells the stress response function of AMPK may promote survival in a
suboptimal environment. While AMPKγ1 is required for colon cancer cell survival 3, the
contribution of other subunit isoforms on cancer cell survival has not been examined. We
examined the expression and function of the AMPK2 subunit in colon cancer cells and used
FUSION to detect a competitive inhibitor of AMPK within a natural product library. This study
highlights the potential of evaluating and targeting specific AMPK isoforms and serves as a
proof-of-concept for FUSION-based detection of small molecule inhibitors of therapeutic targets.
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Results
AMPKγ1 depletion is preferentially toxic to HCT116 colon cancer cells, but not to HCECs.
To demonstrate that the γ1 subunit of AMPK (AMPKγ1) is required for tumor cell
survival, the metabolic capacity of cells (alamarBlue® Cell Viability Assay) and PARP cleavage
(marker of apoptosis) was examined in immortalized, non-transformed human colon epithelial
cells (HCECs) and HCT116 colon cancer cells following RNAi-mediated depletion of AMPKγ1
for 72 hours. AMPKγ1 depletion substantially reduced the metabolic capacity of HCT116 cancer
cells, but did not decrease the metabolic capacity of HCECs (Fig 6.1A). AMPKγ1 depletion for
the previous assay was verified and PARP cleavage was assessed by immunoblot. AMPKγ1
protein expression was reduced following RNAi-mediated depletion in both cell lines assessed,
but PARP cleavage was only increased in the HCT116 colon cancer cell lines following AMPKγ1
depletion (Fig 6.1B).
AMPKγ1 depletion caused variable levels of toxicity in colon cancer cell lines, which
correlated with its ability to inhibit autophagy.
AMPK is known to regulate autophagy in cells through phosphorylation of ULK1 (Fig.
6.2A), and this function could contribute to its specific requirement in cancer cells where
autophagy is known to be upregulated. To evaluate whether this known function of AMPK is
contributing to its requirement in colon cancer cells, we examined beclin 1 levels following
AMPKγ1 depletion. In HCT116 cells, beclin 1 levels were decreased, suggesting a decrease in
autophagy, following AMPKγ1 depletion. In contrast, there was no induction of PARP cleavage
or decrease in beclin 1 levels in SW480 colon cancer cells with AMPKγ1 depletion (Fig. 6.2B-C),
which suggests the regulation of autophagy may mediate the detrimental effect AMPKγ1
depletion has on HCT116 colon cancer cells (Fig 6.2B). When HCT116 cells were starved of
serum for 16 hours prior to collection to induce autophagy, AMPKγ1 depletion resulted in an
even more robust decrease in beclin 1 levels and decreased phosphorylation of ULK1 (Fig. 6.2C).
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Fig. 6.1: AMPKγ1 depletion is preferentially toxic to HCT116 colon cancer cells, but not to
HCECs. (A and B) Cell viability assay (N=6) (A) and immunoblot (B) of AMPKγ1 and PARP
following RNAi-mediated AMPKγ1 depletion for 72 hours in HCECs and HCT116 cells.
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Fig. 6.2: AMPKγ1 depletion induces apoptosis and blocks autophagy in HCT116 colon
cancer cells, but not SW480 colon cancer cells. (A) Cartoon of AMPK in autophagy. (B)
Immunoblot of AMPK subunits, PARP, and an autophagy marker (beclin 1) following RNAimediated AMPKγ1 depletion for 72 hours in HCT116 and SW480 cells. (C) Immunoblot of
AMPK subunits, PARP, and autophagy markers (beclin 1, pULK1) following RNAi-mediated
AMPKγ1 depletion for 72 hours in HCT116 and SW480 cells with serum starvation for the 16
hours prior to collection.
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In contrast, AMPKγ1 depletion did not affect beclin 1 levels or ULK1 phosphorylation in SW480
colon cancer cells even with serum starvation; however, the level of knockdown was not as robust
in the SW480 cells as compared to the HCT116 cells, which could also be limiting its effects.
Interestingly, AMPKγ1 depletion also resulted in a decrease in AMPK2 in HCT116 cells, but
did not affect AMPK2 levels in SW480s. This observation raises the possibility that AMPKγ1 is
required for the formation and stabilization of the AMPK heterotrimer in HCT116 cells, but not
SW480s, and that stabilization of the holoenzyme is required for HCT116 cell survival.
AMPK2 is differentially expressed in colon cancer cell lines.
AMPK functions as a heterotrimeric complex consisting of a catalytic  subunit that
possesses kinase activity and regulatory β and  subunits328. The 2, β2, and 1 AMPK subunits,
but not the 1 and β1 subunits, promoted the survival of HCT116 colon cancer cells3. However,
AMPK1 was not required for survival in SW480 colon cancer cells (Fig. 6.2B-C). To further
evaluate the importance of the individual AMPK subunits, the expression of various AMPK
subunits in a panel of colon cancer cell lines was examined. AMPK1, AMPKγ1, and AMPKβ1
expression was relatively consistent across cancer cells lines and was comparable to
immortalized, non-transformed human colon epithelial cells (HCEC) expression (Fig. 6.3).
However, the expression of AMPK2 and AMPKβ2 was variable between cancer cell lines. Of
note, the highest expression of AMPK2 was observed in the SW480 and SW620 cancer cells.
HCECs, as well as the LoVo and HCT116 cancer cells had moderate expression. While, HCT15,
DLD1 and SK-CO-1 cells demonstrated very low AMPK2 expression (Fig. 6.3).
AMPK2, but not AMPK1, is required for colon cancer cell survival.
To evaluate the role the kinase activity of AMPK plays in promoting colon cancer cell
survival, the effect of AMPK1 or AMPK2 depletion on colon cancer cells was examined. Cell
lines with moderate (HCT116) and high (SW480) AMPK1 and AMPK2 expression were
selected for analysis, and propidium iodide staining followed by flow cytometry analysis and
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Fig. 6.3: AMPK subunit expression in a panel of colon cancer cell lines as compared
to immortalized, non-transformed human colon epithelial cells (HCEC).
(Part of Fig. 6.3 has been previously published in 1).

187

PARP cleavage assessment were used to evaluate cell death after AMPK1 or AMPK2
depletion by RNAi for 72 hours. AMPK2 depletion increased cell death in both HCT116 and
SW480 colon cancer cell lines, while AMPK1 depletion did not (Fig. 6.4A-C). These data
indicate that AMPK2, and therefore AMPK activity, is required for colon cancer cell survival
even though individual AMPK subunits (AMPK1) may be dispensable. These data suggest that
while individual AMPK subunits likely have overlapping roles in cells, they also have unique,
non-redundant functions. Of note, individual AMPK1 or AMPK2 depletion or combination
depletion of AMPK1/2 does not induce apoptosis in HCECs (Fig 6.4D), suggesting that colon
cancer cells have developed a unique dependence upon AMPK activity. Thus, identifying a
compound that selectively inhibits the functional AMPK heterotrimer may be an efficacious
therapeutic strategy to selectively target cancer cells regardless of their preference or requirement
for specific AMPK subunits.
AMPK2 is required for autophagy and increased metabolic capacity.
To evaluate the effects of AMPK2 depletion in cancer cells, phosphorylation of ULK-1
and beclin 1 expression, a marker of autophagy, was examined. Following AMPK2 depletion
for 72 hours, ULK1 phosphorylation and beclin-1 levels decreased; however, these changes were
modest and more robustly seen in HCT116 cells and to a lesser extent seen in SW480 cells (Fig
6.5A). In HCT116 cells, AMPK2 depletion, but not AMPK1 depletion, caused a decrease in
PGC1β and ERR expression, two proteins that have previously been shown to be required for
HCT116 colon cancer cell survival (Fig 6.5B), which opens the possibility that AMPK2 has
multiple mechanisms by which it promotes colon cancer cell survival.
FUSION identifies a natural product that inhibits AMPK kinase activity.
Functional Signature Ontology (FUSION) detects functional relationships between genes
and microRNAs based on changes to a gene expression-based functional signature3,101,346.
Previously, FUSION identified AMPKγ1 as a genetic functional analog of KSR1 based on
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Fig. 6.4: AMPK2 is selectively required for colon cancer cell survival, but not HCEC survival. (A)
Apoptosis (percent of cells in the sub-G1 peak) in HCT116 and SW480 cells after AMPKα1 or AMPKα2
depletion by RNAi for 72 hours. Apoptosis was evaluated using propidium iodide staining followed by
flow cytometry analysis. (N=3). (B) Immunoblot of AMPKα2 expression and PARP cleavage in HCT116
and SW480 cells following RNAi-mediated AMPKα2 depletion for 72 hours. (C) Immunoblot of
AMPKα1 expression and PARP cleavage in HCT116 and SW480 cells following RNAi-mediated
AMPKα1 depletion for 72 hours. (D) Immunoblot of AMPKα1, AMPKα2, and PARP cleavage in HCECs
following RNAi-mediated AMPKα1 or AMPKα2 depletion for 72 hours. (Part of Fig. 6.4 has been
previously published in 1).
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Fig. 6.5: AMPK2 depletion reduces phosphorylation of ULK-1 and expression of beclin 1, PGC1β,
and ERR. (A) Immunoblot of AMPK2, PARP, total- and phospho-ULK1, and beclin 1 following
RNAi-mediated depletion of AMPK2 for 72 hours in HCT116 and SW480 cells. (B) Immunoblot of
AMPK1, AMPK2, PGC1β, and ERR following AMPK1 or AMPK2 depletion for 72 hours in
HCT116 cells. (Experiment 6.5B was done in collaboration with Binita Das and is published in 3. Part of
Fig. 6.5A has been previously published in 1).
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unsupervised hierarchical clustering and quantification of similarity metrics (Euclidean distance
and Pearson correlation) based on reporter gene expression following RNAi-mediated depletion
of individual genes from a genome-scale human siRNA library. Biological validation
demonstrated AMPKγ1 is also required for the survival of colon tumor cells, but not
immortalized, non-transformed colon epithelial cells3. We hypothesized this approach could be
used to identify small molecule inhibitors that mimic the effects of AMPK inhibition and be
preferentially toxic to human colon tumor cells. As a proof-of-concept experiment, reporter gene
expression signatures were generated for 1,186 unique chemical fractions isolated from a natural
product library derived from a diverse selection of marine bacteria 101. Comparing the gene
expression signature of Compound C (also known as Dorsomorphin), a drug known to inhibit
AMPK333, with fractions isolated from the natural product library, FUSION identified several
fractions whose biologic activity was similar to Compound C treatment 101,347.
Several fractions isolated from the Streptomyces bacillaris strain SN-B-004 clustered
with Compound C (Fig. 6.6A). Based on this observation, we hypothesized that the SN-B-004
fractions that clustered with Compound C contained an inhibitor of AMPK. Treatment with SNB-004 fractions 13-17 decreased viability of colon tumor cell line HCT116 (Fig. 6.6B) and SN-B004 fractions 13-16 decreased phosphorylation of two AMPK substrates acetyl-CoA carboxylase
(ACC) at Ser79 and RAPTOR at Ser792 (Fig. 6.6C). In contrast, SN-B-004 fraction 12, which
clustered further away from Compound C, but was collected in series with fractions 13-16, did
not affect cell viability or phosphorylation of AMPK downstream targets (Fig. 6.6B-C).
SN-B-004 fractions 13-17 appeared pharmacologically and mechanistically distinct from
Compound C because they demonstrate a limited ability to prevent the phosphorylation of
AMPK at Thr172 (Fig. 6.6C), which is critical for AMPK activity348, while Compound C was
able to decrease phosphorylation at Thr172. While Compound C has been shown to inhibit
AMPK activity by decreasing phosphorylation on downstream targets, the mechanism behind its
inhibition has not been fully elucidated. Increasing activating AMPK signals (AICAR or
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Fig. 6.6: FUSION identified natural product fractions that inhibit AMPK. (A) Unsupervised
hierarchical clustering of fractions isolated from the Streptomyces bacillaris strain SN-B-004 with
Compound C. (B) Cell viability assay in HCT116 cells treated for 24 hours with the indicated natural
product fractions. Data are shown as mean relative light units (RLU) ± SD. ***p<0.001 (N=3). (C)
Immunoblots of total and phosphorylated ACC (Ser79), RAPTOR (Ser792) and AMPK (Thr172) in
HCT116 cells treated for 48 hours with the indicated natural product fractions. (Experiment 6.6A was
completed in collaboration with Hyun Seok Kim and Michael White. Experiments 6.6B-C were
completed by Kurt Fisher and Binita Das. Fig. 6.6 has been previously published in 1).
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metformin treatment) is sufficient to overcome inhibition of Compound C suggesting that it does
not directly inhibit the kinase activity of AMPK, but instead may act by regulating the activation
of AMPK itself, which is likely based on its detrimental effect on AMPK phosphorylation333. In
contrast, direct inhibition of the kinase activity of AMPK would lead to decreased
phosphorylation of downstream targets of AMPK without directly affecting AMPK
phosphorylation, though it may paradoxically increase the phosphorylation of AMPK itself due to
loss of negative feedback loops.
The active compound within the impure fraction SN-B-004-16 was isolated and the
structure was determined using mass spectrometry and nuclear magnetic resonance spectroscopy
to be 5´-hydroxy-staurosporine349 (5-OH-S, Fig. 6.7A), a derivative of the well-known, nonspecific kinase inhibitor staurosporine 350. To date, 5-OH-S has only been described in one other
report in the literature in which it was isolated from another marine bacterium Micromonospora
sp. strain L-31-CLCO-002349. To determine if 5-OH-S directly inhibits AMPK kinase activity, we
performed in vitro kinase assays of AMPK using SAMS peptide as a substrate, in the presence or
absence of 5-OH-S. The IC50 of 5-OH-S for recombinant AMPKα1β1γ1 and AMPKα2β1γ1 was
similar at 517.5 nM and 583.3 nM, respectively (Fig. 6.7B). The Ki for 5-OH-S inhibition of ATP
binding to recombinant AMPK α1β1γ1 was 347 nM (Fig. 6.7C).
AMPK inhibition via 5-OH-S treatment is selectively toxic to colon cancer cells.
AMPKγ1 and AMPK2 were selectively required for colon cancer cell survival, but not
HCECs survival (Fig 6.1 and 6.4) 3, which led to the prediction that tumor cells would also be
selectively sensitive to 5-OH-S as an inhibitor of AMPK. Treatment with 5-OH-S inhibited
anchorage independent growth of HCT116 cells in a soft agar assay (Fig. 6.8A), and 5-OH-S was
preferentially toxic to the colon cancer cells lines (HCT116 and SW480) as compared to the
HCECs (Fig. 6.8B). The induction of cell death following 5-OH-S treatment was verified in
HCT116 and SW480 cells by analyzing PARP cleavage (Fig. 6.8C), which demonstrated
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Fig. 6.7. The identified active molecule, 5-OH-S, inhibits AMPK kinase activity. (A) Structure of 5OH-S. (B) Dose-dependent inhibition of recombinant AMPKα1β11 and recombinant AMPKα2β11
kinase activity by 5-OH-S. (C) Lineweaver-Burke plots of AMPK substrate phosphorylation in the
presence of DMSO or 500 nM 5-OH-S. (Natural product identification in 6.7A was completed by our
collaborator Youcai Hu and John MacMillan. Experiments 6.7B-C were completed by Binita Das and
Dee Volle. Fig. 6.7 has been previously published in 1).
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Fig. 6.8. 5-OH-S treatment preferentially inhibits colon cancer cell survival by reducing
phosphorylation of known downstream AMPK targets. (A) Colony formation following
treatment with 7.5 M 5-OH-S. **** p < 0.0001 (B) Dose-dependent apoptosis in HCT116 and
SW480 colon cancer cells and HCECs following treatment with 5-OH-S. (N=3). (C) Immunoblots of
total and phosphorylated ACC (Ser79), RAPTOR (Ser792) and AMPK (Thr172) after 48-hour
treatment with 7.5 μM 5-OH-S in HCT116 and SW480 cells. (D) Immunoblot of total and
phosphorylated ACC (Ser79) and beclin 1 after 48-hour treatment with 7.5 μM 5-OH-S in HCT116
and SW480 cells. (Experiment 6.8A was completed by Binita Das. Experiment 6.8B was completed
by Drew Gehring. Part of Fig. 6.8 has been previously published in 1).
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increased PARP cleavage with 5-OH-S treatment. Similar to the SN-B-004 fractions, 5-OH-S
decreased the phosphorylation of ACC at Ser79 and of RAPTOR at Ser792, known AMPK
downstream targets, without decreasing the phosphorylation of AMPK at Thr172 in colon cancer
cell lines HCT116 and SW480 (Fig. 6.8C). Treatment with 5-OH-S decreased AMPK kinase
activity in all cell lines tested as illustrated by reduced phosphorylation of ACC and RAPTOR
(Fig. 6.8C); however, 5-OH-S treatment only decreased beclin-1 levels in HCT116s, but not
SW480s. This correlated with the much higher level of cell death in HCT116 cells following 5OH-S treatment. Similarly, 5-OH-S treatment inhibited AMPK activity in HCECs as evidenced
by reduced phosphorylation of ACC and RAPTOR (unpublished data, Binita Das), but did not
cause cell death in these cells (Fig. 6.8B). This suggests therapeutic targeting of AMPK could
lead to efficacious cancer therapeutics as the cancer cells have either developed a generalized
increased dependence on AMPK activity or depend on AMPK to perform functions that it does
not normally perform in normal cells.
In Ras-driven cancer, disruption of ERK signaling increased AMPK dependence.
Tumor cells evolve in ways such that they develop vulnerabilities. Clinically, these are
taken advantage of when inhibitors are developed that target characteristics only present in cancer
cells such as mutations, aberrantly expressed genes, or uniquely required pathways. These are
called targeted therapies. Unfortunately, however, cells often find ways to develop resistance and
evade these therapies by further adapting and shedding these targetable characteristics. Ras
mutations commonly activate the Ras/Raf/MEK/ERK signaling cascade, and a multitude of drugs
targeting multiple levels of this pathway have been developed. Even though these inhibitors have
demonstrated selective inhibition on the desired targets, most have shown limited efficacy. This
suggests cells are able to evolve to avoid the detrimental effects of the inhibitor.
As described earlier, KSR1 is required for full ERK activation downstream of activated
Ras. To evaluate the adaptations that cells undergo when ERK signaling is limited as a result of
KSR1 depletion, gene expression changes were evaluated using an Affymetrix Human Genome
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U133 Plus 2.0 Array in HCT116 cells with and without KSR1. In HCT116 cells that are stably
depleted of KSR1, AMPK2 expression is dramatically increased based on an online GEO2R
analysis (default settings) of the GEO dataset GSE653513 (Fig 6.9A). In fact, probes for the a2
subunit of AMPK were the top two results of targets that demonstrated altered expression
between the control (no transfection and shCont) and experimental conditions (shKSR1 #1 and
#2). This relationship was further confirmed as transient knockdown of ERK in HCT116 and
SW480 cells caused an increase in AMPK activation based on increased phosphorylation at T172
and increase in beclin 1 (HCT116 only) (Fig 6.9B). MEK depletion had less of an effect on
AMPK phosphorylation and beclin 1 levels, which could be due to residual ERK activation being
sufficient for the cells as phospho-ERK levels are maintained at a level similar to that seen in
control cells (Fig 6.9B). These results suggested that combination ERK and AMPK inhibition
could be synergistic and/or prevent the development of resistance to either agent alone.
Therefore, the effects of ERK inhibition alone and in combination with Compound C, a
known, non-specific AMPK inhibitor, were evaluated using the linear isobol model 351 to
investigate the possibility of synergy between ERK and AMPK inhibition. The linear isobol
model is based on the idea that if a drug has additive effects with another drug, one could plot the
dose required for one drug to reach the ED50 on the x axis and the other on the y axis. Drawing a
line between these points would represent the combination doses that would also achieve the
same ED50 effect. This is called an isobologram. This intuitively makes sense if one considers the
possibility that treatment actually includes a combination of two agents that in reality contained
the same active ingredient. Regardless of differing formulations or dilutions, a given percentage
of the ED50 would still be expected to provide a given amount of effect. For example, if given
half of the ED50 dose for each of the two drug formulations, one would have received a full ED50
dose and therefore a response equivalent to the ED50 would be expected. Plotting this point on the
isobologram would place the point on the line between the ED50 points for each drug. Any other
fractional combination would also be plotted on this same line provided the fractional doses fit
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Fig. 6.9 Disruption of ERK signaling upregulated AMPKa2 activation, and ERK and AMPK
inhibition were synergistic. (A) AMPK2 expression from probes 227892_at and 238441_at on an
Affymetrix Human Genome U133 Plus 2.0 Array in HCT116 cells stably-depleted of KSR1 using shRNA
(N=1). (Data is available on Geo: GSE65351). (HCT116 shKSR1 cells were developed and gene
expression was assessed by microarray by Kurt Fisher). (B) Immunoblot of ERK, total and phoshoAMPK, and beclin 1 following RNAi-mediated depletion of ERK for 72 hours. (C) Viability of HCT116
and SW480 cells following treatment with 1 µM of SCH772984, 20 µM of Compound C, or a
combination of both SCH772984 and Compound C such that the doses fulfill the following criteria
Dosesch772984/1 µM SCH772984 + DoseCompound C/20 µM Compound C = 1 to evaluate synergy between the
two compounds. The horizontal line represents the lower edge of the predicted range of expected drug
additivity (i.e. 500 nM SCH772984 and 10 μM Compound C (50%/50%), 400 nM SCH772984 and 12
μM Compound C (40%/60%), 200 nM SCH772984 and 16 μM Compound C (20%/80%), etc.) (N=3).
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the following formula DoseA/ ED50_A + DoseB/ ED50_B = 1 (i.e., 0.25 of the ED50 of drug A given
in combination with 0.75 of the ED50 of drug B). If any of these combinations demonstrate
increased efficacy relative to both individual agents given at the ED50, this suggests a superadditive effect or synergism in both HCT116 and SW480 colon cancer cells (Fig. 6.9C).
Combination treatment with SCH772984 (ERK inhibitor) and Compound C (AMPK inhibitor)
showed super-additive or synergistic results for various doses of combination drug treatments.

Conclusions
Our data show that AMPK promotes the survival of multiple human colon cancer cell
lines and that variable levels of AMPK alpha subunits may contribute to or predict the cells’
relative sensitivity to AMPK depletion. Interestingly, human colon epithelial cells (HCECs) do no
share this dependence on AMPK. This could be exploited for the development of therapeutics
targeting AMPK that will be selectively detrimental to cancer cells, but less so or not at all lethal
to normal cells. However, cancer cells that have increased or altered AMPK subunit expression or
have employed alternative mechanisms to circumvent AMPK-regulated pathways, may overcome
or lose sensitivity to AMPK depletion or inhibition.
These data also suggest a role for AMPK isoforms with specific subunit composition and
expression level in determining the contribution of AMPK toward tumor cell viability. This study
provides additional evidence that cancer cells evolve diverse mechanisms to overcome obstacles
limiting survival and proliferation. Cancer cells develop defined dependencies and vulnerabilities
that offer a basis for their characterization and specific therapeutic intervention. This may reflect
differing responses to environmental stresses that directed the tumor’s evolution and suggests that
at least a subset of colon tumors may be highly susceptible to AMPK inhibition. In this study, we
showed that colon cancer cells have an increased, but variable, requirement for the AMPK 2
subunit isoform for their survival, more so than a requirement for the 1 subunit. This suggests
that the individual subunits likely have unique, non-redundant functions that add another layer to
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the complexity surrounding the role of AMPK in cancer. This phenomenon is not likely to be
limited to colon cancer as several other groups have demonstrated a requirement for AMPK or its
downstream effects in both prostate and breast cancer and have shown that inhibition of AMPK is
detrimental to cancer cells 352-356.
In this study, we describe a novel, direct kinase AMPK inhibitor, 5´-hydroxystaurosporine (5-OH-S) that has been isolated only from marine bacteria and has yet to be widely
synthesized or made commercially available349. The effects of 5-OH-S appear to exceed those
seen with individual AMPK subunit depletion. This is not surprising as 5-OH-S treatment inhibits
AMPK isoforms containing either  subunit and likely all AMPK trimer complexes. However, a
detailed kinase inhibitor profiling to assess the effects of 5-OH-S on other targets has not been
completed. Therefore, the possibility exists that 5-OH-S may have off-target effects that
contribute to its anticancer effects. A structurally similar compound, 7´-hydroxy-staurosporine
(also known as UCN-01357), has also previously demonstrated significant anti-cancer effects. Like
other staurosporine derivatives, 7´-hydroxy-staurosporine has broad intracellular effects and
inhibits multiple kinases, notably Protein Kinase C358,359. Regardless, 7´-hydroxy-staurosporine
(7-OH-S) has been examined in numerous phase I and phase II trials for multiple types of cancer
including T-cell lymphomas, leukemia, breast cancer, small cell lung cancer, melanoma,
pancreatic cancer, kidney cancer, ovarian/fallopian tube cancer, and many other solid tumors360372

; however, its use has been constrained due to limited single agent efficacy, in conjunction with

a less than optimal pharmacokinetic profile, and undesirable side effects. However, comparing 7OH-S directly to 5-OH-S demonstrated less toxicity in HCECs and increased lethality in HCT116
cells (unpublished data, Das and Lewis) suggesting that further evaluation of 5-OH-S is likely to
reveal its superiority to 7-OH-S. Our data suggest that staurosporine derivatives can act as lead
compounds for the development of more specific AMPK kinase domain inhibitors with the goal
of improved target specificity, anti-cancer efficacy, and reduced treatment complications.
The current study expands upon previous work that used FUSION to identify microRNAs
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and individual genes as potential therapeutic targets in cancer3,101,346. This study demonstrates the
ability of FUSION to identify novel small molecules from an unbiased screen of crude natural
product fractions that inhibit a specific target important for cancer cell survival. In this instance,
FUSION identified 5-OH-S as an inhibitor of AMPK, which can serve as a lead compound that
can be used to understand AMPK activity and could be further developed using medicinal
chemistry for use as a cancer therapeutic.
These results also demonstrate a connection between KSR1 and AMPK signaling based
on the increased dependence on AMPK following disruption of KSR1 or ERK. These data
provide rationale for further studies examining the interconnectedness of these two pathways and
highlight the potential for synergism or the ability to prevent the development of resistance with
this combination of targeted therapies. This potential is unfortunately hampered by the lack of a
specific, high affinity AMPK inhibitor, which further highlights the value of the development of
FUSION as a novel method that can distinguish genes and compounds with particular cellular
functions or phenotypes in an unbiased manner. This proof-of-concept study suggests that
applying FUSION to a larger, more diverse library of small molecules and/or crude natural
product fractions could identify numerous lead compounds that are more specific inhibitors of
AMPK or other promising therapeutic targets, leading to the discovery of new, efficacious
targeted therapies.
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Chapter 7: Discussion/Conclusions
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FUSION
These results demonstrate the value of FUSION as an unbiased function-based screen
that can be applied to identify functionally-related genes and reveal inhibitors of target genes.
This study expands upon previous work by Stegmaier et al. that applied a gene expression-based
signature to identify compounds that induced differentiation in leukemia 103. This original study
revealed the potential to use a gene expression-based signature as a proxy for a phenotype of
interest by evaluating approximately 1700 compounds using PCR and mass spectrometry to
evaluate the expression of five genes that composed the differentiation signature. FUSION further
developed this concept by applying the Affymetrix Quantigene 2.0 Assay to measure gene
expression. This allowed for the gene expression of multiple genes to be measured
simultaneously using a Luminex machine so the screen could be expanded tenfold to evaluate
more than 17,000 perturbations (individual gene depletions and treatments with microRNA,
natural product fractions, and drugs). This method has successfully identified several promising
genetic targets including three genes (TIMELESSS, WDR5, and AMPKγ1) and one natural
product (5-OH-S) that are the subject of several manuscripts and this dissertation 3,42,101.
However, the current application of FUSION is limited by several confounding features
in its implementation that could be eliminated in the future to realize the full potential of this
approach. First, all of the screens were performed in a single Ras-mutated colon cancer cell line,
HCT116. HCT116 colon cancer cells have wildtype p53, an unstable genome, and a high level of
sensitivity to commonly used cancer therapies. This creates the potential of identifying targets in
the genome-scale RNAi screen that are preferentially toxic to HCT116 cells, but potentially less
so to other cancer cells. Based on the results contained herein, this appears to be the case as
HCT116 cells were generally more sensitive to the identified gene depletions (TIMELESS,
WDR5, and AMPK/5-OH-S) than other cell lines. Importantly, the FUSION screen was
successful in identifying targets that were preferentially required in cancer as the cancer cell lines
were more sensitive to the gene depletions than immortalized, but non-transformed human colon

203

epithelial cells. Expanding the FUSION screen to test multiple cell lines, preferably from
additional cancer types or with different tumor characteristics, is likely to reveal common targets
that are ubiquitously required for cancer cell survival, but dispensable for normal cell survival. At
the very least, as new genetic targets or therapeutics are identified that are predicted to be
selectively required for cancer cell survival, it is extremely important to evaluate their effect in a
panel of cancer cells early in biological validation in order to focus research efforts on studying
targets that are not specific to HCT116 cells.
Based on the issues with off-target effects identified with the individual siRNA oligos
targeting WDR5 (Fig. 5.6), an additional follow-up screen evaluating the consistency of the gene
depletion effects using individual oligos could have further helped to prioritize the hits and
eliminated targets that were likely only hits due to off-target effects. This is a common practice
where four individual oligos targeting the genes identified as being hits in the initial screen are
individually tested to evaluate the consistency of the gene depletion effect. However, this followup screen can substantially increase the cost of a screen, even if a more cost-effective assay is
used in the follow-up screen. Additionally, it is not uncommon for individual oligos to fail to
decrease target expression despite having sequences that match the target gene such that the
expected phenotype may not be seen and true positives may inadvertently be excluded from
further evaluation.
While two algorithms were applied to identify the potential of off-target seed sequence
effects, both of these algorithms are based on seed sequences starting with the first nucleotide in
the siRNA oligo. The experimentally identified likely off-target effects in the WDR5 oligo #6 are
the result of the oligo almost completely matching another gene, ME1; however, the matching
sequence actually starts with the second nucleotide in the siRNA sequence providing rationale for
why both of the seed sequence off-target effect algorithms failed to recognize this potential offtarget effect.
Finally, when undertaking an experiment of this scale that will require substantial
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computational analysis to evaluate the results, ideally the individuals that will be performing the
analysis should be included in the experimental planning from the beginning. This allows them to
understand the experiment prior to planning their computational approach and provides the
opportunity for them to contribute to the experimental design to simplify the subsequent
computational analysis. In this screen, the non-random plating of control wells and grouping of
functionally related genes on the same plate limited the options for robust normalization. This
precludes the use of plate-position normalization, and therefore any effects that were caused by
plate positioning, if present, could not be taken into account. While completely random plating is
likely impossible, and increasing the randomness of plating would increase the biological
experiment complexity, the benefits for subsequent computational analysis may have outweighed
the increased experimental requirements. Therefore, the effort required to complete the biological
experiment and computational evaluation needs to be balanced and discussed to ensure the most
appropriate biological and computational approaches are applied to generate the most robust and
easily interpretable results.
Finally, FUSION was initially designed based upon a gene expression signature of KSR1
depletion making it particularly suited to identify targets that are KSR1-like. However, a
modified FUSION screen has the potential to reveal genes that are functionally similar to any
specified gene of interest. Ultimately, the success of such a screen would be dependent upon the
quality of the set of genes used for the gene expression-based signature. Therefore, designing a
modified FUSION screen that could be used to evaluate the functional similarity between any two
genes would require the establishment of an expanded or revised panel of genes to be used in the
gene expression-base signature. Ideally, these genes would be independent and not covary, and
reveal effects of different downstream pathways. This would include avoiding the inclusion of
multiple genes with the same or highly similar functions as these would have a high likelihood of
covarying and would be less likely to provide additional resolving power in the screen. One
method to identify potential genes would be to individually deplete cells of known key regulators,
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particularly targets that are implicated in cancer (e.g. Ras, MYC, p53, PI3K, AMPK, ATM/ATR,
β-catenin, PKCs, hexokinase, BCL-2, TGFβ, NFκB, etc.) and evaluate gene expression using
microarrays or RNASeq to identify genes whose expression either increases or decreases
following each perturbation. Identifying changes that are specific to a limited number of
perturbations and that demonstrate independence would provide a good starting point for a gene
panel. Genes that would provide additional refinement could be identified by treating with drugs
known to activate various pathways as an additional mechanism to increase the delineating power
of the FUSION screen. In the current application of FUSION, all of the genes from the gene
expression-based signature were decreased following KSR1 depletion. Therefore, selecting genes
that decrease as well as genes that increase in expression following a given perturbation may
increase the resolving power of the screen.
After the identification of a gene set for the gene expression-based signatures, several
additional factors would need to be considered in order for an experiment on this scale to be
fruitful. Multiple cell lines would need to be selected for the screen in order for the results to be
generalizable. Additionally, performing a screen on this scale would be technically difficult. An
alternative would be to simulate this analysis bioinformatically.
Instead of experimentally screening multiple cells lines for similarities in gene expression
for a panel of genes, one could analyze publicly available microarray or RNASeq data to simulate
a similar analysis. In this situation, the gene expression of thousands of genes could be evaluated
for a given genetic or drug-induced perturbation of interest to identify a subset of genes whose
expression changed in response to the given manipulation. This could then be used to screen for
other genetic manipulations or drug treatments that had a similar effect. This computational
analysis would be limited by the availability of applicable data (i.e. the cell lines or models used
may not match, the timing may be different for each dataset, the specific assay performed or
microarray used is likely to be different, and the experiments would have been performed by
different groups), but this method would benefit from being able to compare a huge number of
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gene expression changes. Computational screening would also be substantially cheaper than
biological screening, but would require substantial expertise in bioinformatic analysis, which is
currently a substantial limiting factor in re-use of data in medical research.

TIMELESS
This work expands upon the preliminary studies that have indicated TIMELESS is
overexpressed in cancer and correlates with poorer patient outcomes and reveals a common
mechanism by which loss of TIMELESS induces G2/M arrest and slows cancer cell proliferation.
This work demonstrates that TIMELESS is overexpressed in multiple types of cancer and is
likely required for increased DNA synthesis and cell proliferation. TIMELESS is overexpressed
at the mRNA and protein level in cancer. In colon cancer, TIMELESS mRNA overexpression is
not due to changes in promoter methylation. Transcriptionally, TIMELESS is thought to be
regulated via transcription factor binding to E-box elements in its promoter in conjunction with
chromatin modifications including acetylation of K3-K9 and trimethylation of H3K4 (H3K4Me3)
122,123,373

. H3K4Me3 is added by the histone methyltransferase KMT2A/MLL1, which permits

circadian oscillation 374. This suggests the possibility that WDR5 overexpression in cancer could
facilitate, if not promote, circadian dysregulation in cancer.
Independent of a mechanism that upregulates TIMELESS mRNA, oncogenic Ras
increases ERK activation, which subsequently increases TIMELESS expression. However, ERK
inhibition did not globally reduce TIMELESS expression in colon cancer cells. In cells that were
resistant to ERK inhibition-induced changes in TIMELESS expression, mTOR inhibition
decreased TIMELESS expression. ERK and mTOR are known to regulate translation, which is
likely the mechanism by which they regulate TIMELESS expression in colon cancer.
Likely as a result of oncogenic signaling aberrantly driving its expression, TIMELESS
expression is constitutively high, is no longer circadianly regulated, and is not decreased with
increasing cell confluency. In contrast, in immortalized, yet non-transformed human colon
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epithelial cells (HCECs), TIMELESS expression follows a circadian pattern after circadian
synchronization and is inversely related to cell confluency. TIMELESS expression is known to
vary based on cell cycle phase and is highest in the S and G2 phases of the cell cycle. Therefore,
the changes in TIMELESS expression in HCECs relative to their confluency could be the result
of an accumulation of cells in the G0/G1 phase. Interestingly, this change in expression mirrored
changes in ERK phosphorylation. Considering this in conjunction with data demonstrating that
ERK inhibition decreased TIMELESS levels even in HCECs suggests that ERK activation
downstream of Ras promotes TIMELESS expression even in normal cells. Importantly, Ras/ERK
and AKT/mTOR signaling has been shown to affect circadian rhythms 375,376. Circadian
oscillations of ERK phosphorylation have been seen, and AKT/TOR regulates Sgg/GSK3 to
affect the nuclear accumulation of TIMELESS 376.
In colon cancer, TIMELESS depletion did not affect ERK phosphorylation as was
previously predicted 205 or reduce MYC expression in colon cancer as was previously shown in
breast cancer 207. Instead, TIMELESS depletion decreased cell proliferation and induced G2/M
arrest in HCT116, SW480, SW620, and RKO colon cancer cells as a result of increased γH2AX
and downstream CHK1 and CDK1 phosphorylation. This mechanism is preserved in HCECs, but
is seen to a lesser extent than in the colon cancer cells.
ERK inhibition induces an increase in γH2AX that cannot be rescued by exogenous
TIMELESS expression, yet fails to induce CHK1 and CDK1 phosphorylation. ERK inhibition
may also indirectly inhibit CHK1 phosphorylation as previous studies have shown that CHK1
nuclear localization is dependent upon p90RSK phosphorylation of CHK1 at S280. This
phosphorylation by p90RSK and subsequent nuclear localization is a prerequisite for DNAdamage induced ATR-mediated phosphorylation of CHK1 at S345 222.
The increased and aberrant expression of TIMELESS represents a unique vulnerability
downstream of oncogenic Ras signaling and reveals a novel mechanism cancer cells employ to
circumvent normal proliferative constraints. This suggests circadian dysregulation may be
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essential within cancer cells for increased cell cycle advancement and implies that the
development of therapeutics targeting this pathway may be efficacious in the treatment of cancer.
This work is limited by the lack of an in vivo model to substantiate that TIMELESS is
playing a vital role for the proliferation of cancer cells, and future work should be applied to
evaluate the in vivo utility of targeting TIMELESS. This is particularly important as cells lose
their organism-wide circadian entrainment in vitro. Even though intracellular circadian cycles are
intact in this context, the potential exists that TIMELESS functions differently or is subject to
additional regulation in vivo in the presence of constant organism-wide circadian entrainment.
Additionally, TIMELESS has also been shown to be required for transcriptional upregulation of
steroid hormone-producing enzymes 377 and regulates bacteria phagocytosis in Drosophila as
Drosophila lacking TIMELESS are more sensitive to infection by S. pneumoniae 378.
Phagocytosis is circadianly regulated with a higher level of phagocytosis at night. Loss of PER,
another circadian gene, has a similar phenotype, and normal Drosophila demonstrate oscillating
resistance to S. pneumoniae that is absent in TIMELESS mutants. Therefore, the effect of
TIMELESS depletion on phagocytosis is likely a result of defective circadian cycle, which opens
the possibility that circadian disruption in cancer may also affect immune system function. Based
on these observations regarding other cellular functions of TIMELESS, additional mechanisms
might exist in vivo that either contribute to its requirement for cancer cell survival and
proliferation or preclude its use as a therapeutic target due to currently unforeseen side effects of
inhibiting TIMELESS.
Clearly, TIMELESS represents a novel vulnerability that is present in cancer cells, but
not normal cells, that can be used to selectively target cancer cells and may be particularly
effective if paired with a circadian dosing regimen; however, future work is needed to evaluate
TIMELESS in vivo.

WDR5
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KMT2/MLL proteins are commonly mutated in colon cancer, but their role in tumor
development and maintenance is still being debated. In contrast, WDR5 is rarely mutated in colon
tumors, and preliminary studies have shown it is pro-tumorigenic. Several colon cancer cell lines
including HCT116, RKO, and LoVo cells have WDR5 mutations, but their functional impact is
unknown. WDR5 is also ubiquitously overexpressed in colon cancer cells. This overexpression
could be the result of oncogenic signaling, but this has yet to be shown. WDR5 depletion or
inhibition is selectively, but variably, toxic in colon cancer cells, more so than in HCECs. WDR5
depletion induces γH2AX in HCT116, SW620, and RKO cells and decreases H3K4Me3 in
HCT116, HCT15, SW620, and RKO cells. WDR5 inhibition with OICR-9429 treatment only
induced γH2AX in the two cell lines with wildtype WDR5, HCT15 and SW620, and decreased
H3K4Me3 in HCT116. Combination of WDR5 with ionizing radiation further increased the level
of γH2AX. Future work is required to evaluate the role of WDR5 within in vivo tumors.
Interestingly, both TIMELESS and WDR5 depletion induced γH2AX. Two additional
hits from FUSION were MAP2K7 and MAP4K4, two kinases that phosphorylate JNK1. One
study demonstrated that JNK1 may also contribute to increased H2AX phosphorylation (γH2AX)
and DNA damage repair 379. The fact that this common mechanism is shared between multiple
hits from FUSION suggests that DNA damage repair may be a pathway that is highly required in
cancer. While this may be true, the genes within the KSR1-depletion gene expression-based
signature may also have been primed or more likely to identify targets that share this specific
mechanism of action and/or this pathway could be preferentially necessary in HCT116 cells.
Further work to evaluate if KSR1 depletion also induces an increase in γH2AX may
reveal additional mechanisms by which KSR1 promotes Ras-driven tumor formation and
maintenance. KSR1 is known to be required for cell cycle restart following DNA damage repair,
but further elucidating the downstream effects of KSR1 depletion on CHK1 and CDK1
phosphorylation and the mechanism behind the cell cycle arrest could reveal additional functional
similarities between KSR1 and other hits identified by FUSION.
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AMPK/5-OH-S
The gamma 1 subunit of AMPK is selectively required for HCT116 colon cancer cell
survival, but not HCEC cell survival. In HCT116 cells, AMPKγ1 depletion causes a decrease in
AMPK2 expression, which likely mediates this effect as AMPK2, but not AMPK1 is
required for HCT116 and SW480 colon cancer cell survival. AMPK1, AMPK2, or
combination AMPK1/2 depletion does not cause apoptosis in HCECs.
AMPK2 depletion decreases P-ULK1 and beclin 1 expression suggesting AMPK2
depletion decreases autophagy. AMPK2, but not AMPK1 depletion reduced PGC1β and
ERR expression. FUSION discovered a natural product fraction that inhibited AMPK. The
active compound was identified as 5-OH-S and was shown to directly inhibit AMPK kinase
activity. 5-OH-S was preferentially required for HCT116 and SW480 cell survival, but was
largely dispensable for HCEC survival. A related 7’-hydroxy-staurosporine, aka UCN-01, has
been examined intensively for its anticancer properties and has been the subject of several clinical
trials. UCN-01 is known to inhibit several kinases including AKT, PKC, several CDKs, CHK1,
and AMPK. UCN-01 induces G1/S arrest and prevents DNA damage repair, which is thought to
be the result of CHK1 inhibition. This suggests that in addition to inhibiting AMPK, 5-OH-S may
also disrupt DNA damage repair and/or induce cell cycle arrest in addition to inducing apoptosis.
Disruption of ERK signaling, through KSR1, ERK1/2, or MEK1/2 depletion, caused an
increase in AMPK expression and/or activation suggesting cells may have an increased
dependence on AMPK following disruption of Ras signaling. Combination treatment with
SCH772984 and Compound C demonstrated synergy.

Synergistic Interactions
Previous reports indicated that combination inhibition with Torin-2, an ATP-competitive
inhibitor of mTOR, ATM, and ATR, and AZD6244, a MEK inhibitor, yielded significant growth
inhibition 380. Another group demonstrated that treatment with UCN-01 (7’-
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hydroxystaurosporine) induces MEK1/2 and ERK1/2 in malignant hematopoietic cells, while
combination UCN-01 and MEK1/2 or Ras inhibition prevented the ERK activation and induced
apoptosis 381-384. These reports demonstrate the potential benefit of treating cells with multiple
targeted therapies to prevent the development of resistance. UCN-01 is structurally similar to the
FUSION-identified AMPK inhibitor, 5-OH-S. Therefore, considering the previous reports that
UCN-01 prevented the development of resistance to MEK or Ras inhibition in conjunction with
results herein that KSR1 or ERK depletion induced AMPK2 expression and phosphorylation,
the interplay between these two pathways is clearly demonstrated. Further, ERK and AMPK
inhibition demonstrated additive to synergistic effects on colon cancer cell viability revealing the
benefit of simultaneously targeting these pathways.
Combination treatment with TIMELESS depletion and DNA damaging agents or ionizing
radiation showed little if any increase in efficacy. The effect was most promising with the
combination of TIMELESS depletion with ionizing radiation. HCT116 cells may not be the best
cell line to test the potential for synergistic effects either as they have an intrinsically unstable
genome. Therefore, if TIMELESS is required for DNA damage repair, HCT116 cells would be
likely to be more dependent upon TIMELESS expression than other more genomically stable cell
lines, and the addition of a DNA-damaging agent to these cells may not increase their dependence
on TIMELESS further.
However, combination treatment with TIMELESS depletion in conjunction with Wee1 or
CHK1 inhibition had at least additive, if not synergistic, effects on efficacy suggesting this
combination may be a viable approach for the treatment of colon cancer.

Final Thoughts
These results have revealed the importance of genes that sit in between multiple
regulatory pathways and coordinate communication or signal between these pathways to regulate
their execution. Clearly, TIMELESS sits at the cross-roads and regulates the balance and
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coordinated execution of the DNA synthesis, DNA damage repair, circadian rhythm and cell
cycle pathways. This regulation forces these pathways to be inextricably linked such that cells
undergo coordinated regulation to ensure balance is maintained. Unfortunately, in cancer,
oncogenes disrupt the balance by forcing cells to pursue unregulated proliferation. In order to
maintain some semblance of order and prevent cell suicide, oncogenes simultaneously alter the
regulation of a subset of genes that are required to allow the cancer cells to survive and thrive
despite all of the external and internal signals to the contrary. Revealing the key players that are
required for cancer cells to survive and maintain their transformed phenotype will lay the
groundwork for the development of selective, efficacious therapeutics to treat cancer.
Our results demonstrate the ability of FUSION to identify oncogene-induced changes in
cancer that promote proliferation and cell survival, but also leave the cancer cell vulnerable to
selective targeting that disrupts these co-opted pathways. The potential exists for all of the
identified genes, TIMELESS, WDR5, and AMPK, to be required in other types of cancer as their
identified mechanisms of action are likely to be present in other tissues and favorable for cancer
regardless of the tissue of origin. Further characterizing these vulnerabilities and demonstrating
their presence in vivo will determine their potential to serve as selective therapeutic targets for the
development of targeted therapies for the treatment of cancer.

213

Appendix A: Biological validation of other FUSION hits:
ECE2, HAS2, DYRK1A, and BMP4
Rationale:
FUSION identified 788 genes that are predicted to be required for colon cancer cell
survival, but not normal cell survival. Preliminary biological validation was performed for several
of these targets including ECE2, HAS2, DYRK1A, and BMP4.

Results/Discussion:
RNAi-mediated ECE2 depletion decreased cell viability in HCT116 colon cancer cells,
but not in HCECs (Fig. A.1A). Cell count was also decreased in HCT116 cells following ECE2
depletion (Fig. A.1B). ECE2 mRNA expression, but not ECE1 mRNA expression, is increased in
colon cancer based on RNASeq evaluation of data from the COAD dataset within TCGA (Fig.
A.1C). RNAi-mediated HAS2 depletion decreased cell viability similar to KSR1 depletion in
anchorage-independent conditions when replated on polyHEMA-coated plates (Fig. A.2A).
RNAi-mediated HAS2 depletion decreased cell viability in HCT116 cells, but not HCT15 colon
cancer cells in normal culture conditions (Fig. A.2B). Unfortunately, due to a lack of quality
reagents (particularly a lack of antibodies that could be validated) for ECE2 and HAS2 these
targets were not pursued further.
RNAi-mediated depletion of DYRK1A decreased cell counts in HCT116 colon cancer
cells (Fig. A.3A). However, DYRK1A is known to serve as a scaffold for Ras/Raf/MEK kinase
cascade. Therefore, DYRK1A was not pursued further.
RNAi-mediated depletion of BMP4 decreased cell viability in HCT116, but not in
HCT15 colon cancer cells (Fig. A.4A). The mRNA expression of BMP4, BMP2, BMP7,
GREM2, and BMP3 in human tumors was evaluated in the COAD TCGA dataset. BMP4 and
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BMP7 were increased in colon tumors compared to normal tissue, whereas BMP2, GREM2, and
BMP3 were decreased in colon tumors (Fig. A.4B). BMP4 and BMP7 mRNA expression was
increased in a panel of colon cancer cells as compared to human colon epithelial cells (Fig. A.4C
and D).
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Fig. A.1: Biological validation of ECE2. (A) Viability of HCECs and HCT116 colon cancer cells
measured using alamarBlue following RNAi-mediated depletion of KSR1, TIMELESS, or ECE2 for 72
hours. (B) Cell counts in HCT116 cells following RNAi-mediated ECE2 depletion. (C) ECE2 and ECE1
gene expression (RNA-Seq) data from the Colon Adenocarcinoma (COAD) dataset within TCGA for
unpaired and paired primary colon tumors and normal solid tissue samples. The results published here
are in whole or part based upon data generated by the TCGA Research
Network: http://cancergenome.nih.gov/. (Fig. A.1B was completed in collaboration with Eyerusalem
Lemma).
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Fig. A.2: Biological validation of HAS2. (A) Viability of HCT116 colon cancer cells measured using
CellTiter-Glo® following RNAi-mediated depletion of KSR1 or HAS2 that were replated on polyHEMAcoated plates 48 hours following transfection to simulate anchorage-independent conditions. Cell viability
is measured immediately after replating (Hrs: 0) and 24 hours later. (B) Viability of HCT116 and HCT15
colon cancer cells measured using alamarBlue following RNAi-mediated depletion of HAS2 for 72 hours.
(Experiments A.2 were done in collaboration with Danielle Frodyma).
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Fig. A.3: Biological validation of DYRK1A. (A) Cell counts in HCT116 cells
following RNAi-mediated ECE2 depletion. (B) Western blot of DYRK1A after RNAimediated depletion of DYRK1A with individual siRNA oligos.
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Fig. A.4: Biological Validation of BMP4. (A) Viability of HCT116 and HCT15 colon cancer cells
measured using alamarBlue following RNAi-mediated depletion of BMP4 for 72 hours. (B) BMP4,
BMP2, BMP7, GREM2, and BMP3 gene expression (RNA-Seq) data from the Colon Adenocarcinoma
(COAD) dataset within TCGA for unpaired primary colon tumors and normal solid tissue samples. The
results published here are in whole or part based upon data generated by the TCGA Research
Network: http://cancergenome.nih.gov/. (C and D) RT-qPCR of BMP4 (C) and BMP7 (D) in a panel of
colon tumor cell lines as compared to immortalized, non-transformed HCECs. RT-qPCR data is shown as
mean ± SD. ** p < 0.01 *** p < 0.001 **** p < 0.0001 (Experiments A.4C-D were done in collaboration
with Danielle Frodyma).
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Appendix B: Other mechanisms regulating TIMELESS
expression
Rationale:
TIMELESS expression appears to be regulated through several mechanisms. The most
prominent mechanism regulating TIMELESS expression in colon cancer discovered thus far
appears to be via translation regulation by ERK or mTOR as described in Chapter 4: TIMELESS;
however, even these mechanisms cannot completely explain the increased level of TIMELESS
expression. Evaluating the effect of genetic depletions on TIMELESS expression is complicated
because TIMELESS expression varies with cell cycle with the highest expression being seen in S
and G2 phases. Therefore, any manipulation that affects the percentage of cells in each phase of
the cell cycle could indirectly affect TIMELESS expression.

Results/Discussion:
RNAi-mediated depletion of MYC in HCEC and HCT116 cells decreased TIMELESS
expression (Fig. B.1A). RNAi-mediated depletion of WDR5 with individual siRNA oligos in
HCT116 also decreased TIMELESS expression, but oligos #5 and #6 had a much more dramatic
effect (Fig. B.1B).
RNAi-mediated depletion of BMP4 decreased TIMELESS expression at the protein (Fig.
B.2A). RNAi-mediated depletion of BMP4, but not BMP7, decreased TIMELESS expression at
the mRNA level (Fig. B.2B and C). RNAi-mediated depletion of CRY1 decreased TIMELESS
expression at the mRNA level (Fig. B.2D).
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Fig. B.1: MYC and WDR5 may promote TIMELESS expression. (A) Western
blot of TIMELESS and MYC following RNAi-mediated MYC depletion for 72
hours in HCEC and HCT116 cells. (B) Western blot of TIMELESS and WDR5
following RNAi-mediated WDR5 depletion with individual siRNA oligos for 72
hours.
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Fig. B.2: BMP4 and CRY1 may promote TIMELESS expression. (A-C) Western blot (A) and
RT-qPCR (B and C) of TIMELESS following RNAi-mediated depletion of BMP4 and/or BMP7
for 72 hours in HCT116 cells. (D) RT-qPCR of CRY1 and TIMELESS following RNAi-mediated
depletion of CRY1 for 72 hours in HCT116 cells. (Experiments B.2 were completed in
collaboration with Danielle Frodyma).
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Appendix C: Cross-referencing the results from FUSION with
other datasets
Rationale:
Hits identified from the FUSION screen are predicted to be selectively required for colon
cancer cell survival, but not normal cell survival. Cross referencing these hits with screens
performed by other groups can reveal additional features or characteristics of the FUSION hits.

Results/Discussion:
Cross referencing the 788 FUSION hits with results from ERR ChIP-Seq in A549 cells
revealed a subset of probably ERR genetic targets that are also predicted to be required for
colon cancer cell survival. Further limiting this list to targets that have increased mRNA
expression in colon cancer based on RNASeq analysis in the COAD dataset within TCGA
identified eleven genes (Fig. C.1).
Cross referencing the 788 FUSION hits with genes that whose expression was increased
via increased translation downstream of oncogenic Ras and MYC revealed a subset of genes that
were predicted to be selectively required for colon cancer cell survival and overexpressed in
cancer through oncogene-driven increases in translation (Fig. C.2)
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Fig. C.1: FUSION hits predicted to be regulated by ERRα and upregulated in colon cancer.
(A)Table with a list of FUSION hits that are also predicted to be targets of ERRα based on publically
available ChipSeq data that was performed in A549 cells (GSE91793). (B) PIGL, NUDT4, TCFL5,
DDX47, MAP4K4, PODXL, FUBP3, PLCB4, LTBP2, and TAZ gene expression (RNASeq) data from
the Colon Adenocarcinoma (COAD) dataset within TCGA for unpaired primary colon tumors and
normal solid tissue samples. The results published here are in whole or part based upon data generated
by the TCGA Research Network: http://cancergenome.nih.gov/. Note: EPHB4 is not included in B
because those results were previously published.
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Table C.1: FUSION hits that are also predicted to be regulated by Ras- or MYC-driven
translation.
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Appendix D: Sequences of qPCR primers and siRNA duplexes
Target

CRY1

ECE2

HAS2

ERK1

ERK2

AMPKa1

AMPKa2

WDR5b

Item #

J-015421

J-005858

J-012053

J-003592

J-003555

J-005027

J-005361

LU-013375

Table D.1: siRNA Sequences

siRNA

Target Sequence

5

CAGCAGCUUUCACGAUAUA

6

GGAGUAGAAGUCAUUGUAA

7

UAUAUGACCUAGACAAGAU

8

CAACUGUUAUGGCGUGAAU

6

CAAGCAUCCUGAACAAUUA

7

CCUACUACCUUCCAACUAA

8

GGAUGACGCCCUUGGCUUU

9

GCAUUCGAGUGGCUGGAAA

19

GGGUGUGUUCAGUGCAUUA

20

GGAUUAAAGUUGUCAUGGU

21

CCAAACGGAUAAUUACUAU

22

GGUUUGUGAUUCAGACACU

7

GACCGGAUGUUAACCUUUA

8

CCUGCGACCUUAAGAUUUG

9

CCAAUAAACGGAUCACAGU

10

AGACUGACCUGUACAAGUU

11

UCGAGUAGCUAUCAAGAAA

12

CACCAACCAUCGAGCAAAU

13

GGUGUGCUCUGCUUAUGAU

14

ACACCAACCUCUCGUACAU

6

CCAUACCCUUGAUGAAUUA

7

GCCCAGAGGUAGAUAUAUG

8

GAGGAUCCAUCAUAUAGUU

9

ACAAUUGGAUUAUGAAUGG

6

CGACUAGCCCAAAUCUUU

7

GAGCAUGUACCUACGUUAU

8

GACAGAAGAUUCGCAGUUU

9

GUCUGGAGGUGAAUUAUUU

5

CAUCGCAUCAGCAGCAUUA

6

AAACAUACACUGGUCAUAA

7

CAAACUAUGCUCUCAAAUG

8

GGACAACACUCUUAAACUA
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Target

WDR5

TIMELESS

BMP4

BMP7

KSR1

PRKAG1

MAP2K1

MAP2K2

RBBP5

Non-targeting

Item #

L-013383

J-019488

J-011221

J-011592

J-003570

J-009056

L-003571

J-003573

LU-012008

siRNA

Target Sequence

5

GACGAAAGCGUGAGGAUAU

6

GUGGAAGAGUGACUGCUAA

7

GACGUGAGCUCGGGCAAGU

8

GAUGGAUCCUUGAUAGUUU

5

UCAAUCGUCUGCUUAGUGA

6

CAGGGUAGCUUAGUCCUUU

7

GAGGGAGACACUUACCAUA

8

CUACUGCUGGUCAGAAAUA

5

GAGCCAUGCUAGUUUGAUA

6

UAGCAAGAGUGCCGUCAUU

7

CGACACUUCUGCAGAUGUU

8

CAGGAUUAGCCGAUCGUUA

5

GAGGUGCACUCGAGCUUCA

6

CAUCGAGAGUUCCGGUUUG

7

GAUCAGCGUUUAUCAGGUG

8

GCACAACUCGGCACCCAUG

7

GAGCAAGUCCCAUGAGUCU

8

GGAAUGAAGCGUGUCCUGA

9

AGAAAGAGGUGAUGAACUA

5

GAGGUUCACCGACUUGUAG

6

UCAAUAUCCUGCACCGCUA

7

GGAACAAGAUCCACAGGCU

6

CCAUGCUGCUGGCGUCUAA

7

GAGGUUCUCUGGAUCAAGU

8

CGACGGCUCUGCAGUUAAC

9

GCACAAGGUCCUACAUGUC

8

CGACAGCGCAUGCAGGAAC

9

GAUCAGCAUUUGCAUGGAA

10

GGUCCGAGGUGGAAGAAGU

11

UCUUUGAACUCCUGGACUA

5

UAACACGGCAGAUCGAAUA

6

UAUAGAACUUCAAGGAGUA

7

GCAAUACCACAGCCAUUAA

8

GAUGGAACUUUGGAUUGUA

D-001810

ContContinued: siRNA Sequences
Table D.1

UGGUUUACAUGUCGACUAA
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HPRT1

GAPDH

Myc

BMP7

BMP4

WDR5

TIMELESS

Target

NM_000194

NM_002046.1

NM_002467.4

NM_001719

NM_001202

NM_052821

NM_003920

Accession #

128

111

119

121

111

135

120

Amplicon
size (bp)

6-8

2-3

3

1-2

3-4

8-10

10-11

Exons

60

58

58

61

61

58

62

Tm (°C)

GTATTCATTATAGTCAAGGGCATATCC

GGTGAAGGTCGGAGTCAACGG

GGCTCCTGGCAAAAGGTCA

ATCAAACCGGAACTCTCGATG

GAGCCTTTCCAGCAAGTTTG

ATGCGACAGAGACCATCATAG

GAGACTTCTGCTCTGAGTTCC

F primer 5’ -> 3’

AGATGGTCAAGGTCGCAAG

GAGGTCAATGAAGGGGTCATTG

CTGCGTAGTTGTGCTGATGT

CAGCCTGCAAGATAGCCATT

CCATCAGCATTCGGTTACCA

CGTGAGGATATGGGATGTGAA

CCAAGGCCCACATATAATAGGT

R primer 5’ -> 3’

Table D.2 Sequences of qPCR Primers

228

Literature Cited:
1

2

3

4
5
6
7
8
9

10
11

12

13
14
15

16
17

18
19
20
21
22
23
24

Das, B. et al. A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with
selective toxicity toward human colon tumor cells. Scientific reports 8, 3770, doi:10.1038/s41598018-22090-6 (2018).
Neilsen, B. K., Frodyma, D. E., Lewis, R. E. & Fisher, K. W. KSR as a therapeutic target for Rasdependent cancers. Expert opinion on therapeutic targets 21, 499-509,
doi:10.1080/14728222.2017.1311325 (2017).
Fisher, K. W. et al. AMPK Promotes Aberrant PGC1beta Expression To Support Human Colon
Tumor Cell Survival. Molecular and cellular biology 35, 3866-3879, doi:10.1128/MCB.00528-15
(2015).
American Cancer Society. Cancer Facts and Figures 2018. (2018).
Murphy SL, X. J., Kochanek KD, Curtin SC, Arias E. Deaths: Final data for 2015 National Vital
Statistics Reports. Hyattsville, MD: National Center for Health Statistics. 66 (2017).
Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic acids research 39, D945-950, doi:10.1093/nar/gkq929 (2011).
Fernandez-Medarde, A. & Santos, E. Ras in cancer and developmental diseases. Genes & cancer
2, 344-358, doi:10.1177/1947601911411084 (2011).
Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer.
Cancer research 72, 2457-2467, doi:10.1158/0008-5472.CAN-11-2612 (2012).
Ostrem, J. M. & Shokat, K. M. Direct small-molecule inhibitors of KRAS: from structural insights
to mechanism-based design. Nature reviews. Drug discovery 15, 771-785,
doi:10.1038/nrd.2016.139 (2016).
Young, A. et al. Ras signaling and therapies. Advances in cancer research 102, 1-17,
doi:10.1016/S0065-230X(09)02001-6 (2009).
Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated
nucleotide exchange activity. Proceedings of the National Academy of Sciences of the United
States of America 109, 5299-5304, doi:10.1073/pnas.1116510109 (2012).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors
allosterically control GTP affinity and effector interactions. Nature 503, 548-551,
doi:10.1038/nature12796 (2013).
Sun, Q. et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated
activation. Angewandte Chemie 51, 6140-6143, doi:10.1002/anie.201201358 (2012).
Welsch, M. E. et al. Multivalent Small-Molecule Pan-RAS Inhibitors. Cell 168, 878-889 e829,
doi:10.1016/j.cell.2017.02.006 (2017).
James, G., Goldstein, J. L. & Brown, M. S. Resistance of K-RasBV12 proteins to
farnesyltransferase inhibitors in Rat1 cells. Proceedings of the National Academy of Sciences of
the United States of America 93, 4454-4458 (1996).
Whyte, D. B. et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein
transferase inhibitors. The Journal of biological chemistry 272, 14459-14464 (1997).
Shima, F. et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity
by blocking the Ras-effector interaction. Proceedings of the National Academy of Sciences of the
United States of America 110, 8182-8187, doi:10.1073/pnas.1217730110 (2013).
Samatar, A. A. & Poulikakos, P. I. Targeting RAS-ERK signalling in cancer: promises and
challenges. Nature reviews. Drug discovery 13, 928-942, doi:10.1038/nrd4281 (2014).
Kornfeld, K., Hom, D. B. & Horvitz, H. R. The ksr-1 gene encodes a novel protein kinase
involved in Ras-mediated signaling in C. elegans. Cell 83, 903-913 (1995).
Sundaram, M. & Han, M. The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved
in Ras-mediated signal transduction. Cell 83, 889-901 (1995).
Therrien, M. et al. KSR, a novel protein kinase required for RAS signal transduction. Cell 83,
879-888 (1995).
Downward, J. KSR: a novel player in the RAS pathway. Cell 83, 831-834 (1995).
Morrison, D. K. KSR: a MAPK scaffold of the Ras pathway? Journal of cell science 114, 16091612 (2001).
Nguyen, A. et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated

229

25
26
27

28
29
30

31

32
33

34

35

36

37

38

39
40
41

42

43
44

protein kinase activation in vivo. Molecular and cellular biology 22, 3035-3045 (2002).
Ritt, D. A., Daar, I. O. & Morrison, D. K. KSR regulation of the Raf-MEK-ERK cascade. Methods
in enzymology 407, 224-237, doi:10.1016/S0076-6879(05)07019-9 (2006).
Brennan, D. F. et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of
MEK. Nature 472, 366-369, doi:10.1038/nature09860 (2011).
McKay, M. M., Freeman, A. K. & Morrison, D. K. Complexity in KSR function revealed by Raf
inhibitor and KSR structure studies. Small GTPases 2, 276-281, doi:10.4161/sgtp.2.5.17740
(2011).
Kolch, W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nature reviews.
Molecular cell biology 6, 827-837, doi:10.1038/nrm1743 (2005).
Claperon, A. & Therrien, M. KSR and CNK: two scaffolds regulating RAS-mediated RAF
activation. Oncogene 26, 3143-3158, doi:10.1038/sj.onc.1210408 (2007).
Raabe, T. & Rapp, U. R. KSR--a regulator and scaffold protein of the MAPK pathway. Science's
STKE : signal transduction knowledge environment 2002, pe28, doi:10.1126/stke.2002.136.pe28
(2002).
Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D. & Therrien, M. KSR is a scaffold
required for activation of the ERK/MAPK module. Genes & development 16, 427-438,
doi:10.1101/gad.962902 (2002).
Kortum, R. L. & Lewis, R. E. The molecular scaffold KSR1 regulates the proliferative and
oncogenic potential of cells. Molecular and cellular biology 24, 4407-4416 (2004).
Kortum, R. L. et al. The molecular scaffold kinase suppressor of Ras 1 (KSR1) regulates
adipogenesis. Molecular and cellular biology 25, 7592-7604, doi:10.1128/MCB.25.17.75927604.2005 (2005).
Liu, L. et al. Proteomic characterization of the dynamic KSR-2 interactome, a signaling scaffold
complex in MAPK pathway. Biochimica et biophysica acta 1794, 1485-1495,
doi:10.1016/j.bbapap.2009.06.016 (2009).
Huang, L. et al. Simulating EGFR-ERK signaling control by scaffold proteins KSR and MP1
reveals differential ligand-sensitivity co-regulated by Cbl-CIN85 and endophilin. PloS one 6,
e22933, doi:10.1371/journal.pone.0022933 (2011).
Kortum, R. L. et al. Caveolin-1 is required for kinase suppressor of Ras 1 (KSR1)-mediated
extracellular signal-regulated kinase 1/2 activation, H-RasV12-induced senescence, and
transformation. Molecular and cellular biology 34, 3461-3472, doi:10.1128/MCB.01633-13
(2014).
Karthik, D., Majumder, P., Palanisamy, S., Khairunnisa, K. & Venugopal, V. Targeting cysteine
rich C1 domain of Scaffold protein Kinase Suppressor of Ras (KSR) with anthocyanidins and
flavonoids - a binding affinity characterization study. Bioinformation 10, 580-585,
doi:10.6026/97320630010580 (2014).
Razidlo, G. L., Kortum, R. L., Haferbier, J. L. & Lewis, R. E. Phosphorylation regulates KSR1
stability, ERK activation, and cell proliferation. The Journal of biological chemistry 279, 4780847814, doi:10.1074/jbc.M406395200 (2004).
Razidlo, G. L. et al. KSR1 is required for cell cycle reinitiation following DNA damage. The
Journal of biological chemistry 284, 6705-6715, doi:10.1074/jbc.M806457200 (2009).
Klutho, P. J., Costanzo-Garvey, D. L. & Lewis, R. E. Regulation of glucose homeostasis by KSR1
and MARK2. PloS one 6, e29304, doi:10.1371/journal.pone.0029304 (2011).
Fisher, K. W., Das, B., Kortum, R. L., Chaika, O. V. & Lewis, R. E. Kinase suppressor of ras 1
(KSR1) regulates PGC1alpha and estrogen-related receptor alpha to promote oncogenic Rasdependent anchorage-independent growth. Molecular and cellular biology 31, 2453-2461,
doi:10.1128/MCB.05255-11 (2011).
McCall, J. L. et al. KSR1 and EPHB4 Regulate Myc and PGC1beta To Promote Survival of
Human Colon Tumors. Molecular and cellular biology 36, 2246-2261, doi:10.1128/MCB.0008716 (2016).
Ohmachi, M. et al. C. elegans ksr-1 and ksr-2 have both unique and redundant functions and are
required for MPK-1 ERK phosphorylation. Current biology : CB 12, 427-433 (2002).
Hansen, L. A. et al. Genetically null mice reveal a central role for epidermal growth factor
receptor in the differentiation of the hair follicle and normal hair development. The American
journal of pathology 150, 1959-1975 (1997).

230

45
46

47

48
49

50
51
52

53

54
55

56

57
58

59

60

61
62

63
64

65

66

Lozano, J. et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Cancer research 63, 4232-4238 (2003).
Fusello, A. M. et al. The MAPK scaffold kinase suppressor of Ras is involved in ERK activation
by stress and proinflammatory cytokines and induction of arthritis. Journal of immunology 177,
6152-6158 (2006).
Le Borgne, M., Filbert, E. L. & Shaw, A. S. Kinase suppressor of Ras 1 is not required for the
generation of regulatory and memory T cells. PloS one 8, e57137,
doi:10.1371/journal.pone.0057137 (2013).
Revelli, J. P. et al. Profound obesity secondary to hyperphagia in mice lacking kinase suppressor
of ras 2. Obesity 19, 1010-1018, doi:10.1038/oby.2010.282 (2011).
Henry, M. D., Costanzo-Garvey, D. L., Klutho, P. J. & Lewis, R. E. Obesity-dependent
dysregulation of glucose homeostasis in kinase suppressor of ras 2-/- mice. Physiological reports
2, doi:10.14814/phy2.12053 (2014).
Costanzo-Garvey, D. L. et al. KSR2 is an essential regulator of AMP kinase, energy expenditure,
and insulin sensitivity. Cell metabolism 10, 366-378, doi:10.1016/j.cmet.2009.09.010 (2009).
Guo, L. et al. Cell non-autonomous regulation of hepatic IGF-1 and neonatal growth by Kinase
Suppressor of Ras 2 (KSR2). Scientific reports 6, 32093, doi:10.1038/srep32093 (2016).
Fernandez, M. R., Henry, M. D. & Lewis, R. E. Kinase suppressor of Ras 2 (KSR2) regulates
tumor cell transformation via AMPK. Molecular and cellular biology 32, 3718-3731,
doi:10.1128/MCB.06754-11 (2012).
Dougherty, M. K. et al. KSR2 is a calcineurin substrate that promotes ERK cascade activation in
response to calcium signals. Molecular cell 34, 652-662, doi:10.1016/j.molcel.2009.06.001
(2009).
Dhawan, N. S., Scopton, A. P. & Dar, A. C. Small molecule stabilization of the KSR inactive state
antagonizes oncogenic Ras signalling. Nature 537, 112-116, doi:10.1038/nature19327 (2016).
Joneson, T. et al. Kinase suppressor of Ras inhibits the activation of extracellular ligand-regulated
(ERK) mitogen-activated protein (MAP) kinase by growth factors, activated Ras, and Ras
effectors. The Journal of biological chemistry 273, 7743-7748 (1998).
Kortum, R. L. et al. The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12induced and replicative senescence. Molecular and cellular biology 26, 2202-2214,
doi:10.1128/MCB.26.6.2202-2214.2006 (2006).
Stewart, S. et al. Kinase suppressor of Ras forms a multiprotein signaling complex and modulates
MEK localization. Molecular and cellular biology 19, 5523-5534 (1999).
McKay, M. M., Ritt, D. A. & Morrison, D. K. Signaling dynamics of the KSR1 scaffold complex.
Proceedings of the National Academy of Sciences of the United States of America 106, 1102211027, doi:10.1073/pnas.0901590106 (2009).
Udell, C. M., Rajakulendran, T., Sicheri, F. & Therrien, M. Mechanistic principles of RAF kinase
signaling. Cellular and molecular life sciences : CMLS 68, 553-565, doi:10.1007/s00018-0100520-6 (2011).
Koveal, D. et al. A CC-SAM, for coiled coil-sterile alpha motif, domain targets the scaffold KSR1 to specific sites in the plasma membrane. Science signaling 5, ra94,
doi:10.1126/scisignal.2003289 (2012).
Michaud, N. R. et al. KSR stimulates Raf-1 activity in a kinase-independent manner. Proceedings
of the National Academy of Sciences of the United States of America 94, 12792-12796 (1997).
Zhou, M., Horita, D. A., Waugh, D. S., Byrd, R. A. & Morrison, D. K. Solution structure and
functional analysis of the cysteine-rich C1 domain of kinase suppressor of Ras (KSR). Journal of
molecular biology 315, 435-446, doi:10.1006/jmbi.2001.5263 (2002).
Therrien, M., Michaud, N. R., Rubin, G. M. & Morrison, D. K. KSR modulates signal propagation
within the MAPK cascade. Genes & development 10, 2684-2695 (1996).
Jacobs, D., Glossip, D., Xing, H., Muslin, A. J. & Kornfeld, K. Multiple docking sites on substrate
proteins form a modular system that mediates recognition by ERK MAP kinase. Genes &
development 13, 163-175 (1999).
Cacace, A. M. et al. Identification of constitutive and ras-inducible phosphorylation sites of KSR:
implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR
overexpression. Molecular and cellular biology 19, 229-240 (1999).
Muller, J., Cacace, A. M., Lyons, W. E., McGill, C. B. & Morrison, D. K. Identification of B-

231

67
68
69

70
71

72
73

74
75

76

77
78

79

80

81
82

83

84
85
86

87

KSR1, a novel brain-specific isoform of KSR1 that functions in neuronal signaling. Molecular and
cellular biology 20, 5529-5539 (2000).
Pearce, L. R. et al. KSR2 mutations are associated with obesity, insulin resistance, and impaired
cellular fuel oxidation. Cell 155, 765-777, doi:10.1016/j.cell.2013.09.058 (2013).
Guo, L., Volle, D. J. & Lewis, R. E. Identification of a truncated kinase suppressor of Ras 2
mRNA in sperm. FEBS open bio 4, 420-425, doi:10.1016/j.fob.2014.04.004 (2014).
Yu, W., Fantl, W. J., Harrowe, G. & Williams, L. T. Regulation of the MAP kinase pathway by
mammalian Ksr through direct interaction with MEK and ERK. Current biology : CB 8, 56-64
(1998).
Volle, D. J. et al. Phosphorylation of the kinase suppressor of ras by associated kinases.
Biochemistry 38, 5130-5137, doi:10.1021/bi983050d (1999).
Fantz, D. A., Jacobs, D., Glossip, D. & Kornfeld, K. Docking sites on substrate proteins direct
extracellular signal-regulated kinase to phosphorylate specific residues. The Journal of biological
chemistry 276, 27256-27265, doi:10.1074/jbc.M102512200 (2001).
Muller, J., Ory, S., Copeland, T., Piwnica-Worms, H. & Morrison, D. K. C-TAK1 regulates Ras
signaling by phosphorylating the MAPK scaffold, KSR1. Molecular cell 8, 983-993 (2001).
McKay, M. M., Ritt, D. A. & Morrison, D. K. RAF inhibitor-induced KSR1/B-RAF binding and
its effects on ERK cascade signaling. Current biology : CB 21, 563-568,
doi:10.1016/j.cub.2011.02.033 (2011).
Ritt, D. A. et al. CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase
activation. Current biology : CB 17, 179-184, doi:10.1016/j.cub.2006.11.061 (2007).
McKay, M. M. & Morrison, D. K. Caspase-dependent cleavage disrupts the ERK cascade
scaffolding function of KSR1. The Journal of biological chemistry 282, 26225-26234,
doi:10.1074/jbc.M702692200 (2007).
Frodyma, D., Neilsen, B., Costanzo-Garvey, D., Fisher, K. & Lewis, R. Coordinating ERK
signaling via the molecular scaffold Kinase Suppressor of Ras. F1000Research 6, 1621,
doi:10.12688/f1000research.11895.1 (2017).
Denouel-Galy, A. et al. Murine Ksr interacts with MEK and inhibits Ras-induced transformation.
Current biology : CB 8, 46-55 (1998).
Sugimoto, T., Stewart, S., Han, M. & Guan, K. L. The kinase suppressor of Ras (KSR) modulates
growth factor and Ras signaling by uncoupling Elk-1 phosphorylation from MAP kinase
activation. The EMBO journal 17, 1717-1727, doi:10.1093/emboj/17.6.1717 (1998).
Levchenko, A., Bruck, J. & Sternberg, P. W. Scaffold proteins may biphasically affect the levels
of mitogen-activated protein kinase signaling and reduce its threshold properties. Proceedings of
the National Academy of Sciences of the United States of America 97, 5818-5823 (2000).
Morrison, D. K. & Davis, R. J. Regulation of MAP kinase signaling modules by scaffold proteins
in mammals. Annual review of cell and developmental biology 19, 91-118,
doi:10.1146/annurev.cellbio.19.111401.091942 (2003).
Matheny, S. A. et al. Ras regulates assembly of mitogenic signalling complexes through the
effector protein IMP. Nature 427, 256-260, doi:10.1038/nature02237 (2004).
Ory, S., Zhou, M., Conrads, T. P., Veenstra, T. D. & Morrison, D. K. Protein phosphatase 2A
positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3
binding sites. Current biology : CB 13, 1356-1364 (2003).
Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerizationdependent mechanism drives RAF catalytic activation. Nature 461, 542-545,
doi:10.1038/nature08314 (2009).
Lavoie, H. & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nature reviews.
Molecular cell biology 16, 281-298, doi:10.1038/nrm3979 (2015).
Casar, B., Pinto, A. & Crespo, P. ERK dimers and scaffold proteins: unexpected partners for a
forgotten (cytoplasmic) task. Cell cycle 8, 1007-1013, doi:10.4161/cc.8.7.8078 (2009).
Casar, B., Pinto, A. & Crespo, P. Essential role of ERK dimers in the activation of cytoplasmic but
not nuclear substrates by ERK-scaffold complexes. Molecular cell 31, 708-721,
doi:10.1016/j.molcel.2008.07.024 (2008).
Lin, W. C. et al. H-Ras forms dimers on membrane surfaces via a protein-protein interface.
Proceedings of the National Academy of Sciences of the United States of America 111, 2996-3001,
doi:10.1073/pnas.1321155111 (2014).

232

88

89
90
91

92

93
94
95

96

97
98

99

100
101
102

103
104
105

106

107

108

109

Nan, X. et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.
Proceedings of the National Academy of Sciences of the United States of America 112, 7996-8001,
doi:10.1073/pnas.1509123112 (2015).
Santos, E. Dimerization opens new avenues into Ras signaling research. Science signaling 7, pe12,
doi:10.1126/scisignal.2005318 (2014).
Kortum, R. L. & Morrison, D. K. Path Forward for RAF Therapies: Inhibition of Monomers and
Dimers. Cancer cell 28, 279-281, doi:10.1016/j.ccell.2015.08.006 (2015).
Gibney, G. T., Messina, J. L., Fedorenko, I. V., Sondak, V. K. & Smalley, K. S. Paradoxical
oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nature reviews. Clinical
oncology 10, 390-399, doi:10.1038/nrclinonc.2013.83 (2013).
Freeman, A. K., Ritt, D. A. & Morrison, D. K. Effects of Raf dimerization and its inhibition on
normal and disease-associated Raf signaling. Molecular cell 49, 751-758,
doi:10.1016/j.molcel.2012.12.018 (2013).
Freeman, A. K., Ritt, D. A. & Morrison, D. K. The importance of Raf dimerization in cell
signaling. Small GTPases 4, 180-185, doi:10.4161/sgtp.26117 (2013).
Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce
dimerization. Nature chemical biology 9, 428-436, doi:10.1038/nchembio.1257 (2013).
Yao, Z. et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that
Determine Their Sensitivity to Pharmacologic Inhibition. Cancer cell 28, 370-383,
doi:10.1016/j.ccell.2015.08.001 (2015).
Kholodenko, B. N. Drug Resistance Resulting from Kinase Dimerization Is Rationalized by
Thermodynamic Factors Describing Allosteric Inhibitor Effects. Cell reports 12, 1939-1949,
doi:10.1016/j.celrep.2015.08.014 (2015).
Zhang, Y. et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 89, 63-72
(1997).
Brennan, J. A., Volle, D. J., Chaika, O. V. & Lewis, R. E. Phosphorylation regulates the
nucleocytoplasmic distribution of kinase suppressor of Ras. The Journal of biological chemistry
277, 5369-5377, doi:10.1074/jbc.M109875200 (2002).
Zhang, J. et al. Downregulation of KSR1 in pancreatic cancer xenografts by antisense
oligonucleotide correlates with tumor drug uptake. Cancer biology & therapy 7, 1490-1495
(2008).
Brown, M. D. & Sacks, D. B. Protein scaffolds in MAP kinase signalling. Cellular signalling 21,
462-469, doi:10.1016/j.cellsig.2008.11.013 (2009).
Potts, M. B. et al. Using functional signature ontology (FUSION) to identify mechanisms of
action for natural products. Science signaling 6, ra90, doi:10.1126/scisignal.2004657 (2013).
Roig, A. I. et al. Immortalized epithelial cells derived from human colon biopsies express stem
cell markers and differentiate in vitro. Gastroenterology 138, 1012-1021 e1011-1015,
doi:10.1053/j.gastro.2009.11.052 (2010).
Stegmaier, K. et al. Gene expression-based high-throughput screening(GE-HTS) and application
to leukemia differentiation. Nature genetics 36, 257-263, doi:10.1038/ng1305 (2004).
Sigoillot, F. D. et al. A bioinformatics method identifies prominent off-targeted transcripts in
RNAi screens. Nature methods 9, 363-366, doi:10.1038/nmeth.1898 (2012).
Yilmazel, B. et al. Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi
screen data by seed region analysis. BMC bioinformatics 15, 192, doi:10.1186/1471-2105-15-192
(2014).
Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. Nature genetics 34, 267-273, doi:10.1038/ng1180
(2003).
Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J. P. GSEA-P: a desktop
application for Gene Set Enrichment Analysis. Bioinformatics 23, 3251-3253,
doi:10.1093/bioinformatics/btm369 (2007).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United
States of America 102, 15545-15550, doi:10.1073/pnas.0506580102 (2005).
Croft, D. et al. The Reactome pathway knowledgebase. Nucleic acids research 42, D472-477,
doi:10.1093/nar/gkt1102 (2014).

233

110
111

112
113
114

115
116
117
118
119

120

121
122

123
124
125
126
127
128
129
130

131

132
133

134

Fabregat, A. et al. The Reactome Pathway Knowledgebase. Nucleic acids research 46, D649D655, doi:10.1093/nar/gkx1132 (2018).
Sangoram, A. M. et al. Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1
interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron 21, 1101-1113
(1998).
Zylka, M. J. et al. Molecular analysis of mammalian timeless. Neuron 21, 1115-1122 (1998).
Benna, C. et al. A second timeless gene in Drosophila shares greater sequence similarity with
mammalian tim. Current biology : CB 10, R512-513 (2000).
Gotter, A. L., Suppa, C. & Emanuel, B. S. Mammalian TIMELESS and Tipin are evolutionarily
conserved replication fork-associated factors. Journal of molecular biology 366, 36-52,
doi:10.1016/j.jmb.2006.10.097 (2007).
Gotter, A. L. A Timeless debate: resolving TIM's noncircadian roles with possible clock function.
Neuroreport 17, 1229-1233, doi:10.1097/01.wnr.0000233092.90160.92 (2006).
Koike, N. et al. Identification of the mammalian homologues of the Drosophila timeless gene,
Timeless1. FEBS letters 441, 427-431 (1998).
Holzer, S. et al. Crystal structure of the N-terminal domain of human Timeless and its interaction
with Tipin. Nucleic acids research 45, 5555-5563, doi:10.1093/nar/gkx139 (2017).
Gotter, A. L. et al. A time-less function for mouse timeless. Nature neuroscience 3, 755-756,
doi:10.1038/77653 (2000).
Takumi, T. et al. A mammalian ortholog of Drosophila timeless, highly expressed in SCN and
retina, forms a complex with mPER1. Genes to cells : devoted to molecular & cellular
mechanisms 4, 67-75 (1999).
Tischkau, S. A. et al. Oscillation and light induction of timeless mRNA in the mammalian
circadian clock. The Journal of neuroscience : the official journal of the Society for Neuroscience
19, RC15 (1999).
Barnes, J. W. et al. Requirement of mammalian Timeless for circadian rhythmicity. Science 302,
439-442, doi:10.1126/science.1086593 (2003).
McDonald, M. J., Rosbash, M. & Emery, P. Wild-type circadian rhythmicity is dependent on
closely spaced E boxes in the Drosophila timeless promoter. Molecular and cellular biology 21,
1207-1217, doi:10.1128/MCB.21.4.1207-1217.2001 (2001).
Wang, G. K. et al. Regulation of the cycling of timeless (tim) RNA. Journal of neurobiology 47,
161-175 (2001).
Gekakis, N. et al. Isolation of timeless by PER protein interaction: defective interaction between
timeless protein and long-period mutant PERL. Science 270, 811-815 (1995).
Myers, M. P., Wager-Smith, K., Wesley, C. S., Young, M. W. & Sehgal, A. Positional cloning and
sequence analysis of the Drosophila clock gene, timeless. Science 270, 805-808 (1995).
Sehgal, A. et al. Rhythmic expression of timeless: a basis for promoting circadian cycles in period
gene autoregulation. Science 270, 808-810 (1995).
Hunter-Ensor, M., Ousley, A. & Sehgal, A. Regulation of the Drosophila protein timeless suggests
a mechanism for resetting the circadian clock by light. Cell 84, 677-685 (1996).
Lee, C., Parikh, V., Itsukaichi, T., Bae, K. & Edery, I. Resetting the Drosophila clock by photic
regulation of PER and a PER-TIM complex. Science 271, 1740-1744 (1996).
Darlington, T. K. et al. Closing the circadian loop: CLOCK-induced transcription of its own
inhibitors per and tim. Science 280, 1599-1603 (1998).
Darlington, T. K., Lyons, L. C., Hardin, P. E. & Kay, S. A. The period E-box is sufficient to drive
circadian oscillation of transcription in vivo. Journal of biological rhythms 15, 462-471,
doi:10.1177/074873040001500603 (2000).
Lee, C., Bae, K. & Edery, I. PER and TIM inhibit the DNA binding activity of a Drosophila
CLOCK-CYC/dBMAL1 heterodimer without disrupting formation of the heterodimer: a basis for
circadian transcription. Molecular and cellular biology 19, 5316-5325 (1999).
Glossop, N. R., Lyons, L. C. & Hardin, P. E. Interlocked feedback loops within the Drosophila
circadian oscillator. Science 286, 766-768 (1999).
Yu, W., Zheng, H., Houl, J. H., Dauwalder, B. & Hardin, P. E. PER-dependent rhythms in CLK
phosphorylation and E-box binding regulate circadian transcription. Genes & development 20,
723-733, doi:10.1101/gad.1404406 (2006).
Griffin, E. A., Jr., Staknis, D. & Weitz, C. J. Light-independent role of CRY1 and CRY2 in the

234

135
136

137
138
139
140

141

142

143

144

145

146
147
148

149

150
151

152
153

154
155
156

mammalian circadian clock. Science 286, 768-771 (1999).
Kloss, B. et al. The Drosophila clock gene double-time encodes a protein closely related to human
casein kinase Iepsilon. Cell 94, 97-107 (1998).
Kloss, B., Rothenfluh, A., Young, M. W. & Saez, L. Phosphorylation of period is influenced by
cycling physical associations of double-time, period, and timeless in the Drosophila clock. Neuron
30, 699-706 (2001).
Lin, J. M. et al. A role for casein kinase 2alpha in the Drosophila circadian clock. Nature 420,
816-820, doi:10.1038/nature01235 (2002).
Akten, B. et al. A role for CK2 in the Drosophila circadian oscillator. Nature neuroscience 6, 251257, doi:10.1038/nn1007 (2003).
Harms, E., Young, M. W. & Saez, L. CK1 and GSK3 in the Drosophila and mammalian circadian
clock. Novartis Foundation symposium 253, 267-277; discussion 102-269, 277-284 (2003).
Meissner, R. A., Kilman, V. L., Lin, J. M. & Allada, R. TIMELESS is an important mediator of
CK2 effects on circadian clock function in vivo. The Journal of neuroscience : the official journal
of the Society for Neuroscience 28, 9732-9740, doi:10.1523/JNEUROSCI.0840-08.2008 (2008).
Bae, K. & Edery, I. Regulating a circadian clock's period, phase and amplitude by
phosphorylation: insights from Drosophila. Journal of biochemistry 140, 609-617,
doi:10.1093/jb/mvj198 (2006).
Zheng, X., Sowcik, M., Chen, D. & Sehgal, A. Casein kinase 1 promotes synchrony of the
circadian clock network. Molecular and cellular biology 34, 2682-2694,
doi:10.1128/MCB.01571-13 (2014).
Hara, T., Koh, K., Combs, D. J. & Sehgal, A. Post-translational regulation and nuclear entry of
TIMELESS and PERIOD are affected in new timeless mutant. The Journal of neuroscience : the
official journal of the Society for Neuroscience 31, 9982-9990, doi:10.1523/JNEUROSCI.099311.2011 (2011).
Jang, A. R., Moravcevic, K., Saez, L., Young, M. W. & Sehgal, A. Drosophila TIM binds
importin alpha1, and acts as an adapter to transport PER to the nucleus. PLoS genetics 11,
e1004974, doi:10.1371/journal.pgen.1004974 (2015).
Top, D., Harms, E., Syed, S., Adams, E. L. & Saez, L. GSK-3 and CK2 Kinases Converge on
Timeless to Regulate the Master Clock. Cell reports 16, 357-367,
doi:10.1016/j.celrep.2016.06.005 (2016).
Price, J. L. et al. double-time is a novel Drosophila clock gene that regulates PERIOD protein
accumulation. Cell 94, 83-95 (1998).
Naidoo, N., Song, W., Hunter-Ensor, M. & Sehgal, A. A role for the proteasome in the light
response of the timeless clock protein. Science 285, 1737-1741 (1999).
Myers, M. P., Wager-Smith, K., Rothenfluh-Hilfiker, A. & Young, M. W. Light-induced
degradation of TIMELESS and entrainment of the Drosophila circadian clock. Science 271, 17361740 (1996).
Koh, K., Zheng, X. & Sehgal, A. JETLAG resets the Drosophila circadian clock by promoting
light-induced degradation of TIMELESS. Science 312, 1809-1812, doi:10.1126/science.1124951
(2006).
Lamaze, A. et al. The E3 ubiquitin ligase CTRIP controls CLOCK levels and PERIOD
oscillations in Drosophila. EMBO reports 12, 549-557, doi:10.1038/embor.2011.64 (2011).
Grima, B., Dognon, A., Lamouroux, A., Chelot, E. & Rouyer, F. CULLIN-3 controls TIMELESS
oscillations in the Drosophila circadian clock. PLoS biology 10, e1001367,
doi:10.1371/journal.pbio.1001367 (2012).
Grima, B. et al. The F-box protein slimb controls the levels of clock proteins period and timeless.
Nature 420, 178-182, doi:10.1038/nature01122 (2002).
O'Reilly, L. P., Zhang, X. & Smithgall, T. E. Individual Src-family tyrosine kinases direct the
degradation or protection of the clock protein Timeless via differential ubiquitylation. Cellular
signalling 25, 860-866, doi:10.1016/j.cellsig.2012.12.009 (2013).
Agrawal, P. & Hardin, P. E. An RNAi Screen To Identify Protein Phosphatases That Function
Within the Drosophila Circadian Clock. G3 6, 4227-4238, doi:10.1534/g3.116.035345 (2016).
Gotter, A. L. Tipin, a novel timeless-interacting protein, is developmentally co-expressed with
timeless and disrupts its self-association. Journal of molecular biology 331, 167-176 (2003).
Li, Z. et al. A role for Timeless in epithelial morphogenesis during kidney development.

235

157

158
159

160

161

162

163

164

165
166
167

168

169

170

171

172

173

174

Proceedings of the National Academy of Sciences of the United States of America 97, 1003810043 (2000).
Xiao, J., Li, C., Zhu, N. L., Borok, Z. & Minoo, P. Timeless in lung morphogenesis.
Developmental dynamics : an official publication of the American Association of Anatomists 228,
82-94, doi:10.1002/dvdy.10346 (2003).
Inaguma, Y. et al. Morphological characterization of mammalian timeless in the mouse brain
development. Neuroscience research 92, 21-28, doi:10.1016/j.neures.2014.10.017 (2015).
O'Reilly, L. P., Watkins, S. C. & Smithgall, T. E. An unexpected role for the clock protein
timeless in developmental apoptosis. PloS one 6, e17157, doi:10.1371/journal.pone.0017157
(2011).
Urtishak, K. A. et al. Timeless Maintains Genomic Stability and Suppresses Sister Chromatid
Exchange during Unperturbed DNA Replication. The Journal of biological chemistry 284, 87778785, doi:10.1074/jbc.M806103200 (2009).
Schalbetter, S. A., Mansoubi, S., Chambers, A. L., Downs, J. A. & Baxter, J. Fork rotation and
DNA precatenation are restricted during DNA replication to prevent chromosomal instability.
Proceedings of the National Academy of Sciences of the United States of America 112, E45654570, doi:10.1073/pnas.1505356112 (2015).
Smith, K. D., Fu, M. A. & Brown, E. J. Tim-Tipin dysfunction creates an indispensible reliance on
the ATR-Chk1 pathway for continued DNA synthesis. The Journal of cell biology 187, 15-23,
doi:10.1083/jcb.200905006 (2009).
Leman, A. R., Noguchi, C., Lee, C. Y. & Noguchi, E. Human Timeless and Tipin stabilize
replication forks and facilitate sister-chromatid cohesion. Journal of cell science 123, 660-670,
doi:10.1242/jcs.057984 (2010).
Smith-Roe, S. L. et al. Separation of intra-S checkpoint protein contributions to DNA replication
fork protection and genomic stability in normal human fibroblasts. Cell cycle 12, 332-345,
doi:10.4161/cc.23177 (2013).
Dheekollu, J. et al. Timeless links replication termination to mitotic kinase activation. PloS one 6,
e19596, doi:10.1371/journal.pone.0019596 (2011).
Leman, A. R. et al. Timeless preserves telomere length by promoting efficient DNA replication
through human telomeres. Cell cycle 11, 2337-2347, doi:10.4161/cc.20810 (2012).
Akamatsu, Y. & Kobayashi, T. The Human RNA Polymerase I Transcription Terminator
Complex Acts as a Replication Fork Barrier That Coordinates the Progress of Replication with
rRNA Transcription Activity. Molecular and cellular biology 35, 1871-1881,
doi:10.1128/MCB.01521-14 (2015).
Chou, D. M. & Elledge, S. J. Tipin and Timeless form a mutually protective complex required for
genotoxic stress resistance and checkpoint function. Proceedings of the National Academy of
Sciences of the United States of America 103, 18143-18147, doi:10.1073/pnas.0609251103
(2006).
Cho, W. H. et al. Human Tim-Tipin complex affects the biochemical properties of the replicative
DNA helicase and DNA polymerases. Proceedings of the National Academy of Sciences of the
United States of America 110, 2523-2527, doi:10.1073/pnas.1222494110 (2013).
Numata, Y., Ishihara, S., Hasegawa, N., Nozaki, N. & Ishimi, Y. Interaction of human MCM2-7
proteins with TIM, TIPIN and Rb. Journal of biochemistry 147, 917-927, doi:10.1093/jb/mvq028
(2010).
Cali, F., Bharti, S. K., Di Perna, R., Brosh, R. M., Jr. & Pisani, F. M. Tim/Timeless, a member of
the replication fork protection complex, operates with the Warsaw breakage syndrome DNA
helicase DDX11 in the same fork recovery pathway. Nucleic acids research 44, 705-717,
doi:10.1093/nar/gkv1112 (2016).
Xu, X., Wang, J. T., Li, M. & Liu, Y. TIMELESS Suppresses the Accumulation of Aberrant
CDC45.MCM2-7.GINS Replicative Helicase Complexes on Human Chromatin. The Journal of
biological chemistry 291, 22544-22558, doi:10.1074/jbc.M116.719963 (2016).
Unsal-Kacmaz, K. et al. The human Tim/Tipin complex coordinates an Intra-S checkpoint
response to UV that slows replication fork displacement. Molecular and cellular biology 27, 31313142, doi:10.1128/MCB.02190-06 (2007).
Smith-Roe, S. L. et al. Timeless functions independently of the Tim-Tipin complex to promote
sister chromatid cohesion in normal human fibroblasts. Cell cycle 10, 1618-1624,

236

175
176

177

178
179
180

181
182

183

184
185

186

187
188

189

190
191
192
193
194

195
196

doi:10.4161/cc.10.10.15613 (2011).
Chan, R. C. et al. Chromosome cohesion is regulated by a clock gene paralogue TIM-1. Nature
423, 1002-1009, doi:10.1038/nature01697 (2003).
Dheekollu, J., Chen, H. S., Kaye, K. M. & Lieberman, P. M. Timeless-dependent DNA
replication-coupled recombination promotes Kaposi's Sarcoma-associated herpesvirus episome
maintenance and terminal repeat stability. Journal of virology 87, 3699-3709,
doi:10.1128/JVI.02211-12 (2013).
Dheekollu, J. & Lieberman, P. M. The replisome pausing factor Timeless is required for episomal
maintenance of latent Epstein-Barr virus. Journal of virology 85, 5853-5863,
doi:10.1128/JVI.02425-10 (2011).
Matsuo, T. et al. Control mechanism of the circadian clock for timing of cell division in vivo.
Science 302, 255-259, doi:10.1126/science.1086271 (2003).
Dekens, M. P. et al. Light regulates the cell cycle in zebrafish. Current biology : CB 13, 20512057 (2003).
Nagoshi, E. et al. Circadian gene expression in individual fibroblasts: cell-autonomous and selfsustained oscillators pass time to daughter cells. Cell 119, 693-705, doi:10.1016/j.cell.2004.11.015
(2004).
You, S. et al. Daily coordination of cancer growth and circadian clock gene expression. Breast
cancer research and treatment 91, 47-60, doi:10.1007/s10549-004-6603-z (2005).
Unsal-Kacmaz, K., Mullen, T. E., Kaufmann, W. K. & Sancar, A. Coupling of human circadian
and cell cycles by the timeless protein. Molecular and cellular biology 25, 3109-3116,
doi:10.1128/MCB.25.8.3109-3116.2005 (2005).
Yang, X., Wood, P. A. & Hrushesky, W. J. Mammalian TIMELESS is required for ATMdependent CHK2 activation and G2/M checkpoint control. The Journal of biological chemistry
285, 3030-3034, doi:10.1074/jbc.M109.050237 (2010).
Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA
damage checkpoint. Genes & development 14, 1448-1459 (2000).
Niida, H., Katsuno, Y., Banerjee, B., Hande, M. P. & Nakanishi, M. Specific role of Chk1
phosphorylations in cell survival and checkpoint activation. Molecular and cellular biology 27,
2572-2581, doi:10.1128/MCB.01611-06 (2007).
Yoshizawa-Sugata, N. & Masai, H. Human Tim/Timeless-interacting protein, Tipin, is required
for efficient progression of S phase and DNA replication checkpoint. The Journal of biological
chemistry 282, 2729-2740, doi:10.1074/jbc.M605596200 (2007).
Witosch, J., Wolf, E. & Mizuno, N. Architecture and ssDNA interaction of the Timeless-TipinRPA complex. Nucleic acids research 42, 12912-12927, doi:10.1093/nar/gku960 (2014).
Engelen, E. et al. Mammalian TIMELESS is involved in period determination and DNA damagedependent phase advancing of the circadian clock. PloS one 8, e56623,
doi:10.1371/journal.pone.0056623 (2013).
Kemp, M. G. et al. Tipin-replication protein A interaction mediates Chk1 phosphorylation by
ATR in response to genotoxic stress. The Journal of biological chemistry 285, 16562-16571,
doi:10.1074/jbc.M110.110304 (2010).
Sercin, O. & Kemp, M. G. Characterization of functional domains in human Claspin. Cell cycle
10, 1599-1606, doi:10.4161/cc.10.10.15562 (2011).
Yang, X. H., Shiotani, B., Classon, M. & Zou, L. Chk1 and Claspin potentiate PCNA
ubiquitination. Genes & development 22, 1147-1152, doi:10.1101/gad.1632808 (2008).
Yang, X. H. & Zou, L. Dual functions of DNA replication forks in checkpoint signaling and
PCNA ubiquitination. Cell cycle 8, 191-194, doi:10.4161/cc.8.2.7357 (2009).
Xie, S. et al. Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair.
Molecular cell 60, 163-176, doi:10.1016/j.molcel.2015.07.031 (2015).
Young, L. M. et al. TIMELESS Forms a Complex with PARP1 Distinct from Its Complex with
TIPIN and Plays a Role in the DNA Damage Response. Cell reports 13, 451-459,
doi:10.1016/j.celrep.2015.09.017 (2015).
Fu, L. & Lee, C. C. The circadian clock: pacemaker and tumour suppressor. Nature reviews.
Cancer 3, 350-361, doi:10.1038/nrc1072 (2003).
Lamont, E. W., James, F. O., Boivin, D. B. & Cermakian, N. From circadian clock gene
expression to pathologies. Sleep medicine 8, 547-556, doi:10.1016/j.sleep.2006.11.002 (2007).

237

197
198
199

200
201

202
203
204
205
206

207
208
209
210

211

212

213

214

215

216
217
218

Hansen, J. Increased breast cancer risk among women who work predominantly at night.
Epidemiology 12, 74-77 (2001).
Buja, A. et al. Cancer incidence among female flight attendants: a meta-analysis of published data.
Journal of women's health 15, 98-105, doi:10.1089/jwh.2006.15.98 (2006).
Mormont, M. C. et al. Marked 24-h rest/activity rhythms are associated with better quality of life,
better response, and longer survival in patients with metastatic colorectal cancer and good
performance status. Clinical cancer research : an official journal of the American Association for
Cancer Research 6, 3038-3045 (2000).
Sephton, S. E., Sapolsky, R. M., Kraemer, H. C. & Spiegel, D. Diurnal cortisol rhythm as a
predictor of breast cancer survival. Journal of the National Cancer Institute 92, 994-1000 (2000).
Rafnsson, V., Tulinius, H., Jonasson, J. G. & Hrafnkelsson, J. Risk of breast cancer in female
flight attendants: a population-based study (Iceland). Cancer causes & control : CCC 12, 95-101
(2001).
Altman, B. J. et al. MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. Cell
metabolism 22, 1009-1019, doi:10.1016/j.cmet.2015.09.003 (2015).
Kiessling, S. et al. Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC
biology 15, 13, doi:10.1186/s12915-017-0349-7 (2017).
Yoshida, K. et al. TIMELESS is overexpressed in lung cancer and its expression correlates with
poor patient survival. Cancer science 104, 171-177, doi:10.1111/cas.12068 (2013).
Mao, Y. et al. Potential cancer-related role of circadian gene TIMELESS suggested by expression
profiling and in vitro analyses. BMC cancer 13, 498, doi:10.1186/1471-2407-13-498 (2013).
Zhang, W. et al. Aberrant TIMELESS expression is associated with poor clinical survival and
lymph node metastasis in early-stage cervical carcinoma. International journal of oncology 50,
173-184, doi:10.3892/ijo.2016.3784 (2017).
Chi, L. et al. TIMELESS contributes to the progression of breast cancer through activation of
MYC. Breast cancer research : BCR 19, 53, doi:10.1186/s13058-017-0838-1 (2017).
Elgohary, N. et al. Protumorigenic role of Timeless in hepatocellular carcinoma. International
journal of oncology 46, 597-606, doi:10.3892/ijo.2014.2751 (2015).
Yang, M. Y. et al. Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome
in Acute Leukemia. Anticancer research 35, 6615-6622 (2015).
Mazzoccoli, G. et al. Clock gene expression levels and relationship with clinical and pathological
features in colorectal cancer patients. Chronobiology international 28, 841-851,
doi:10.3109/07420528.2011.615182 (2011).
Liu, S. L. et al. TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating
the Wnt/beta-catenin signaling pathway and promoting the epithelial mesenchymal transition.
Cancer letters 402, 117-130, doi:10.1016/j.canlet.2017.05.022 (2017).
Tozlu-Kara, S. et al. Oligonucleotide microarray analysis of estrogen receptor alpha-positive
postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding
candidate markers to predict the response to tamoxifen. Journal of molecular endocrinology 39,
305-318, doi:10.1677/JME-07-0001 (2007).
Schepeler, T. et al. A high resolution genomic portrait of bladder cancer: correlation between
genomic aberrations and the DNA damage response. Oncogene 32, 3577-3586,
doi:10.1038/onc.2012.381 (2013).
Kawada, M., Fukazawa, H., Mizuno, S. & Uehara, Y. Inhibition of anchorage-independent growth
of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed
against K-ras. Biochemical and biophysical research communications 231, 735-737,
doi:10.1006/bbrc.1997.6179 (1997).
Xu, L. H. et al. The focal adhesion kinase suppresses transformation-associated, anchorageindependent apoptosis in human breast cancer cells. Involvement of death receptor-related
signaling pathways. The Journal of biological chemistry 275, 30597-30604,
doi:10.1074/jbc.M910027199 (2000).
Reszka, E. & Przybek, M. Circadian Genes in Breast Cancer. Advances in clinical chemistry 75,
53-70, doi:10.1016/bs.acc.2016.03.005 (2016).
Fu, A. et al. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer
risk. Molecular carcinogenesis 51, 923-929, doi:10.1002/mc.20862 (2012).
Wiegering, A. et al. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms

238

219
220

221

222
223

224
225

226

227

228

229

230
231

232
233
234
235

236
237
238
239
240

That Maintain High MYC Levels in Colorectal Cancer. Cancer discovery 5, 768-781,
doi:10.1158/2159-8290.CD-14-1040 (2015).
Kandel, E. S. et al. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint
induced by DNA damage. Molecular and cellular biology 22, 7831-7841 (2002).
Katayama, K., Fujita, N. & Tsuruo, T. Akt/protein kinase B-dependent phosphorylation and
inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Molecular and
cellular biology 25, 5725-5737, doi:10.1128/MCB.25.13.5725-5737.2005 (2005).
Tang, D. et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage
independently of p53. The Journal of biological chemistry 277, 12710-12717,
doi:10.1074/jbc.M111598200 (2002).
Li, P. et al. P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell
proliferation. Molecular biology of the cell 23, 1582-1592, doi:10.1091/mbc.E11-10-0883 (2012).
Green, C. B. Time for chronotherapy? Clock genes dictate sensitivity to cyclophosphamide.
Proceedings of the National Academy of Sciences of the United States of America 102, 3529-3530,
doi:10.1073/pnas.0500552102 (2005).
Mormont, M. C. & Levi, F. Cancer chronotherapy: principles, applications, and perspectives.
Cancer 97, 155-169, doi:10.1002/cncr.11040 (2003).
Vincenzi, B., Santini, D., La Cesa, A. & Tonini, G. Cancer chronotherapy: principles,
applications, and perspectives. Cancer 98, 881-882; author reply 882-883, doi:10.1002/cncr.11600
(2003).
Gori, F. & Demay, M. B. BIG-3, a novel WD-40 repeat protein, is expressed in the developing
growth plate and accelerates chondrocyte differentiation in vitro. Endocrinology 145, 1050-1054,
doi:10.1210/en.2003-1314 (2004).
Gori, F., Divieti, P. & Demay, M. B. Cloning and characterization of a novel WD-40 repeat
protein that dramatically accelerates osteoblastic differentiation. The Journal of biological
chemistry 276, 46515-46522, doi:10.1074/jbc.M105757200 (2001).
Dias, J. et al. Structural analysis of the KANSL1/WDR5/KANSL2 complex reveals that WDR5 is
required for efficient assembly and chromatin targeting of the NSL complex. Genes &
development 28, 929-942, doi:10.1101/gad.240200.114 (2014).
Ruthenburg, A. J. et al. Histone H3 recognition and presentation by the WDR5 module of the
MLL1 complex. Nature structural & molecular biology 13, 704-712, doi:10.1038/nsmb1119
(2006).
Dou, Y. et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components.
Nature structural & molecular biology 13, 713-719, doi:10.1038/nsmb1128 (2006).
Couture, J. F., Collazo, E. & Trievel, R. C. Molecular recognition of histone H3 by the WD40
protein WDR5. Nature structural & molecular biology 13, 698-703, doi:10.1038/nsmb1116
(2006).
Han, Z. et al. Structural basis for the specific recognition of methylated histone H3 lysine 4 by the
WD-40 protein WDR5. Molecular cell 22, 137-144, doi:10.1016/j.molcel.2006.03.018 (2006).
Ang, Y. S. et al. Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core
transcriptional network. Cell 145, 183-197, doi:10.1016/j.cell.2011.03.003 (2011).
Yang, Y. W. et al. Essential role of lncRNA binding for WDR5 maintenance of active chromatin
and embryonic stem cell pluripotency. eLife 3, e02046, doi:10.7554/eLife.02046 (2014).
Wysocka, J. et al. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4
methylation and vertebrate development. Cell 121, 859-872, doi:10.1016/j.cell.2005.03.036
(2005).
Migliori, V., Mapelli, M. & Guccione, E. On WD40 proteins: propelling our knowledge of
transcriptional control? Epigenetics 7, 815-822, doi:10.4161/epi.21140 (2012).
Wysocka, J. et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with
chromatin remodelling. Nature 442, 86-90, doi:10.1038/nature04815 (2006).
Wang, K. C. et al. A long noncoding RNA maintains active chromatin to coordinate homeotic
gene expression. Nature 472, 120-124, doi:10.1038/nature09819 (2011).
Xu, Z. et al. Synergistic effect of SRY and its direct target, WDR5, on Sox9 expression. PloS one
7, e34327, doi:10.1371/journal.pone.0034327 (2012).
Shilatifard, A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in
development and disease pathogenesis. Annual review of biochemistry 81, 65-95,

239

241
242

243

244

245
246
247

248

249
250
251

252

253
254

255

256

257

258

259
260

261

doi:10.1146/annurev-biochem-051710-134100 (2012).
Ford, D. J. & Dingwall, A. K. The cancer COMPASS: navigating the functions of MLL
complexes in cancer. Cancer genetics 208, 178-191, doi:10.1016/j.cancergen.2015.01.005 (2015).
Yang, W. & Ernst, P. Distinct functions of histone H3, lysine 4 methyltransferases in normal and
malignant hematopoiesis. Current opinion in hematology 24, 322-328,
doi:10.1097/MOH.0000000000000346 (2017).
Risner, L. E. et al. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage
leukemia. The Journal of biological chemistry 288, 29901-29910, doi:10.1074/jbc.M113.474858
(2013).
Bach, C., Mueller, D., Buhl, S., Garcia-Cuellar, M. P. & Slany, R. K. Alterations of the CxxC
domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene 28, 815-823,
doi:10.1038/onc.2008.443 (2009).
Chen, Y. et al. MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute
Myeloid Leukemia. Cancer cell 31, 755-770 e756, doi:10.1016/j.ccell.2017.05.002 (2017).
Lee, J. E. et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation
during cell differentiation. eLife 2, e01503, doi:10.7554/eLife.01503 (2013).
Hu, D. et al. The MLL3/MLL4 branches of the COMPASS family function as major histone
H3K4 monomethylases at enhancers. Molecular and cellular biology 33, 4745-4754,
doi:10.1128/MCB.01181-13 (2013).
Wang, C. et al. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition.
Proceedings of the National Academy of Sciences of the United States of America 113, 1187111876, doi:10.1073/pnas.1606857113 (2016).
Chen, C. et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.
Cancer cell 25, 652-665, doi:10.1016/j.ccr.2014.03.016 (2014).
Santos, M. A. et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer
barrier. Nature 514, 107-111, doi:10.1038/nature13483 (2014).
Chauhan, C., Zraly, C. B. & Dingwall, A. K. The Drosophila COMPASS-like Cmi-Trr coactivator
complex regulates dpp/BMP signaling in pattern formation. Developmental biology 380, 185-198,
doi:10.1016/j.ydbio.2013.05.018 (2013).
Kanda, H., Nguyen, A., Chen, L., Okano, H. & Hariharan, I. K. The Drosophila ortholog of MLL3
and MLL4, trithorax related, functions as a negative regulator of tissue growth. Molecular and
cellular biology 33, 1702-1710, doi:10.1128/MCB.01585-12 (2013).
Goo, Y. H. et al. Activating signal cointegrator 2 belongs to a novel steady-state complex that
contains a subset of trithorax group proteins. Molecular and cellular biology 23, 140-149 (2003).
Mo, R., Rao, S. M. & Zhu, Y. J. Identification of the MLL2 complex as a coactivator for estrogen
receptor alpha. The Journal of biological chemistry 281, 15714-15720,
doi:10.1074/jbc.M513245200 (2006).
Bledau, A. S. et al. The H3K4 methyltransferase Setd1a is first required at the epiblast stage,
whereas Setd1b becomes essential after gastrulation. Development 141, 1022-1035,
doi:10.1242/dev.098152 (2014).
Li, Y. et al. Setd1a and NURF mediate chromatin dynamics and gene regulation during erythroid
lineage commitment and differentiation. Nucleic acids research 44, 7173-7188,
doi:10.1093/nar/gkw327 (2016).
Ziemin-van der Poel, S. et al. Identification of a gene, MLL, that spans the breakpoint in 11q23
translocations associated with human leukemias. Proceedings of the National Academy of
Sciences of the United States of America 88, 10735-10739 (1991).
Bolouri, H. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent
structural alterations and age-specific mutational interactions. Nature medicine,
doi:10.1038/nm.4439 (2017).
Meyer, C. et al. The MLL recombinome of acute leukemias in 2017. Leukemia,
doi:10.1038/leu.2017.213 (2017).
Weirich, S., Kudithipudi, S. & Jeltsch, A. Somatic cancer mutations in the MLL1 histone
methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L
complex. Molecular oncology 11, 373-387, doi:10.1002/1878-0261.12041 (2017).
de Boer, J., Walf-Vorderwulbecke, V. & Williams, O. In focus: MLL-rearranged leukemia.
Leukemia 27, 1224-1228, doi:10.1038/leu.2013.78 (2013).

240

262
263

264
265
266
267
268

269
270
271

272
273
274

275
276

277

278

279

280
281

282
283
284

Xu, J. et al. MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic
transcription program. Cell discovery 2, 16008, doi:10.1038/celldisc.2016.8 (2016).
Dawkins, J. B. et al. Reduced Expression of Histone Methyltransferases KMT2C and KMT2D
Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. Cancer research 76,
4861-4871, doi:10.1158/0008-5472.CAN-16-0481 (2016).
Guo, C. et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4
monomethylation. Oncotarget 4, 2144-2153, doi:10.18632/oncotarget.1555 (2013).
Zhang, C. et al. KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway.
Cell death & disease 8, e2940, doi:10.1038/cddis.2017.285 (2017).
Esposito, M. T. et al. Synthetic lethal targeting of oncogenic transcription factors in acute
leukemia by PARP inhibitors. Nature medicine 21, 1481-1490, doi:10.1038/nm.3993 (2015).
Toska, E. et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the
epigenetic regulator KMT2D. Science 355, 1324-1330, doi:10.1126/science.aah6893 (2017).
Kim, J. Y. et al. A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4
methylation on histone H3 during androgen signaling and in prostate cancer. Molecular cell 54,
613-625, doi:10.1016/j.molcel.2014.03.043 (2014).
Malik, R. et al. Targeting the MLL complex in castration-resistant prostate cancer. Nature
medicine 21, 344-352, doi:10.1038/nm.3830 (2015).
Lu, Y. W. et al. Colorectal Cancer Genetic Heterogeneity Delineated by Multi-Region
Sequencing. PloS one 11, e0152673, doi:10.1371/journal.pone.0152673 (2016).
Mouradov, D. et al. Colorectal cancer cell lines are representative models of the main molecular
subtypes of primary cancer. Cancer research 74, 3238-3247, doi:10.1158/0008-5472.CAN-140013 (2014).
Benayoun, B. A. et al. H3K4me3 breadth is linked to cell identity and transcriptional consistency.
Cell 158, 673-688, doi:10.1016/j.cell.2014.06.027 (2014).
Chen, K. et al. Broad H3K4me3 is associated with increased transcription elongation and enhancer
activity at tumor-suppressor genes. Nature genetics 47, 1149-1157, doi:10.1038/ng.3385 (2015).
Ali, A., Veeranki, S. N., Chinchole, A. & Tyagi, S. MLL/WDR5 Complex Regulates Kif2A
Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis.
Developmental cell 41, 605-622 e607, doi:10.1016/j.devcel.2017.05.023 (2017).
Kantidakis, T. et al. Mutation of cancer driver MLL2 results in transcription stress and genome
instability. Genes & development 30, 408-420, doi:10.1101/gad.275453.115 (2016).
Thompson, B. A., Tremblay, V., Lin, G. & Bochar, D. A. CHD8 is an ATP-dependent chromatin
remodeling factor that regulates beta-catenin target genes. Molecular and cellular biology 28,
3894-3904, doi:10.1128/MCB.00322-08 (2008).
Suganuma, T. et al. ATAC is a double histone acetyltransferase complex that stimulates
nucleosome sliding. Nature structural & molecular biology 15, 364-372, doi:10.1038/nsmb.1397
(2008).
Wang, Y. L., Faiola, F., Xu, M., Pan, S. & Martinez, E. Human ATAC Is a GCN5/PCAFcontaining acetylase complex with a novel NC2-like histone fold module that interacts with the
TATA-binding protein. The Journal of biological chemistry 283, 33808-33815,
doi:10.1074/jbc.M806936200 (2008).
Mendjan, S. et al. Nuclear pore components are involved in the transcriptional regulation of
dosage compensation in Drosophila. Molecular cell 21, 811-823,
doi:10.1016/j.molcel.2006.02.007 (2006).
Brown, S. A. et al. PERIOD1-associated proteins modulate the negative limb of the mammalian
circadian oscillator. Science 308, 693-696, doi:10.1126/science.1107373 (2005).
Migliori, V. et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that
supports euchromatin maintenance. Nature structural & molecular biology 19, 136-144,
doi:10.1038/nsmb.2209 (2012).
Thomas, L. R. et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis
by MYC. Molecular cell 58, 440-452, doi:10.1016/j.molcel.2015.02.028 (2015).
Thomas, L. R., Foshage, A. M., Weissmiller, A. M. & Tansey, W. P. The MYC-WDR5 Nexus and
Cancer. Cancer research 75, 4012-4015, doi:10.1158/0008-5472.CAN-15-1216 (2015).
Sun, Y. et al. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic
Gene Expression Signature in Neuroblastoma. Cancer research 75, 5143-5154, doi:10.1158/0008-

241

285

286
287

288

289

290
291
292
293

294

295

296
297

298
299
300
301
302
303

304
305
306
307

5472.CAN-15-0423 (2015).
Ullius, A. et al. The interaction of MYC with the trithorax protein ASH2L promotes gene
transcription by regulating H3K27 modification. Nucleic acids research 42, 6901-6920,
doi:10.1093/nar/gku312 (2014).
Lorenzin, F. et al. Different promoter affinities account for specificity in MYC-dependent gene
regulation. eLife 5, doi:10.7554/eLife.15161 (2016).
Carugo, A. et al. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies
WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell reports 16, 133-147,
doi:10.1016/j.celrep.2016.05.063 (2016).
Blumenthal, D. T. et al. Clinical utility and treatment outcome of comprehensive genomic
profiling in high grade glioma patients. Journal of neuro-oncology 130, 211-219,
doi:10.1007/s11060-016-2237-3 (2016).
Bailey, J. K. et al. WD repeat-containing protein 5 (WDR5) localizes to the midbody and regulates
abscission. The Journal of biological chemistry 290, 8987-9001, doi:10.1074/jbc.M114.623611
(2015).
Sun, W., Guo, F. & Liu, M. Up-regulated WDR5 promotes gastric cancer formation by induced
cyclin D1 expression. Journal of cellular biochemistry, doi:10.1002/jcb.26491 (2017).
Dai, X. et al. WDR5 Expression Is Prognostic of Breast Cancer Outcome. PloS one 10, e0124964,
doi:10.1371/journal.pone.0124964 (2015).
Ge, Z. et al. WDR5 high expression and its effect on tumorigenesis in leukemia. Oncotarget 7,
37740-37754, doi:10.18632/oncotarget.9312 (2016).
Chen, X. et al. Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in
bladder cancer via mediating H3K4 trimethylation. Scientific reports 5, 8293,
doi:10.1038/srep08293 (2015).
Quagliata, L. et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with
disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 59,
911-923, doi:10.1002/hep.26740 (2014).
Mungamuri, S. K., Murk, W., Grumolato, L., Bernstein, E. & Aaronson, S. A. Chromatin
modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers. Cell
reports 5, 302-313, doi:10.1016/j.celrep.2013.09.009 (2013).
Yoshimaru, T. et al. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast
cancer cells. Nature communications 4, 2443, doi:10.1038/ncomms3443 (2013).
Cheng, Y., Jutooru, I., Chadalapaka, G., Corton, J. C. & Safe, S. The long non-coding RNA
HOTTIP enhances pancreatic cancer cell proliferation, survival and migration. Oncotarget 6,
10840-10852, doi:10.18632/oncotarget.3450 (2015).
Wu, M. Z. et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelialmesenchymal transition. Molecular cell 43, 811-822, doi:10.1016/j.molcel.2011.07.012 (2011).
Tan, X. et al. PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis
by directly targeting ZNF407. Cell death & disease 8, e2686, doi:10.1038/cddis.2017.111 (2017).
Chung, C. Y. et al. Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis.
Cell reports 16, 472-486, doi:10.1016/j.celrep.2016.06.002 (2016).
Malek, R. et al. TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer
Metastasis. Cancer research 77, 3181-3193, doi:10.1158/0008-5472.CAN-16-2797 (2017).
Fu, Z. et al. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer
by regulating HOXA9. Cancer letters 410, 68-81, doi:10.1016/j.canlet.2017.09.019 (2017).
Lin, C. et al. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP
facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells. Oncogene 36,
5392-5406, doi:10.1038/onc.2017.133 (2017).
Chang, S. et al. HOTTIP and HOXA13 are oncogenes associated with gastric cancer progression.
Oncology reports 35, 3577-3585, doi:10.3892/or.2016.4743 (2016).
Kim, K. et al. Gene dysregulation by histone variant H2A.Z in bladder cancer. Epigenetics &
chromatin 6, 34, doi:10.1186/1756-8935-6-34 (2013).
Chen, X. et al. Gene expression profiling of WDR5 regulated genes in bladder cancer. Genomics
data 5, 27-29, doi:10.1016/j.gdata.2015.05.003 (2015).
Sun, T. T. et al. LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular
Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. Cancer

242

308

309

310
311

312

313

314

315

316
317

318
319

320

321
322

323
324
325

326

327

discovery 6, 784-801, doi:10.1158/2159-8290.CD-15-0921 (2016).
Dharmarajan, V., Lee, J. H., Patel, A., Skalnik, D. G. & Cosgrove, M. S. Structural basis for
WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases. The
Journal of biological chemistry 287, 27275-27289, doi:10.1074/jbc.M112.364125 (2012).
Patel, A., Dharmarajan, V. & Cosgrove, M. S. Structure of WDR5 bound to mixed lineage
leukemia protein-1 peptide. The Journal of biological chemistry 283, 32158-32161,
doi:10.1074/jbc.C800164200 (2008).
Schuetz, A. et al. Structural basis for molecular recognition and presentation of histone H3 by
WDR5. The EMBO journal 25, 4245-4252, doi:10.1038/sj.emboj.7601316 (2006).
Karatas, H. et al. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic
(MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia
(MLL) Protein-Protein Interaction. Journal of medicinal chemistry 60, 4818-4839,
doi:10.1021/acs.jmedchem.6b01796 (2017).
Karatas, H., Townsend, E. C., Bernard, D., Dou, Y. & Wang, S. Analysis of the binding of mixed
lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design
of inhibitors of the MLL1-WDR5 interaction. Journal of medicinal chemistry 53, 5179-5185,
doi:10.1021/jm100139b (2010).
Karatas, H. et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5
protein-protein interaction. Journal of the American Chemical Society 135, 669-682,
doi:10.1021/ja306028q (2013).
Alicea-Velazquez, N. L. et al. Targeted Disruption of the Interaction between WD-40 Repeat
Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically
Inhibits MLL1 and SETd1A Methyltransferase Complexes. The Journal of biological chemistry
291, 22357-22372, doi:10.1074/jbc.M116.752626 (2016).
Li, D. D. et al. Structure-based design of ester compounds to inhibit MLL complex catalytic
activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorganic &
medicinal chemistry 24, 6109-6118, doi:10.1016/j.bmc.2016.09.073 (2016).
Senisterra, G. et al. Small-molecule inhibition of MLL activity by disruption of its interaction with
WDR5. The Biochemical journal 449, 151-159, doi:10.1042/BJ20121280 (2013).
Bolshan, Y. et al. Synthesis, Optimization, and Evaluation of Novel Small Molecules as
Antagonists of WDR5-MLL Interaction. ACS medicinal chemistry letters 4, 353-357,
doi:10.1021/ml300467n (2013).
Cao, F. et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Molecular cell 53, 247-261, doi:10.1016/j.molcel.2013.12.001 (2014).
Getlik, M. et al. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction
Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
Journal of medicinal chemistry 59, 2478-2496, doi:10.1021/acs.jmedchem.5b01630 (2016).
Li, D. D. et al. Structure-based design and synthesis of small molecular inhibitors disturbing the
interaction of MLL1-WDR5. European journal of medicinal chemistry 118, 1-8,
doi:10.1016/j.ejmech.2016.04.032 (2016).
Grebien, F. et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha Nterminal leukemia. Nature chemical biology 11, 571-578, doi:10.1038/nchembio.1859 (2015).
Jiang, P., Du, W., Mancuso, A., Wellen, K. E. & Yang, X. Reciprocal regulation of p53 and malic
enzymes modulates metabolism and senescence. Nature 493, 689-693, doi:10.1038/nature11776
(2013).
Lu, F. et al. Regulation of DNA replication and chromosomal polyploidy by the MLL-WDR5RBBP5 methyltransferases. Biology open 5, 1449-1460, doi:10.1242/bio.019729 (2016).
De Haro, L. P. et al. Metnase promotes restart and repair of stalled and collapsed replication forks.
Nucleic acids research 38, 5681-5691, doi:10.1093/nar/gkq339 (2010).
Vaughn, C. P., Zobell, S. D., Furtado, L. V., Baker, C. L. & Samowitz, W. S. Frequency of
KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50, 307312, doi:10.1002/gcc.20854 (2011).
Ciombor, K. K., Wu, C. & Goldberg, R. M. Recent therapeutic advances in the treatment of
colorectal cancer. Annual review of medicine 66, 83-95, doi:10.1146/annurev-med-051513-102539
(2015).
Dolinski, K. & Botstein, D. Orthology and functional conservation in eukaryotes. Annual review

243

328
329
330
331
332
333
334

335
336
337

338

339
340
341

342

343
344

345

346
347
348
349

350

of genetics 41, 465-507, doi:10.1146/annurev.genet.40.110405.090439 (2007).
Chuang, H. C., Chou, C. C., Kulp, S. K. & Chen, C. S. AMPK as a potential anticancer target friend or foe? Current pharmaceutical design 20, 2607-2618 (2014).
Hardie, D. G., Carling, D. & Gamblin, S. J. AMP-activated protein kinase: also regulated by
ADP? Trends in biochemical sciences 36, 470-477, doi:10.1016/j.tibs.2011.06.004 (2011).
Jeon, S. M., Chandel, N. S. & Hay, N. AMPK regulates NADPH homeostasis to promote tumour
cell survival during energy stress. Nature 485, 661-665, doi:10.1038/nature11066 (2012).
Faubert, B. et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor
growth in vivo. Cell metabolism 17, 113-124, doi:10.1016/j.cmet.2012.12.001 (2013).
Hardie, D. G. The LKB1-AMPK pathway-friend or foe in cancer? Cancer cell 23, 131-132,
doi:10.1016/j.ccr.2013.01.009 (2013).
Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. The
Journal of clinical investigation 108, 1167-1174, doi:10.1172/JCI13505 (2001).
Laderoute, K. R. et al. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and
glucose deprivation conditions found in solid-tumor microenvironments. Molecular and cellular
biology 26, 5336-5347, doi:10.1128/MCB.00166-06 (2006).
Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular
cell 30, 214-226, doi:10.1016/j.molcel.2008.03.003 (2008).
Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through
direct phosphorylation of Ulk1. Nature cell biology 13, 132-141, doi:10.1038/ncb2152 (2011).
Ng, T. L. et al. The AMPK stress response pathway mediates anoikis resistance through inhibition
of mTOR and suppression of protein synthesis. Cell death and differentiation 19, 501-510,
doi:10.1038/cdd.2011.119 (2012).
Zadra, G., Batista, J. L. & Loda, M. Dissecting the Dual Role of AMPK in Cancer: From
Experimental to Human Studies. Molecular cancer research : MCR 13, 1059-1072,
doi:10.1158/1541-7786.MCR-15-0068 (2015).
Pineda, C. T. et al. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160, 715728, doi:10.1016/j.cell.2015.01.034 (2015).
Sanduja, S. et al. AMPK promotes tolerance to Ras pathway inhibition by activating autophagy.
Oncogene, doi:10.1038/onc.2016.70 (2016).
Decensi, A. et al. Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis. Cancer prevention research 3, 1451-1461, doi:10.1158/1940-6207.CAPR-10-0157
(2010).
Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. & Morris, A. D. Metformin and
reduced risk of cancer in diabetic patients. Bmj 330, 1304-1305,
doi:10.1136/bmj.38415.708634.F7 (2005).
Mehenni, H. et al. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for
allelic and locus heterogeneity. American journal of human genetics 63, 1641-1650 (1998).
Jang, T. et al. 5'-AMP-activated protein kinase activity is elevated early during primary brain
tumor development in the rat. International journal of cancer. Journal international du cancer
128, 2230-2239, doi:10.1002/ijc.25558 (2011).
Kato, K. et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer
cells to nutrient deprivation and tumor formation. Oncogene 21, 6082-6090,
doi:10.1038/sj.onc.1205737 (2002).
McCall, J. L. et al. KSR1 and EPHB4 regulate Myc and PGC1beta to promote survival of human
colon tumor cells. Molecular and cellular biology, doi:10.1128/MCB.00087-16 (2016).
Yu, P. B. et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron
metabolism. Nature chemical biology 4, 33-41, doi:10.1038/nchembio.2007.54 (2008).
Stein, S. C., Woods, A., Jones, N. A., Davison, M. D. & Carling, D. The regulation of AMPactivated protein kinase by phosphorylation. The Biochemical journal 345 Pt 3, 437-443 (2000).
Hernandez, L. M. et al. 4'-N-methyl-5'-hydroxystaurosporine and 5'-hydroxystaurosporine, new
indolocarbazole alkaloids from a marine Micromonospora sp. strain. The Journal of antibiotics 53,
895-902 (2000).
Tanramluk, D., Schreyer, A., Pitt, W. R. & Blundell, T. L. On the Origins of Enzyme Inhibitor
Selectivity and Promiscuity: A Case Study of Protein Kinase Binding to Staurosporine. Chemical
Biology & Drug Design 74, 16-24, doi:10.1111/j.1747-0285.2009.00832.x (2009).

244

351
352
353

354

355
356

357
358

359

360

361

362

363

364

365

366

367

368

369
370

Gessner, P. K. Isobolographic analysis of interactions: an update on applications and utility.
Toxicology 105, 161-179 (1995).
Tennakoon, J. B. et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC1alpha-mediated metabolic switch. Oncogene 33, 5251-5261, doi:10.1038/onc.2013.463 (2014).
Park, H. U. et al. AMP-activated protein kinase promotes human prostate cancer cell growth and
survival. Molecular cancer therapeutics 8, 733-741, doi:10.1158/1535-7163.MCT-08-0631
(2009).
Hindupur, S. K. et al. Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth
of mammary cells. Breast cancer research : BCR 16, 420, doi:10.1186/s13058-014-0420-z
(2014).
Chen, E. I. et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer
research 67, 1472-1486, doi:10.1158/0008-5472.CAN-06-3137 (2007).
Frigo, D. E. et al. CaM kinase kinase beta-mediated activation of the growth regulatory kinase
AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer research 71,
528-537, doi:10.1158/0008-5472.CAN-10-2581 (2011).
Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M. & Nakano, H. UCN-01, a selective inhibitor
of protein kinase C from Streptomyces. The Journal of antibiotics 40, 1782-1784 (1987).
Takahashi, I., Asano, K., Kawamoto, I., Tamaoki, T. & Nakano, H. UCN-01 and UCN-02, new
selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation. The
Journal of antibiotics 42, 564-570 (1989).
Takahashi, I. et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II.
Purification, physico-chemical properties, structural determination and biological activities. The
Journal of antibiotics 42, 571-576 (1989).
Sugiyama, K. et al. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells
which is mediated through S and/or G(2) checkpoint abrogation. International journal of cancer.
Journal international du cancer 85, 703-709 (2000).
Kortmansky, J. et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C
inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid
tumors. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 23, 1875-1884, doi:10.1200/JCO.2005.03.116 (2005).
Lara, P. N., Jr. et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced
solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative
trial. Clinical cancer research : an official journal of the American Association for Cancer
Research 11, 4444-4450, doi:10.1158/1078-0432.CCR-04-2602 (2005).
Sampath, D. et al. Pharmacodynamics of cytarabine alone and in combination with 7hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107,
2517-2524, doi:10.1182/blood-2005-08-3351 (2006).
Edelman, M. J. et al. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and
carboplatin in advanced solid tumors. Clinical cancer research : an official journal of the
American Association for Cancer Research 13, 2667-2674, doi:10.1158/1078-0432.CCR-06-1832
(2007).
Marti, G. E. et al. Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo
evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Leukemia & lymphoma 52, 2284-2292, doi:10.3109/10428194.2011.589547 (2011).
Fracasso, P. M. et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with
resistant solid tumor malignancies. Cancer chemotherapy and pharmacology 67, 1225-1237,
doi:10.1007/s00280-010-1410-1 (2011).
Li, T. et al. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma:
a California Cancer Consortium trial. Investigational new drugs 30, 741-748, doi:10.1007/s10637010-9562-8 (2012).
Ma, C. X. et al. A phase II study of UCN-01 in combination with irinotecan in patients with
metastatic triple negative breast cancer. Breast cancer research and treatment 137, 483-492,
doi:10.1007/s10549-012-2378-9 (2013).
Bloy, N. et al. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology 3,
e954929, doi:10.4161/21624011.2014.954929 (2014).
Manic, G., Obrist, F., Sistigu, A. & Vitale, I. Trial Watch: Targeting ATM-CHK2 and ATR-

245

371

372

373

374

375

376
377

378
379

380
381

382

383

384

CHK1 pathways for anticancer therapy. Molecular & cellular oncology 2, e1012976,
doi:10.1080/23723556.2015.1012976 (2015).
Obrist, F., Manic, G., Kroemer, G., Vitale, I. & Galluzzi, L. Trial Watch: Proteasomal inhibitors
for anticancer therapy. Molecular & cellular oncology 2, e974463,
doi:10.4161/23723556.2014.974463 (2015).
Sistigu, A., Manic, G., Obrist, F. & Vitale, I. Trial watch - inhibiting PARP enzymes for
anticancer therapy. Molecular & cellular oncology 3, e1053594,
doi:10.1080/23723556.2015.1053594 (2016).
Taylor, P. & Hardin, P. E. Rhythmic E-box binding by CLK-CYC controls daily cycles in per and
tim transcription and chromatin modifications. Molecular and cellular biology 28, 4642-4652,
doi:10.1128/MCB.01612-07 (2008).
Katada, S. & Sassone-Corsi, P. The histone methyltransferase MLL1 permits the oscillation of
circadian gene expression. Nature structural & molecular biology 17, 1414-1421,
doi:10.1038/nsmb.1961 (2010).
Williams, J. A., Su, H. S., Bernards, A., Field, J. & Sehgal, A. A circadian output in Drosophila
mediated by neurofibromatosis-1 and Ras/MAPK. Science 293, 2251-2256,
doi:10.1126/science.1063097 (2001).
Zheng, X. & Sehgal, A. AKT and TOR signaling set the pace of the circadian pacemaker. Current
biology : CB 20, 1203-1208, doi:10.1016/j.cub.2010.05.027 (2010).
Di Cara, F. & King-Jones, K. The Circadian Clock Is a Key Driver of Steroid Hormone
Production in Drosophila. Current biology : CB 26, 2469-2477, doi:10.1016/j.cub.2016.07.004
(2016).
Stone, E. F. et al. The circadian clock protein timeless regulates phagocytosis of bacteria in
Drosophila. PLoS pathogens 8, e1002445, doi:10.1371/journal.ppat.1002445 (2012).
Benzina, S. et al. A kinome-targeted RNAi-based screen links FGF signaling to H2AX
phosphorylation in response to radiation. Cellular and molecular life sciences : CMLS 72, 35593573, doi:10.1007/s00018-015-1901-7 (2015).
Liu, Q. et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and
ATR. Cancer research 73, 2574-2586, doi:10.1158/0008-5472.CAN-12-1702 (2013).
Dai, Y. et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK)
kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction
and apoptosis in human leukemia cells. Cancer research 61, 5106-5115 (2001).
Dai, Y. et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitorinduced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112, 24392449, doi:10.1182/blood-2008-05-159392 (2008).
Dai, Y. et al. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in
human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 109,
4415-4423, doi:10.1182/blood-2006-09-047076 (2007).
Hamed, H. et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01
causes cell death in vitro and in vivo. Molecular cancer therapeutics 7, 616-629,
doi:10.1158/1535-7163.MCT-07-2376 (2008).

